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SUMMARY 
Amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease, is a 
disease that is characterised by the degeneration of motor neurons, their axons and synapses. The 
distal neuromuscular circuitry, consisting of the spinal alpha motor neuron, distal axon, and the 
specialised synapse called the neuromuscular junction (NMJ), is a unique and vulnerable circuit, 
as it resides both in the central and peripheral nervous systems. Denervation of this circuitry leads 
to the ALS phenotype of progressive paralysis and muscle atrophy. Currently, no cure exists to 
combat ALS, with the only disease-modifying drug, Riluzole, showing modest improvements in 
a subset of patients. The lack of therapeutics highlights the need to identify the pathological 
mechanisms that drive the development and progression of this disease. The involvement of 
microtubules in the pathogenesis of ALS is becoming increasingly appreciated, with 
microtubules implicated in axon degeneration, and causing axonal transport dysfunction due to a 
pathogenic increase in the dynamics of the microtubule network. Pharmacological targeting of 
microtubules in neurodegenerative diseases with similar cellular pathology has suggested the 
possible benefit of a microtubule targeting approach in ALS. To this end, the current thesis is 
based upon the hypothesis that stabilising microtubules in the distal neuromuscular circuitry will 
improve outcomes in ALS.  
This thesis investigated the sequence of degenerative events that occur to the distal axon and 
NMJ in the SOD1G93A mouse model of ALS. This was with the intent of identifying the earliest 
distal pathology to develop a targeted therapy regime. The microtubule-targeting compound 
Epothilone D (EpoD) was used with the aim of preserving the integrity and function of the distal 
neuromuscular circuitry by stabilising microtubules. It investigated the behavioural, histological 
and molecular outcomes of targeting microtubules in ALS as a potential therapy. Furthermore, 
using a primary culture in vitro approach, it investigated the dose-dependant effect of stabilising 
microtubules on normal neuronal functioning. 
It was determined that degenerative morphology of the axonal compartment in the neuromuscular 
circuitry is an early pathological event in the hindlimb muscles of the SOD1G93A mouse model of 
ALS. Additionally, a decline in the colocalisation of pre- and post-synaptic markers of the NMJ 
occurs over the disease time course, coupled with aberrant alterations to the levels of synaptic 
proteins in diseased mice. Interestingly, forelimb pathology progresses slower than hindlimb 
pathology, suggesting gross anatomical differences in disease progression of the distal 
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neuromuscular circuitry in this model. Results from this thesis indicate that targeting the distal 
axon with stabilising agents such as EpoD may improve axonal pathology and thus outcomes in 
ALS. 
 
The efficacy of EpoD treatment in ALS was subsequently investigated using the SOD1G93A 
mouse model. EpoD was found to stabilise microtubules in spinal motor neurons, protecting the 
soma and axon of the distal neuromuscular circuitry early in the disease, coupled with modest 
improvements to motor function. However, EpoD was subsequently identified to be detrimental 
to motor behaviour, neurological outcomes and survival in the later stages of the disease. 
Furthermore, EpoD treatment was found to cause increased motor neuron death at end stage. In 
vitro investigations examined the impact of EpoD on normal neuronal functioning. Parameters 
investigated included neuronal viability, initial neurite growth and complexity, microtubule 
protein levels and mitochondrial transport.  
 
Collectively, these studies address the need for therapeutic development for the treatment of 
ALS. This thesis provides evidence that distal pathology is an early and progressive degenerative 
event in the pathogenesis of ALS, with axonal pathology offering a novel target to preserve the 
function of neuromuscular circuitry. This thesis provides evidence in support of the use of EpoD 
to improve pathology early in the disease. Furthermore, it suggests that EpoD affects aspects of 
the microtubule network in a dose-dependant manner, suggesting that the intended target and 
outcome are both vitally important considerations when utilising microtubule stabilising 
compounds in a neurological setting. These results highlight the heterogeneity of ALS pathology, 
and suggest that a combination of therapies with varied doses and timing are most likely needed 
to positively modify or alleviate the disease phenotype. 
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							Chapter	1	
1	
1 Introduction 
 
Amyotrophic Lateral Sclerosis (ALS) is a late onset and ultimately fatal neurodegenerative 
disease, classified primarily by the loss of upper motor neurons (MNs) in the motor cortex and 
brainstem, and lower alpha motor neurons (a-MN) in the spinal cord. The incidence of ALS is 
approximately 2 in every 100,000 individuals, with a mean onset age range of 55 – 60 years 
(Logroscino et al., 2010; Ferraiuolo et al., 2011; Ragonese et al., 2012). The disease can be 
separated into phenotypically distinct classes based on the area of onset: upper ‘bulbar’ onset 
involving cortical and brain stem (hypoglossal nuclei) MN loss, and lower ‘lumbar’ onset spinal 
a-MN loss (Figure 1.1). This is due to the locality of neuronal loss, which leads to these specific 
clinical manifestations. Bulbar onset initially presents as difficulty speaking and swallowing, as 
well as muscle spasticity. Lumbar onset patients initially present with limb muscle weakness and 
reduction in fine motor ability, as well as the pronounced asymmetrical weakness and wasting 
associated with ALS (Mulder et al., 1986). However, in patients with either bulbar or lumbar 
onset, the progressive loss of muscle innervation due to degeneration of firstly the connections 
(synapses), nerves (axons) and finally MN cell bodies, culminates in respiratory failure 
approximately 2-5 years after onset of symptoms. ALS is also considered a spectrum disorder, 
where patients can suffer from cognitive dysfunction (particularly behaviour/mood, personality, 
language disturbances) in frontotemporal dementia (FTD); a pure motor phenotype in classical 
ALS; or a combination of both cognitive and motor dysfunction (Ling et al., 2013). Perplexingly, 
a number of MN populations are spared in the disease course, such as the occulomotor neurons, 
which control eye movement, and the Onufs nucleus, which facilitates bladder control (Bruijn et 
al., 2004). Similarly, higher order cortical functioning is generally spared in both FTD and ALS, 
with dysfunctions in memory, problem solving ability and spatial orientation either not occurring, 
or occurring in the later stages of the disease. There is currently no cure for ALS. A patient’s life 
expectancy is approximately 3-5 years after initial diagnosis, and the current treatment, Riluzole, 
only extends life for 3-6 months (Wood-Allum and Shaw, 2010). 
 
Approximately 10% of ALS cases are inherited (familial ALS, fALS), whereas the vast majority, 
90%, have no inheritable link and are termed sporadic ALS (sALS) (Ticozzi et al., 2011). Both 
the clinical phenotype and neuropathology of ALS are quite similar between fALS and sALS 
FIGURE 1.1. Clinical phenotypes of ALS. Onset of disease is determined by the 
signs and symptoms associated with both site of onset (limb or bulbar) and also the 
MN type affected (upper/cortical or lower/spinal). In most cases, patients will 
experience both limb and bulbar clinical signs over the disease course. It is estimated 
that up to half of ALS patients will suffer from symptoms associated with Fronto-
temporal dementia. 
Adapted from Picher-Martel et al., 2016 
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cases, suggesting that there may be a large variety of mechanisms and initial insults that 
ultimately lead to a similar disease phenotype and the primary damage to MNs (Ticozzi et al., 
2011; Al-Chalabi et al., 2012; Marangi and Traynor, 2015). However, a number of clinical 
differences are observed between fALS and sALS. fALS has an equal male to female sex ratio, 
an earlier disease onset and extended disease duration. Contrastingly, sALS is characterised by 
males being 2.5 times more likely to develop ALS, coupled with a later onset and shorter disease 
duration (Bruijn et al., 2004). The development of ALS has also been attributed to a growing 
number of risk factors, other than genetic susceptibility. These include high physical activity, 
certain toxins, electromagnetic fields, occupation and past neuromuscular injuries (Ingre et al., 
2015).  
 
Neuropathy in ALS results in atrophy of cortical structures represented as shrinkage of the cortex 
and nerves (Mezzapesa et al., 2013). However, the fundamental gross anatomical changes in ALS 
can be seen as muscle wastage; a result of degeneration to neuromuscular circuitry that facilitate 
voluntary movement (Rizzuto et al., 2015). Many possible disease mechanisms have been 
proposed in the development and progression of ALS (reviewed previously (Peters et al., 2015)) 
however the underlying primary mechanism of the disease is yet to be elucidated. Indeed the key 
factor behind the pathological vulnerability of MNs in ALS is still unknown. Contributing factors 
that may result in the selective vulnerability of MNs include their large cell size, polarity, their 
excitable nature as well as their interaction with neighbouring non-neuronal cells (Robberecht 
and Philips, 2013). This vulnerability is further emphasised by higher levels of protein aggregate 
deposition and cellular degeneration in the spinal cord MNs than other populations of neurons 
inside the central nervous system (CNS) (Bruijn et al., 2004). Pathogenic mechanisms implicated 
in ALS pathogenesis include excitotoxicity (Van Damme et al., 2005), oxidative stress (Filezac 
de L'Etang et al., 2015), neuroinflammation (Henkel et al., 2004), dysregulated RNA signalling 
(Cookson, 2016), mitochondrial dysfunction (Park et al., 2013), protein aggregation (Leigh et al., 
1988) and impaired cytoskeletal functioning including microtubule dynamics (Fanara et al., 
2007) and axonal transport (Bilsland et al., 2010) (Figure 1.2).  
 
Whilst the cortex is increasingly implicated in the initial development and maintenance of the 
disease (Vucic et al., 2008; Menon et al., 2015), this literature review will focus on the defining 
hallmarks of ALS spinal cord pathology, particularly of a-MNs, a-MN axons and neuromuscular 
junctions. The impact ALS mutations have on muscle pathology will also be discussed. 
FIGURE 1.2. Mechanisms hypothesised to underlie the dysfunction and degeneration 
of MNs in ALS. Many of the proposed mechanisms have been derived from studies 
utilising mouse models expressing various mutant forms of SOD1. Neurodegeneration 
in ALS may be an accumulation of multiple insults that culminate in the eventual 
death of the cell. These insults include excitotoxicity, oxidative stress, mitochondrial 
dysfunction and axonal transport disruption. Mutations in genes such as SOD1, 
TARDBP and FUS and C9ORF72 repeat expansion is thought to either directly cause 
such insults, or predispose vulnerable cells, thus increasing their risk of dysfunction 
and degeneration.  
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Mechanisms behind the degeneration of a-MNs will also be reviewed, with a particular focus on 
the involvement of the cytoskeletal organelle, microtubules. Lastly, therapeutic strategies 
focusing on ameliorating microtubule pathologies will be examined, particularly in relation to the 
increasing use of microtubule stabilising drugs in the treatment of neurodegenerative disorders. 
1.1 ALS genetics 
For over a century it has been appreciated that the neuromuscular circuitry is particularly 
vulnerable to dysfunction, which can generate clinical symptoms associated with MN loss. ALS 
was first characterised by the French neurologist Jean-Martin Charcot in 1869, although two 
decades earlier in 1850, Aran described a lower MN disease he termed progressive muscle 
atrophy (PMA) (Charcot and Joffroy, 1869). These two pioneering neurologists suggested that 
diseases effecting the neuromuscular circuitry, and thus MNs, are heritable. Indeed, 
approximately 10% of cases are fALS, due to familial inheritance of mutated genes that increase 
the risk of developing ALS (for extensive review see (Marangi and Traynor, 2015)). However, 
the majority of cases (90%) are sALS cases, suggesting there exists some innate property of MNs 
that makes them susceptible to ALS without a genetic cause. These can also include random 
mutations to susceptible genes without any familial inheritance. A breakthrough in the 
understanding of familial ALS occurred in 1993, when mutations to the gene encoding the 
protein superoxide dismutase 1 (SOD1) were first discovered (Rosen et al 1993). As time and 
technology progresses, the detection of disease causing mutations and the prevalence of each 
fALS mutation in the population has expanded, as shown in (Figure 1.3).  
 
The gene SOD1 codes for the superoxide dismutase 1, an enzyme localised to the cytoplasm. This 
specialised enzyme is responsible for superoxide radical (O2-) catabolism; breaking superoxides 
down into hydrogen peroxide (H2O2) and molecular oxygen (O2) (McCord and Fridovich, 1969). 
Superoxide is a reactive oxygen species (ROS) that has the capacity to damage the cytoskeleton, 
organelles, membranes and transcript components of a cell (Rosen et al., 1993; Ferraiuolo et al., 
2011). The enzyme is a 35 kDa metal binding protein that is able to bind zinc and copper. The 
SOD1 gene itself spans 9.3kb on chromosome 21q, consisting of five exons (Getzoff et al., 1989; 
Ticozzi et al., 2011). More than 160 different mutations to the gene encoding for SOD1 have 
been reported (Rosen et al., 1993; Al-Chalabi et al., 2012), accounting for approximately 20% of 
all familial forms of ALS (Andersen and Al-Chalabi, 2011; Robberecht and Philips, 2013). Not 
only was SOD1 the first gene to be linked to ALS development, the glycine to alanine 
FIGURE 1.3. Timeline and representation of disease causing mutations in familial 
ALS (fALS). The first identified ALS causing mutation was in superoxide dismutase 
1 (SOD1), representing approximately 15% of all fALS cases. The other mutations 
with high representation are mutations to TARDBP (gene coding for TDP-43), and 
Fused in Sarcoma (FUS), with 4% each. The hexanucleotide repeat expansion in 
C9ORF72 represents approximately 40% of all mutations in fALS cases. Increasing in 
frequency is the discovery of disease causing rare variant mutations, such as in 
TUBA4A. 
Adapted from Picher-Martel et al., 2016 
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substitution at amino acid 93 SOD1 mutant variant (SOD1G93A) was also the first ALS causing 
mutation to be used to generate the first animal model of the disease (Gurney et al., 1994). 
 
To date, there is no clear explanation for how SOD1 mutations relate to cortical and a-MNs loss 
in ALS. Initially it was hypothesised that impaired enzyme activity would lead to increased levels 
of cellular ROS creating oxidative stress and eventually cell death (Deng et al., 1993). Indeed, 
SOD1 knockout mice show pathological features similar to those described in the ALS patients 
and the mutant SOD1G93A mouse model of ALS, leading to impaired neurotransmitter release and 
decreased NMJ stability (Shi et al., 2014). However, studies have shown that some mutants still 
have catalytic ability, and there appears to be no correlation between lingering enzyme activity, 
disease phenotype and its clinical progression (Radunovic et al., 1997; Ticozzi et al., 2011). 
Several studies have shown that in MNs, SOD1 aggregates into cytoplasmic inclusions, with a 
skein-like morphology (Shibata et al., 1996; Deng et al., 2010). Moreover, it has long been 
established that SOD1 mutations, particularly the most widely studied SOD1G93A mutation, 
causes dysfunction of axonal transport, suggesting an aberrant interaction with the microtubule 
system (Warita et al., 1999; Ligon et al., 2005; Bilsland et al., 2010; Ikenaka et al., 2012). This 
has been reported to be occurring as early as embryonic day 13 in the SOD1G93A mutant mouse 
(Kieran et al., 2005), but is still poorly understood. Recently, mutations in genes coding for 
DNA/RNA binding proteins have been linked to fALS cases. Moreover, a number of the proteins 
involved in fALS related mutations are associated with sALS as well. 
 
Discoveries of mutations in DNA/RNA processing proteins such as TDP-43 (TARDBP) and 
fused in sarcoma (FUS) were both identified as a cause of familial ALS and FTD (Kabashi et al., 
2008; Sreedharan et al., 2008; Kwiatkowski et al., 2009; Vance et al., 2009), and subsequently 
used to generate further models of ALS, which have been reviewed elsewhere (Liu et al., 2013; 
Philips and Rothstein, 2015; Nolan et al., 2016). TDP-43 is a 43-kDa protein that is localised to 
the cell nucleus in unaffected neurons (Buratti and Baralle, 2008). The specific function of TDP-
43 remains unclear, but it is associated with transcription repression (Ou et al., 1995), the 
regulation of slice variants (Buratti and Baralle, 2001), mRNA stability and/or transport 
(Tollervey et al., 2011) and is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) 
family of proteins (Pesiridis et al., 2009). The c-terminal glycine-rich region is thought to 
modulate RNA transcription and metabolism through interactions with other hnRNPs, such as 
hnRNP A2/B1 (Buratti and Baralle, 2001). 
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TDP-43 also interacts with microtubules in the microtubule dependant transport of mRNP 
granules (Kanai et al., 2004; Alami et al., 2014). Approximately 30 TDP-43 mutations have been 
reported, all of which involve a missense substitution, and make up 4% of fALS cases and a 
small percentage of sALS (Ticozzi et al., 2010). The majority of TDP-43 mutations are located in 
the glycine rich c-terminal domain, suggesting that this may impact hnRNP interactions and thus 
promote aberrant RNA metabolism and processing (Sofola et al., 2007; He et al., 2014). There is 
no current clear genotype-phenotype relationship, however, the A382T variant mutation has been 
shown to lead predominantly to a lower MN disease (Corrado et al., 2009). Mutated TDP-43 in 
fALS, as well as native and mutated TDP-43 in sporadic cases, mislocalises from the nucleus to 
the cytoplasm and forms cytoplasmic inclusions (Neumann et al., 2006). Aggregated TDP-43 
found in inclusion bodies is abnormally phosphorylated (Hasegawa et al., 2008), and are found in 
the cortex of the majority of ALS/FTD patients (Ito and Suzuki, 2011). Two main theories 
regarding the role TDP-43 plays in ALS pathogenesis have been put forward. Either the change 
in distribution of TDP-43 from the nucleus, to cytosolic aggregates, is impeding its normal 
nuclear function and/or that TDP-43 aggregates develop a toxic gain-of-function that is 
independent of the proteins normal physiological activities (Lagier-Tourenne et al., 2010; Strong, 
2010; Ticozzi et al., 2010).  
 
Mutations to the gene encoding fused in sarcoma (FUS) on chromosome 16p12.1-q21, have also 
been linked to the development of familial ALS. Pathology includes cytoplasmic inclusions in the 
cortex and spinal cord with neuronal cell loss (Kwiatkowski et al., 2009; Vance et al., 2009). The 
FUS gene encodes for a DNA/RNA binding protein which was originally isolated in cancer-
associated fusion genes, described by Crozat et al. 2003, in their study of mesenchymal tumours 
(Crozat et al., 1993). Studies of ALS cohorts show a disease distribution of approximately 4% of 
fALS cases and 1% of sALS cases, which display a mutated FUS genotype (Belzil et al., 2009; 
Baumer et al., 2010; Yan et al., 2010). The majority of FUS mutations in ALS are missense 
mutations, and the rest being non-sense or frame shift mutations (Ticozzi et al., 2011). 
 
Similar to TDP-43, FUS is localised to the nucleus where it acts to regulate gene expression, with 
implications for gene transcription, splicing and mRNA transport (Kwiatkowski et al., 2009; 
Vance et al., 2009; Dormann et al., 2010). Furthermore, FUS is mislocalised to cytoplasmic 
inclusions due to a loss of nuclear import signalling (Morohoshi et al., 1998; Zakaryan and 
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Gehring, 2006; Dormann et al., 2010). FUS nuclear import disruption appears to promote disease 
progression, as the extent of the blockage of nuclear import can be correlated to the disease 
severity; severe disruption results in an earlier disease onset and faster progression (Dormann and 
Haass, 2011).  However, FUS mutations do not seem to be detrimental to its normal 
physiological function, as it can still bind its RNA targets (Kwiatkowski et al 2009). It is 
hypothesised that FUS positive cytoplasmic inclusions, the loss of nuclear FUS and thus its 
ability to participate in its normal nuclear functions, may contribute to ALS related pathogenesis 
(Ticozzi et al., 2011).  
 
As methods of analysis and new technologies progress into the molecular world, an increased 
number of ALS associated mutations in vastly different genes have been identified. In 2011, three 
independent studies identified the hexanucleotide repeat expansion (G4C2) of the non-coding 
region of reading frame 72 on chromosome 9 (C9ORF72); a mutation that occurs in both 
sporadic and familial ALS/FTD, at greater frequency than other previously known mutations 
(DeJesus-Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012). Initially it was 
postulated that this abnormal mRNA transcript was cytotoxic, however the exact mechanism of 
pathogenesis remains unclear (DeJesus-Hernandez et al., 2011).  More recently it has been 
proposed that the presence of the repeat expansion results in ‘unconventional translation’ 
generating intranuclear RNA foci (Ash et al., 2013; Todd and Petrucelli, 2016). This leads to 
G4C2 hexanucleotide repeat proteins, which accumulate in neurons, and are neurotoxic (Lee et al., 
2013b; Mori et al., 2013). Indeed, C9ORF72 transcripts show striking homology to signalling 
molecules called guanosine nucleotide exchange factors (GEFs) that can impact a vast number of 
intracellular signalling cascades (Levine et al., 2013; Droppelmann et al., 2014). Interestingly, 
C9ORF72 has been shown to intact in the TDP-43/hnRNP A2/B1 RNA processing pathway, 
without direct interaction with TDP-43 (He et al., 2014). It was shown that mutations in 
UBQLN2, which codes for ubiquilin 2 (regulator of degradation of ubiquinated proteins), cause 
dominant X-linked ALS/Dementia pathology (Deng et al., 2011). This was hypothesised by 
Deng, et al (2011) to lead to impairment in protein degradation, abnormal protein aggregation 
and neurodegeneration. As these genetic abnormalities have only recently been discovered, their 
function and pathogenesis in ALS is yet to be determined. 
 
Whilst the majority of fALS follows a dominant pattern of inheritance, mutations to alsin (ALS2) 
have been found to exhibit a recessive pattern of inheritance (Hadano et al., 2001). Mutations in 
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the ALS2 gene have been associated with the development of juvenile onset ALS, as well as a 
range of other conditions such as primary lateral sclerosis and hereditary spastic paraplegia (HSP) 
(Eymard-Pierre et al., 2002; Panzeri et al., 2006), with 12 different mutations identified to 
contribute to the development of such conditions (Chandran et al., 2007). Many of these 
mutations result in a premature stop codon, rendering the ALS2 protein non-functional 
(Yamanaka et al., 2006). ALS2 is a guanine nucleotide exchange factor, which promotes 
guanosine diphosphate (GDP) release and guanosine triphosphate (GTP) binding onto target 
proteins, as well as the stimulation certain signalling cascades (Tudor et al., 2005).  ALS2 
mutations have been suggested to contribute to the pathogenicity of ALS through the disruptions 
of Rab5-dependent exocytosis, endosome trafficking and also glutamate associated 
excitotoxicity, which is considered a hallmark of ALS pathology (Devon et al., 2006; Hadano et 
al., 2006; Lai et al., 2006).  
 
Although this chapter has discussed the major ALS causing mutations, it is appreciated that there 
are many mutations that occur at lower frequency, but are still vitally important in understanding 
disease pathogenesis (as shown in Figure 1.3). Indeed, it is becoming increasingly apparent that 
mutations to proteins that are associated with key structural and functional processes can act as a 
primary driver of pathology in ALS. Familial mutations to proteins associated with microtubules, 
a cytoskeletal element, have been recently identified as the cause of an increasing number of 
fALS cases (Munch et al., 2004; Munch et al., 2005; Levy et al., 2006; Laird et al., 2008; Smith 
et al., 2014). The downstream effects of such mutations will be discussed in later sections of this 
introductory thesis chapter. 
1.2 Motor neurons and non-cell autonomous processes in ALS 
A relatively new concept of selective MN cell death is the involvement of non-cell-autonomous 
processes (Ilieva et al., 2009; Peters et al., 2015). Expressing mutant SOD1 in MNs alone does 
not usually lead to ALS like neuropathy; in some cases it extends the duration of disease 
progression (Clement et al., 2003; Bruijn et al., 2004). This suggests that ALS is not a cell 
autonomous disorder, meaning that damage to the MNs alone does not suffice to produce the 
disease phenotype (Figure 1.4) (Ilieva et al., 2009). Whilst other neuronal populations, such as 
interneurons (Clark et al., 2015), are increasingly being implicated in the pathogenesis of ALS,  
this thesis will focus on spinal neuromuscular circuitry associated cell types, for which there are 
select cellular populations implicated in disease. 
FIGURE 1.4. ALS is recognised as a non-cell autonomous disease. Although motor 
neurons are the cell type whose demise facilitates the clinical phenotype of ALS, 
astrocytes, microglia, myelinating oligodendrocytes and schwann cells, endothelial 
cells and skeletal muscle all play a role in the development and progression of the 
disease. These findings have generally been determined by selectively removing 
mutant SOD1 from these key cell types and evaluating changes to the phenotype of 
the ALS model, typically in the SOD1G93A mouse. 
Adapted from Ilieva et al., 2009
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1.2.1 Glia play an active role in the pathogenesis of ALS 
Glia have been found to have a key role in the pathogenesis in ALS, particularly through 
investigations utilising the SOD1G93A mouse model (Radford et al., 2015). Glia are the non-
neuronal cells of the CNS and are responsible for providing growth factors, a supportive 
framework, monitoring of the CNS environment and the formation and selective transport of the 
blood brain barrier. In 2003 Clement and colleagues reported that mice expressing mSOD1 in 
selective populations of glia developed ALS pathology in the MNs that were surrounded by these 
affected glia (Clement et al., 2003). It was shown that it is not sufficient for MNs, which were 
engineered to be the only cell type to carry mSOD1 through a Cre recombinase system, to 
develop ALS pathology. These results suggest ALS may not be a cell autonomous disorder, 
relying on dysfunctions in non-neuronal cells to produce a disease phenotype. Interestingly, the 
development of axonal swellings and the resulting dysfunction in axonal transport has also been 
attributed to defective neuron-glia crosstalk (King et al., 2011). Moreover, the phenomenon of 
‘reactive gliosis’ occurs in ALS, involving astrocyte activation and microglial proliferation, 
which is localised to areas of neuronal and axonal degeneration (Brettschneider et al., 2012; 
Radford et al., 2015). 
 
Astrocytes are a supporting glial cell with a plethora of functions, with a role in MN upkeep and 
homeostasis. Astrocytes play a crucial role in preventing MN over stimulation by excitatory 
neurotransmission (Howland et al., 2002; Ilieva et al., 2009; Yang et al., 2009). Indeed, 
astrocytes can directly impact MN receptor expression; for example, they promote the expression 
of Ca2+ permeable glutamate receptors in neighbouring MNs (Van Damme et al., 2007). 
Activated astrocytes are also found surrounding degenerating MNs (Zagami et al., 2009) and 
astrocytes isolated from fALS and sALS patients are toxic to control MNs in vitro (Haidet-
Phillips et al., 2011), suggesting astrocytes form a degenerative environment for MNs in ALS. 
This toxicity was subsequently established to be driven by the secretion of neurotoxic factors 
from astrocytes of ALS patients, which activated necroptotic pathways in human MNs, leading to 
selective MN demise (Re et al., 2014). Further supporting that astrocyte toxicity can drive ALS 
pathology, Meyer and Colleagues (2014) showed that C9ORF72 and SOD1 mutant containing 
induced pluripotent stem cells (iPSCs) derived from fALS and sALS patients are also toxic to 
human MNs (Meyer et al., 2014). Conversely, transplantation of astrocytes lacking ALS 
mutations improves MN survival in a SOD1 mouse model of ALS (Kondo et al., 2014). Indeed, 
mice with selective SOD1 removal from astrocytes show a slower disease progression 
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(Yamanaka et al., 2008). These studies highlight that MNs are vulnerable to mutant ALS 
astrocytes, and that astrocyte expression of mutant proteins is sufficient to cause an ALS 
phenotype (Tong et al., 2013; Radford et al., 2015). 
 
Microglia are typically thought of as the resident immune cells of the CNS (Schafer et al., 2012), 
however, they also play a role in synaptic pruning, axonal upkeep and debris clearance (Paolicelli 
et al., 2011; Schafer and Stevens, 2013; Davis et al., 2014). They are involved in the 
neuropathology of ALS, with microglia activation occurring before MN loss (Henkel et al., 2004) 
and reviewed in (Brites and Vaz, 2014). However, it is unclear whether their activation 
(microgliosis) is a direct cause of the disease, or if it is a result of the disease (Boillee et al., 
2006a; Gowing et al., 2008). Mice with selective elimination of mutant SOD1 from microglia 
have a slower disease progression (Boillee et al., 2006b). Moreover, slowing of disease 
progression is produced in mice treated with the tetracycline derivative compound minocycline 
(Yrjanheikki et al., 1999). The attributed main factor of minocycline treatment is its ability to 
reduce macrophage activation (Kriz et al., 2002). However, whilst minocycline is a microglia 
deactivator, is also induces anti apoptotic effects in neurons, therefore it is difficult to determine 
the true effect of microglia on disease progression in ALS (Zhu et al., 2002). More recently, a 
mutant variant in the gene TREM2 was a risk factor for sALS (Thrash et al., 2009). TREM2 codes 
for the TREM2 protein, which is a constituent of the microglial specific signalling complex 
involved in generating the ‘neuroprotective’ microglial phenotype (Takahashi et al., 2005). The 
hypothesised loss of TREM2 function is suggested to aberrantly alter the inflammatory response 
in ALS, resulting in a decrease in phagocytosis and cytokine signalling (Kleinberger et al., 2014). 
Dysfunctional microglial phagocytosis has also been implicated in mutant progranilin (GRN) - 
linked FTD (Petkau and Leavitt, 2014), and loss of function mutations to profiling 1 (PFN1) in 
associated fALS cases (Wu et al., 2012). This suggests that microglial dysfunction can drive ALS 
pathophysiology, with a variety of ALS mutations effecting normal microglia function. 
 
Oligodendrocytes and Schwann cells are responsible for the myelination of axons in both the 
CNS and PNS, respectively. They play a role in the pathogenesis of ALS, with studies indicating 
abnormal myelination of axons in both ALS patients (Hayashi et al., 2001) and also in SOD1G93A 
transgenic rat models (Niebroj-Dobosz et al., 2007). Indeed, TDP-43 and FUS aggregates have 
been described in the cytoplasm of oligodendrocytes from both fALS and sALS cases (Zhang et 
al., 2008b; Seilhean et al., 2009; Nonneman et al., 2014). Recently, it has been identified that the 
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whilst oligodendrocyte loss is an early event in ALS pathogenesis, the inability of precursor cells 
to mature and remyelinate motor axons may compound the effects of oligodendrocyte 
dysfunction in ALS (Kang et al., 2013). In 2009, Keller and colleagues developed a GFAP-
luc/SODG93A mouse model; through which GFAP up regulation in Schwann cells could be 
visualised in vivo utilising live imaging techniques (Keller et al., 2009). Schwann cells associated 
with distal axons of a-MNs show increased levels of GFAP, growth-associated protein-43, low-
affinity nerve growth factor (NGF), the p75 receptor and nestin throughout disease progression, 
suggesting a link between peripheral axon pathology/degeneration and Schwann cell stress 
(Keller et al., 2009; Arbour et al., 2017). Interestingly terminal schwann cells associated with 
denervated NMJs have been shown to extend processes to innervated NMJs, forming ‘bridges’ 
and promoting nerve terminal sprouts (O'Malley et al., 1999; Tallon et al., 2016). Further, 
terminal schwann cells require pre-synaptic acetylcholine release to stimulate repair and 
maintenance of NMJs; a process that is impaired in ALS due to nerve terminal retraction and 
denervation (Arbour et al., 2017). Schwann cell involvement at the NMJ is summarised further in 
section 1.3.4 of this thesis. 
 
An further interesting avenue of research could follow on from a study by Court and Colleagues 
(2008), who described the role of capping cells (kranocytes) in the formation and upkeep of 
NMJs (Court et al., 2008). Their role in ALS pathogenesis has not yet been investigated, and as 
NMJ loss is a pathological hallmark of ALS, it would be prudent to investigate this further. The 
close link of a-MNs and their processes with their surrounding cellular environment, particularly 
neuron-glia interactions and the possible mechanisms at play between the two could result in 
disease development (King et al., 2011). 
1.2.2 Skeletal muscle as an instigator and bystander of disease 
The guidance of developing a-MNs and subsequent innervation of skeletal muscle relies on a 
combination of intrinsic neuronal electrochemical cues (Kastanenka and Landmesser, 2010), and 
extrinsic cues such as ephrin mediated motor axon patterning on muscles (Feng et al., 2000a), 
and tropic factors which induce nerve-muscle branching (Sakuma and Yamaguchi, 2011). Muscle 
development results in functional syncytia of myoblasts (myotubes), which histologically appear 
as large cells with multiple nuclei. Each muscle fibre has one connection (through a NMJ), with a 
single a-MN being able to innervate multiple muscle fibres, creating a functional motor unit. 
These motor units can contract together, creating a directionally orientated and controlled 
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contractile force, which is dependent on the fibre type and the number of fibres presents 
(Gillingwater and Ribchester, 2003). The NMJ, signalling events that lead to muscle contraction 
and description of the pre and post-synaptic apparatus will be discussed shortly. 
 
Muscle weakness, followed by subsequent muscle atrophy, is the first symptomatic signs of ALS 
(Ngo et al., 2012; Lee et al., 2017a). Loss of muscle mass does not always correlate fully with the 
loss of NMJs and distal portions of axons in ALS, suggesting a possible compensatory event 
occurring (Gonzalez de Aguilar et al., 2008). There are currently two hypotheses surrounding a-
MN and skeletal muscle involvement in ALS neuropathy. The first is that ALS begins in the 
skeletal muscle; with a-MN and NMJ degeneration due to the loss of skeletal muscle mass and 
activity. Evidence to support this was presented by Teng and Tang (2008), who described 
increased expression levels of the neurite growth inhibitor Nogo-A, with increased levels of 
disease severity, suggesting skeletal muscle may initiate or regulate neuronal degeneration as 
seen in ALS (Teng and Tang, 2008). Moreover, a study by Wong and colleagues expressed 
mutant human SOD1 selectively in the muscle of mice, which lead to lower a-MN loss, and a 
motor phenotype similar to models where SOD1 is expressed ubiquitously (Wong and Martin, 
2010). However, others showed that depleting SOD1 synthesis in muscle alone does not alter any 
facet of disease progression or pathology (Towne et al., 2008), suggesting that the impact of 
muscle on disease pathogenesis is significantly less than the CNS, but is still sufficient to cause 
degeneration when expressed in muscle alone (Dobrowolny et al., 2008; Wong and Martin, 
2010). Regardless, it is appreciated that mutant SOD1 causes muscle pathology, however the 
sequence of these events remains poorly understood. Others have highlighted that factors released 
from muscle can impact on both the denervation and reinnervation potential of the distal 
neuromuscular circuitry, particularly surrounding the promotion of collateral branching 
(Williams et al., 2009; Taetzsch et al., 2017). Interestingly, in the SOD1G93A mouse model of 
ALS the muscle-specific microRNA miR-206 it unregulated, which promotes compensatory 
regeneration of the neuromuscular circuitry through histone deacetylase 4 and fibroblast growth 
factor signalling pathways (Williams et al., 2009). Conversely, the expression of fibroblast 
growth factor binding protein 1 (FGFBP1) decreases at the NMJ prior to denervation in 
SOD1G93A mice. These studies emphasise the importance of muscle dependant signalling in ALS 
pathogenesis.    
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Conversely, others believe that motor neuropathy is the initial driving force behind ALS, 
resulting in muscle atrophy due to a loss of neuronal innervation (Miller et al., 2006). A-MNs in 
the SOD1G93A mouse model are hyper active, resulting in an increased release of Ach at their 
respective NMJs (Rocha et al., 2013). Indeed, Ach and other AchR agonists increase AchR 
endocytosis (St John and Gordon, 2001); a process that is inhibited by pre-synaptic release of 
neuronal agrin (Misgeld et al., 2005). This suggests that over activation of the NMJ may mediate 
receptor dispersal (Morsch et al., 2013) and decrease synaptic strength (Zhu et al., 2011), leading 
to NMJ degeneration. 
 
It has also been identified that NMJs are plastic; meaning they can regulate and change the fibres 
they innervate, the muscle fibre type and also increase and decrease the size of the motor unit 
(Frey et al., 2000; Santos and Caroni, 2003; Pun et al., 2006). This is suggestive of an innate 
compensatory mechanism available to skeletal muscle. It also poses the problem of determining 
the pathological relevance of NMJ alterations during disease progression, with correlations 
between NMJ pathology and ALS neuropathy being skewed by this ability to re-innervate 
skeletal muscle. Indeed, the sequence of pathological events that transpires in both the pre and 
post synapse in ALS, particularly in comparison to each other remain elusive. It is yet to be 
determined whether pathology in the NMJ presynaptic compartment (of the a-MN) occurs prior 
to that of the postsynaptic muscle, and whether alterations, if any, occur prior to that of disease 
onset. Investigations into this problem will highlight early pathology of the distal synapse and 
cellular components, and hopefully elucidate therapeutic targets to improve pathological 
outcomes. 
1.3 Vulnerability and pathology of motor neurons in ALS 
The vulnerability of select, individual populations of neurons is a key feature in many 
neurodegenerative diseases. Indeed, the aforementioned mutations that occur in ALS highlight 
that MNs are selectively vulnerable to multiple insults, with the end result being MN dysfunction 
and degeneration. However, the inherent vulnerability of MNs to mutations found in ubiquitous 
proteins such as SOD1 and TDP-43 and their aggregation is not fully understood. Contributing 
factors which may result in this selective vulnerability of affected MNs in ALS can include their 
large cell size (energy dependency), intracellular transport, their excitable nature coupled with a 
lack of buffering capacity, their intimate relationship with neighbouring non-neuronal cells as 
well as mRNA trafficking and distribution for localised protein production (Ilieva et al., 2009; 
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Ferraiuolo et al., 2011). Indeed, the narrow margin for MN cellular homeostasis may increase 
their vulnerability to the numerous ALS associated mutations, such as to SOD1, TARDBP, FUS 
and Alsin. Many proteins associated with ALS pathogenesis converge on mechanisms and targets 
in MNs that either regulate or effected signalling cascades and normal neuronal function. This 
can occur as a result of the proteins normal role in various signalling cascades, or through 
mutation dependant gain of function. This will be discussed in subsequent sections regarding the 
microtubule cytoskeleton. 
 
1.3.1 Somatic intracellular inclusions as a hallmark of ALS pathology 
A key theme in the pathology of ALS is the deposition of ubiquinated intracellular inclusions (or 
aggregates) in MNs (Leigh et al., 1988). Indeed, historically ALS was classified as a neurological 
proteinopathy. Intracellular inclusions occur as the direct result of protein mutations, or as the 
downstream effect of particular pathological mechanisms, which drive wild-type proteins to 
deposit in the cell due to abnormal cleavage or posttranslational modifications such as aberrant 
ubiquitination or hyper phosphorylation (Peters et al., 2015). As mentioned previously, misfolded 
SOD1 forms inclusions in a-MNs of both fALS patients harbouring SOD1 mutations, but also in 
many sALS patients (Shibata et al., 1994; Forsberg et al., 2010; Grad et al., 2014). It has also 
been established that oligomeric misfolded SOD1 is more cytotoxic than larger inclusions 
(Redler et al., 2014), with increasing evidence that misfolded SOD1 can be directly transmitted 
between cells in a ‘prion-like’ mechanisms of propagation throughout the CNS (Grad et al., 
2014).  
 
TDP-43 also forms intracellular inclusions that are both ubiquitinated and hyperphosphorylated 
in most cases of fALS, sALS and FTD, with TDP-43 mislocalising from the nucleus to the 
cytoplasm (Neumann et al., 2006). Increasing evidence suggests that TDP-43 mislocalisation 
may drive the aggregation of these proteins, as mutations to the c-terminus of the protein results 
in increases protein-protein interactions, thus increased aggregation (Pesiridis et al., 2009; 
Mutihac et al., 2015). Whilst it is still yet to be determined whether TDP-43 is a gain of function 
due to aberrant cleavage and aggregation of the protein, or a loss of its normal function, it is 
widely appreciated that pathological TDP-43 plays a distinct role in the pathogenesis of ALS 
(Pokrishevsky et al., 2012). Similar to misfolded SOD1, pathogenic TDP-43 has been described 
as a ‘prion-like’ protein, with the ability to propagate through the CNS circuitry, causing further 
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TDP-43 pathology in unaffected cells (Zhang et al., 2009; Budini et al., 2012; Feiler et al., 2015). 
Mutant FUS, similar to TDP-43 and SOD1, has been identified in intracellular inclusions of both 
the cortex and spinal cord of fALS, sALS and FTD patients (Kwiatkowski et al., 2009; Vance et 
al., 2009), but not in patients with SOD1 mutations (Deng et al., 2010).  
 
As described in previous sections, the C9ORF72 G4C2 expansion produces repeat peptides, which 
have the capacity to generate inclusions. However, C9ORF72 inclusions in MNs due to aberrant 
translation of the dipeptide repeat are rare in patients with the G4C2 repeat expansion; these 
patients show robust TDP-43 aggregation (Gomez-Deza et al., 2015). The role inclusions play in 
MN dysfunction and degeneration is still poorly understood. However, a number of mechanisms 
of aggregate-mediated toxicity have been proposed. These include aggregates having an innate 
ability to inhibit proteosome function and protein degradation, decreased chaperone activity and 
disruption to global organelle function (Rothstein, 2009; Ferraiuolo et al., 2011). Indeed, 
cytoplasmic inclusions have also been implicated in causing axonal transport dysfunction, which 
has ramifications for axonal, and ultimately MN, survival (Bosco et al., 2010). 
1.3.2 Axonal inclusions in ALS 
A pathological hallmark of ALS is the formation of neurofilament inclusions or ‘swellings’ in the 
axons of a-MNs, a pathology that is though to physically hinder axonal transport (Hirano et al., 
1984; Bilsland et al., 2010).  Neurofilamentous swellings have been described in the axons wild-
type and mutant SOD1 neurons in vitro and have been demonstrated to induce cytoskeletal 
changes (King et al., 2011). Axonal swellings are also immunoreactive for neurofilament triplet 
proteins and peripherin (Wong et al., 2000), neurofilament-L, neurofilament-M, neurofilament-H, 
α-internexin and in some inclusions, ubiquitin (King et al., 2011). Converse to the pathological 
functions of neurofilament swellings, others have hypothesised that axonal neurofilament 
inclusions may in fact be neuroprotective, acting as a phosphorylation ‘sink’, thus reducing 
aberrant phosphorylation of other more vulnerable intracellular targets (Nguyen et al., 2001). 
Regardless of pathological significance of neurofilaments, axons are a primary site of 
degeneration in ALS, and may be an early event with a large capacity for therapeutic 
intervention. 
1.3.3 Axonal degeneration in ALS 
There are several described methods of axon degeneration, including axon die-back, Wallerian 
degeneration and axonal pruning. Wallerian degeneration is the mechanism that occurs as a result 
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of a transection or crushing injury to the distal portion of an axon (Gillingwater and Ribchester, 
2003). Dying-back of the axon, starting at its most distal region and spreading towards the cell 
body, is a common theme in neurodegenerative diseases (Coleman, 2005). In ALS, axonal die-
back is typical of NMJ and distal axon pathology, leading to a loss of motor units and atrophy of 
the denervated muscle (Pun et al., 2006; Fischer and Glass, 2007). Evidence from both patients 
and ALS disease models suggest that ALS is a dying-back axonopathy; an active and controlled 
process (Fischer et al., 2004; Pun et al., 2006; Vickers et al., 2009; Clark et al., 2016b). This is 
thought to occur independently of the cell soma (Coleman, 2005; Saxena and Caroni, 2007). 
 
Interestingly, similarities exist between axonal degeneration seen in neurodegenerative diseases 
and normal phasic pruning of neuronal processes in normal circuitry growth and maintenance 
(Yaron and Schuldiner, 2016). For example, the Ubiquitin Proteosome System (UPS), the 
intracellular system responsible for protein metabolism and recycling, is used to degrade and alter 
the proteinacious axonal structure prior to membrane disintegration; similar processes occur in 
ALS during axon degeneration (Watts et al., 2003). However, axonal degeneration initiated by 
Wallerian mechanisms is thought to begin with a loss of axonal survival factors, either by 
physical blockage of the axon or by a decrease in axonal transport (Pun et al., 2006; Wang et al., 
2012). Although still not fully understood, this loss of survival factors, including trophic 
signalling (Taetzsch et al., 2017), mRNA, and energy depletion due to decrease mitochondria 
recycling, lead to a localised increase in intracellular calcium in the axon (Coleman, 2005). 
Cytoskeletal disintegration is one of the first identified signs of Wallerian degeneration, 
particularly the neurofilament and microtubules networks (Griffin et al., 1995; Watts et al., 2003; 
Zhai et al., 2003). However, the precise timeline of these events in ALS are unknown. Indeed, 
over a decade after these initial observations, our understanding of the process of cytoskeletal 
disintegration in axonal degeneration remains limited. Nevertheless, it is appreciated that a sharp 
rise in intracellular calcium in the axon activates caspases and calpain enzymatic pathways, 
leading to protein degradation and cytoskeletal abnormalities (as both neurofilaments and 
microtubule proteins are caspase/calpain substrates), and has been reviewed previously (Watts et 
al., 2003; Wang et al., 2012; Ma, 2013).  
 
The first clinical sign of ALS is muscle weakness, which is attributed to the loss of muscle 
innervation by MNs as a result of axon degeneration (Boillee et al., 2006a). Axonal degeneration 
by Wallerian mechanisms starts with axonal beading, a result of cytoskeletal proteins being 
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dismantled. The axon then fragments, with surrounding glia removing the axonal debris 
(reviewed in (Coleman, 2005)). The initial insult that results in axonal degeneration can be due to 
metabolic stress, axonal transport dysfunction, ischemia and neuroinflammation, as stated 
previously. However, it is increasingly being appreciated that compensatory responses to axonal 
and synaptic degeneration occur in ALS.  The reinnervation of recently denervated synapses to 
maintain muscle function has been shown to occur in ALS (Schaefer et al., 2005; Pun et al., 
2006; Clark et al., 2016b), thus illuminating the extended asymptomatic stage of the disease that 
may begin decades before symptoms are apparent. Axon pruning is a intrinsic form of functional 
remodelling and rearrangement of neuronal processes in the developing central nervous system 
through the destruction of redundant or excessive amounts of synapses (Katz and Shatz, 1996; 
Luo and O'Leary, 2005). Indeed, axons in ALS show plasticity via their ability to collaterally 
branch, forming new axonal offshoots and innervating recently denervated endplates; a 
characteristic of ALS pathology (Pun et al., 2006; Ketschek et al., 2015b; Clark et al., 2016b). 
This ability of the neuromuscular circuitry to maintain this plastic, reinnervative state is thought 
to lose its efficiency, leading to an environment where neuromuscular loss exposes a clinical 
phenotype.  
1.3.4 NMJs and ALS  
As mentioned previously, NMJs are the anatomical connections between the nervous system and 
muscle, and are located at the terminus of motor axons, ending on a motor unit. They are a part of 
a two-way interface of communication that includes orthograde depolarisation events that initiate 
muscle contraction; and retrograde transmission, which is involved in neurotrophic signalling, 
leading to regulation and functional adjustments to the a-MN (Northcutt, 1989). Contraction of 
the muscle is firstly initiated by the a-MN (presynaptic compartment), which stimulates the NMJ 
to release the neurotransmitter acetylcholine (ACh) into the synaptic cleft (Figure 1.5). ACh 
binds to cholinergic receptors, a specifically nicotinic receptor subtype, on the muscle cell 
surface. Upon receptor activation, Na+ is diffused across the receptor, which in itself is a voltage 
gated ion channel, leading to a depolarisation event in the muscle (Martyn et al., 2009). This 
event is called an excitatory post-synaptic potential (EPSP), or more specifically to the muscle 
fibre, an endplate potential. If the EPSP is large enough, a postsynaptic action potential in the 
muscle will occur, leading to the release of internal calcium stores and contraction of the muscle 
fibre through contractile protein (actin and myosin) activation (Bear and Connors, 2007; Martyn 
et al., 2009). 
FIGURE 1.5. The NMJ consists of the pre-synaptic motor neuron end terminal, basal 
lamina, synaptic cleft, and the post-synaptic myocyte. It is made up of a plethora of 
pre- and post-synaptic proteins that are involved in the development, maintenance and 
stability of the synapse. Many trans-membrane and cytosolic post-synaptic proteins 
are involved in initial NMJ formation through signalling, such as the Agrin-LRP4-
MuSK signalling complex, as well as structural support through proteins such as 
rapsyn and nestin.   
Adapted from Ghazanfari et al, 2011
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The development and maturation of the NMJ is a complex process. A pioneering study by Sanes 
and Colleagues (1978) showed that reinnervating frog motor nerve terminals, in specimens that 
have had their associated muscle removed, form new active zones on the basal lamina at original 
synaptic sites (Sanes et al., 1978). This suggested that the synaptic basal lamina contains the 
components that play a pivotal role in NMJ differentiation. Subsequent studies have identified 
that this process involves tri-directional cross talk between the presynaptic a-MN, the 
postsynaptic muscle fibre and perisynaptic schwann cells (PSCs) (Shi et al., 2012; Darabid et al., 
2014). Guidance of the terminal a-MN axons are controlled primarily by molecular ‘cues’ that 
occur along the path of the axon (Tessier-Lavigne and Goodman, 1996). Muscle fibres destined 
to be innervated by approaching axons already show basal levels of postsynaptic maturation, with 
expression, and in many cases clustering (pre-patterning) of AChRs on the cell surface (Lin et al., 
2001; Yang et al., 2001). Once contacted with muscle, axons will innervate the muscle fiber, with 
multiple axons being able to innervate one NMJ (polyinnervation) (Wyatt and Balice-Gordon, 
2003). Following this, maturation of the synapse ensues, with alterations to the presynaptic and 
postsynaptic compartments, as well as controlled synaptic elimination to obtain mature NMJs 
innervated by a single axon. Presynaptic maturation, whilst being the least understood process of 
NMJ development, involves the contribution of structural and signalling molecular in the 
synaptic end terminal and lamina. For example, the laminin family of glycoproteins have many 
isoforms and subunits involved in NMJ maintenance and stability. Laminin laminin-beta2 is the 
laminin isoform involved in the enhancement and clustering of P/Q voltage gated calcium 
channel ‘active zones’ at the NMJ (Knight et al., 2003; Nishimune et al., 2004; Chand et al., 
2015). A decline in laminin-alpha4 expression results in both the pre- and post-synaptic function 
and stability (Chand et al., 2017), and its absence accelerates NMJ aging and fragmentation (Lee 
et al., 2017b). Further roles of laminins are the orchestration of synaptic vesicle clustering, 
prevent PSC invasion (Knight et al., 2003), and the physical alignment of the synapse (Patton et 
al., 2001).  
 
Indeed, similar mechanisms of presynaptic maturation are also regulated by type IV collagen 
(Miner and Sanes, 1994), and type XIII (Latvanlehto et al., 2010). Synaptic vesicle clustering in 
the pre-synaptic terminal can also be regulated by signal regulatory protein-α, suggesting that 
multiple presynaptic lamina proteins are necessary for presynaptic maturation (Umemori and 
Sanes, 2008). The involvement of extracellularly active growth factors has also been implicated 
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in NMJ maturation. For example, fibroblast growth factors (FGFs), which are produced primarily 
by muscle, promotes presynaptic vesicle clustering and synaptic varicosities (Fox et al., 2007). 
Similarly, glial-derived neurotropic factor (GDNF), produced by both muscle and Schwann cells, 
promotes a-MN survival by retrograde signalling (Henderson et al., 1994). Interestingly, brain-
derived neurotropic factor (BDNF), which is found in precursor (Pro-BDNF) and mature 
(mBDNF) form, shows vastly different effects dependant on processing. Pro-BDNF promotes 
synaptic elimination, whereas mBDNF favour synaptic maturation and survival (Je et al., 2013). 
 
Postsynaptic maturation of the NMJ involves dynamic alterations to receptors and architectural 
proteins in relation to synaptic activity and various signalling mechanisms. For example, synaptic 
activity, driven by Ach concentration at both the terminal, can alter the expression and clustering 
of AChRs on the postsynaptic membrane (Misgeld et al., 2005). Indeed, as discussed in Section 
1.2.2 of this thesis, activity at the NMJ promotes its maturation, whereas hyper-activity of AchRs 
can promote their dispersal; a process that is countered by the activation of the agrin-LRP4-
MuSK signalling complex, the main pathway of postsynaptic maturation (St John and Gordon, 
2001; Misgeld et al., 2005). Agrin, a proteoglycan released from a-MN synaptic terminals, 
muscle and schwann cells (neuronal agrin is more potent), is a ligand for the low-density 
lipoprotein receptor-related protein 4 (LRP4) (Bowen et al., 1996; Burgess et al., 1999). 
Signalling through LRP-4, agrin causes muscle-specific tyrosine kinase (MuSK) 
autophosphorylation (DeChiara et al., 1996), which induce the clustering of AChRs. 
Interestingly, LRP-4 has also been implicated in MuSK independent retrograde signalling in 
concurrent presynaptic maturation (Yumoto et al., 2012). Postsynaptically, LRP-4 interaction 
with MuSK without the precedence of agrin can induce MuSK activation, synonymous with both 
LRP-4 and MuSKs role in the pre-patterning and surface recruitment of AChRs prior to 
presynaptic involvement (Kim et al., 2008; Darabid et al., 2014). MuSK activation also recruits 
scaffolding proteins such as rapsyn, which is responsible for maintaining the clustering of AchRs 
(Gautam et al., 1995; Gervasio and Phillips, 2005), and other important proteins, such as those in 
the dystroglycan complex (Darabid et al., 2014). Furthermore, maturation of the postsynapse 
apparatus corresponds with an increase in the expression of AChRs, rapsyn and MuSK (Jo et al., 
1995; Sandrock et al., 1997; Rimer et al., 1998). Of note is the involvement of laminins 
(mentioned previously as being involved in presynaptic maturation), in the stabilisation of 
AChRs in the membrane and in regulating aspects of ACh transmission (Jacobson et al., 2001; 
Arikawa-Hirasawa et al., 2002). 
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Although involved in the development and maintenance of NMJs, a number of the 
aforementioned proteins have been implicated in the generation of neuromuscular disorders. 
Autoantibodies that target AChRs, MuSK and LRP-4, as well as mutations to particular 
postsynaptic architectural proteins, have been implicated in the development of myasthenia 
gravis and various congenital neuromuscular diseases (Ohno et al., 2002; Li et al., 2010; Pilgram 
et al., 2010; Pevzner et al., 2012; Ohkawara et al., 2014). This highlights that the NMJ is a site of 
pathological vulnerability. In ALS the denervation of NMJs results in the clinical phenotypes 
associated with the disease, particularly progressive paralysis and muscle wastage. According to 
the distal ‘die-back’ hypothesis of the neuromuscular circuitry in ALS, NMJ and distal axon 
degeneration occurs prior to that of the a-MN cell body, with degeneration progressing in a 
distal-to-proximal direction; see extensive review (Moloney et al., 2014). Loss of motor units 
have been shown to occur in SOD1 transgenic mouse model (Maselli et al., 1993; Frey et al., 
2000; Clark et al., 2016b) and more recently has been shown that loss of synaptic terminals 
occurs via retraction of presynaptic components (McCann et al., 2007). 
 
Further, the neuromuscular circuitry shows vulnerability depending on the fibre type of the 
synapse, as well as the capacity for plasticity that synapse has (a fibre type is a neuromuscular 
unit, made up of a a-MN, NMJ and corresponding type specific muscle fibre). For example, fast-
fatigue synapses (corresponding to fast-fatigue a-MNs/NMJs and fast-fatigue muscle fibres), are 
the most vulnerable fibre type, and are lost early in the disease (Frey et al., 2000). Fast-fatigue 
resistant and slow fibre type NMJs are more resistant to degeneration, with a high capacity for 
remodelling in disease, reinnervating recently denervated synapses (Fischer et al., 2004; Pun et 
al., 2006). However, the capacity for firstly fatigue resistant, then later in disease slow fibre types 
to compensate for denervation wanes, resulting in a significant motor unit loss that unmasks the 
clinical phenotype of ALS (Hegedus et al., 2008). However, our understanding of NMJ 
degeneration is still not fully appreciated. For example, identification of early alterations to the 
presynaptic compartment of the NMJ is still incomplete; this information may allow for the 
development of novel therapeutics to target this structure. Further, the identification of 
pathological events that occur to the NMJs post-synaptic architecture is an area of research that 
has not been fully explored. Much of the research to date has focused on MuSK, with the 
importance of such architectural proteins highlighted by the significant improvement of SOD1 
mice when MuSK expression is increased, resulting in synaptic stabilisation (Perez-Garcia and 
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Burden, 2012). However, the attention given to MuSK has not been shown to other proteins of 
the post-synapse, specifically to those that stabilise and maintain NMJ integrity, such as rapsyn, 
dystrophin and nestin. Indeed, this highlights that NMJ architectural proteins require further 
research into their role in ALS pathogenesis, as they play a key a role in the demise of the NMJ in 
various neuromuscular disorders, and also possibly in ALS (Clark et al., 2016b). 
1.4 Microtubule involvement in ALS 
Neurons are highly refined communicating cells that receive, process and relay information to 
their target cells, with MNs being particularly vulnerable to ALS associated pathology. As 
discussed previously, factors contributing to the selective vulnerability of MNs in ALS include 
their large cell size and therefore energy dependency, their excitable nature coupled with a lack 
of buffering capacity, and their intimate relationship with neighbouring non-neuronal cells. 
Although many disease mechanisms have been described (reviewed in (Peters et al., 2015)), the 
impairment of the axonal transport system highlights the significance of the intracellular 
cytoskeleton, particularly the microtubules, in the neurodegenerative process. The role of this 
cytoskeletal system in ALS will be a focus of this thesis. 
1.4.1 Microtubules are integral to neuronal function 
Microtubules are structural cytoskeletal elements expressed in all eukaryotic cells. Their 
composition and general function is conserved between different cell types and organisms, and is 
essential for cell division and motility. Microtubules are of particular importance to neurons and 
are involved in a great number of additional functions including the development of neuronal cell 
polarity, the generation of neuronal compartments, growth cone mechanics, neurite remodelling 
and intracellular transport (Chen et al., 2006; Baas and Lin, 2011; Sakakibara et al., 2013). 
Within neurons, microtubules form protofilaments from heterodimerised tubulin. These 
cylindrical structures are vitally important for the function of long extending axons, which have a 
high demand for intracellular transport of organelles, proteins and RNA granules. Therefore, it 
can be said microtubules are essential to both the development and maintenance of the neuronal 
circuitry.  
 
Microtubule protofilaments are comprised of dimers of α and β-tubulin, which through lateral 
interactions, form the characteristic microtubule structure (Desai and Mitchison, 1997). 
Microtubules undergo bouts of assembly and disassembly from their ends, a process termed 
dynamic instability (Mitchison and Kirschner, 1984) (Figure 1.6 and 1.7 A). A slow growing α-
FIGURE 1.6. Microtubules are dynamic hollow polymers. (A) Microtubules are 
protofibrils comprised of polymerised α- and β-tubulin. They consist of a slow 
growing minus (-) end, and a fast growing plus (+) end. When not bound to the 
microtubule lattice, α- and β-tubulin exist together as heterodimers.  (B) Microtubules 
undergo the phenomenon of dynamic instability, with a fast growing phase, a stable 
‘paused’ phase, and a shrinking depolymerisation phase. 
Adapted from Conde and Caceres, 2009
FIGURE 1.7. Modifications to neuronal microtubules in ALS. A) Normal 
microtubule +TIP dynamics and kinesin/dynein transport, mRNA granule transport 
and chemical modifications. B) Mutant SOD1 expression leading to microtubule 
hyperdynamics, increased +TIP protein density, decreased transport, increased 
acetylation, phosphorylation of MAPs and accumulation of microtubule protein 
containing aggregates. A global increase in HDAC activity is also present. C) Mutant 
TDP-43 expression causes dysfunction in mRNA granule transport. Decreased local 
translation of MAP mRNA is also implicated in TDP-43 mutants. D) Mutant 
TUBA4A expression alters microtubule dynamics and network stability, with 
unknown impact on +TIP proteins, transport or chemical modifications. Select 
mutations are incorporated into intracellular aggregates. E) Energy depletion and 
calcium dysregulation generates increased microtubule depolymerisation, tubulin 
GTP cap hydrolysis, and increased MAP phosphorylation. F) Neuronal oxidative 
stress leads to tubulin glutathionylation, increased microtubule depolymerisation, 
decreased axonal transport and alterations to MAPs, with unknown impact on 
classical chemical modifications or +TIP proteins. 
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tubulin ‘minus-end’ and fast growing β-tubulin ‘plus-end’ (Allen and Borisy, 1974; van 
Beuningen et al., 2015; Yau et al., 2016) can be accounted for by the GTP cap model. GTP bound 
to β-tubulin confers plus end stability, and upon hydrolysis, leads to microtubule 
depolymerisation (Desai and Mitchison, 1997; Nogales and Wang, 2006). This directionality in 
microtubule structure allows the formation of neuronal compartments and therefore confers 
neuronal polarity. The axonal compartment has exclusively distal facing positive polarity, or 
‘plus-end out’ orientating microtubules (Heidemann et al., 1981). Contrastingly, the 
somatodendritic compartment contains a mixed orientation of microtubule directions, with equal 
quantities of plus and minus-end facing microtubules (Yau et al., 2016).  
 
Neurons, being relatively long-lived and stable cells, require a stable cytoskeleton. Neuronal 
microtubules can be separated into two domains: labile and stable (Baas and Black, 1990; Baas, 
2013). Whilst mature neurons have a microtubule network consisting of both domains, the 
majority of the microtubules are stable (Ferreira and Caceres, 1989; Lim et al., 1989). These 
domains cannot be fully explained by the myriad of tubulin isoforms available in the genome 
(Tischfield and Engle, 2010). This functional diversity has instead been associated with domain 
specific chemical modification to tubulin subunits, which aid in increasing the functionality of 
microtubules, and in some cases, can impact upon their stability (Baas, 2013; Janke, 2014).  
These modifications to neuronal microtubules include, but are not limited to, tubulin tyrosination, 
acetylation, polyamination, glutathyonilation, glutamylation and glycylation (reviewed 
previously in (Janke and Kneussel, 2010; Janke, 2014)). These post-translational modifications 
may confer stability to microtubule structure and alter binding affinity of microtubule associated 
proteins, thereby altering their function. Whilst not being fully understood, these chemical 
modifications can also be utilised as molecular markers of microtubule network stability, and 
alterations to chemical modifications are thought to be an attractive therapeutic target for 
neurodegenerative disorders (d'Ydewalle et al., 2011; Taes et al., 2013).  
 
Perturbations in microtubule and microtubule associated protein (MAP) function have been 
implicated in a range of neurodegenerative diseases (Dubey et al., 2015), including Alzheimer’s 
disease (AD) (Matsuyama and Jarvik, 1989), Parkinson’s disease (PD) (Ren et al., 2003; Cartelli 
et al., 2010), Huntington’s disease (HD), various congenital developmental disorders (Tischfield 
and Engle, 2010), schizophrenia (Morris et al., 2003; Andrieux et al., 2006), as well as ALS 
(Baird and Bennett, 2013; Smith et al., 2014). Of note the microtubule stabiliser, Tau (Drubin and 
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Kirschner, 1986), is involved in the pathophysiology of AD (reviewed in (McMurray, 2000; 
Hanger et al., 2014; Stancu et al., 2014)) as well as other neurodegenerative diseases (collectively 
tauopathies) such as supranuclear palsy, corticobasal degeneration and Picks disease, (reviewed 
in (Cairns et al., 2004)). Alterations to proteins involved in microtubule stability, dynamics and 
microtubule turnover also occur in PD (Alim et al., 2004; Yang et al., 2005; Gillardon, 2009). 
Similarly, microtubule involvement has also been established through 1-methyl-4-
phenylpiridinium (MPP+) (Cappelletti et al., 2005) and Rotenone (Ren et al., 2005) mediated PD 
in in vitro models, with these found to destabilise the microtubule network. Furthermore, it has 
been highlighted that perturbations to microtubule dynamics also leads to microtubule dependent 
transport impairment in a model of PD (Cartelli et al., 2010). The gene disrupted-in-
schizophrenia-1 (DISC-1), whose mutations are associated with familial forms of schizophrenia, 
has been suggested to associate and interact with microtubule components (Morris et al., 2003; 
Callicott et al., 2005), further implicating microtubule alterations as a causal factor in multiple 
neurodegenerative disorders. Conversely, mutations to tubulin genes generally leads to disorders 
associated with dysregulated neurogenesis, due to abnormalities in neuronal migration, cellular 
division of progenitor cells, neuronal differentiation and induction of cell polarity. These 
disorders include lissencephaly, polymicrogyria, mirocephaly, cerebellar dysplasia and some 
occulomotor disorders (Francis et al., 2006; Guerrini et al., 2008; Tischfield et al., 2011). 
In ALS the consequence of microtubule dysfunction has classically been hypothesised as being 
due to the physical length of the axon in affected MNs, with alterations to microtubules being 
thought to impact on axonal transport (De Vos et al., 2007; Millecamps and Julien, 2013). 
However, evidence for microtubule dysfunction having a primary role in ALS has significantly 
increased over the last 15 years. The recent identification of tubulin rare variants and their impact 
on microtubule function, specific interactions with mutant and pathological proteins as well as 
altered function of microtubule associated proteins and signalling pathways which affect 
microtubule dynamics, have all been implicated in ALS pathogenesis.  
1.4.2 The genetic inheritance of ALS: recent insights into microtubule function 
As the familial genetics of ALS become increasingly understood, microtubules and their 
functions are being identified as a site of pathological convergence for various ALS mutations. 
For example, it has long been established that SOD1 mutations can cause axonal transport 
dysfunction, thus suggesting an interaction with the microtubule network (Warita et al., 1999; 
Ligon et al., 2005; Bilsland et al., 2010; Ikenaka et al., 2012). This has been reported to occur as 
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early as embryonic day 13 in the SOD1G93A mutant mouse (Kieran et al., 2005). Recently, 
evidence has been published supporting the hypothesis that alterations to microtubule dynamics 
is driving MN dysfunction in these mice (Fanara et al., 2007; Kleele et al., 2014) (Figure 1.7 B). 
Indeed, mutant SOD1 has been implicated in the alteration of signalling cascades that may affect 
proper microtubule functioning, however, this process is still poorly understood (Evans et al., 
2000; Nguyen et al., 2001; Vadlamudi et al., 2005; Lopez-Fanarraga et al., 2007; Ikeda et al., 
2011; Zyss et al., 2011; Bunton-Stasyshyn et al., 2015). 
 
TDP-43 interacts with microtubules in the microtubule dependant transport of mRNP granules 
(Kanai et al., 2004; Alami et al., 2014) (Figure 1.7 C). This transport is particularly important due 
to TDP-43’s role in local mRNA translation of proteins in dendrites, axons, and synapses, such as 
the neuromuscular junction (NMJ) (Kanai et al., 2004; Belly et al., 2005; Fallini et al., 2012). 
Indeed, TDP-43 is present at the pre-synaptic motor terminal endings, and has been shown to 
bind to several pre-synaptic proteins that are involved in regulating neurotransmitter release 
(Narayanan et al., 2013; Alami et al., 2014). Similarly, TDP-43 interacts directly with proteins 
involved in RNA transport (Freibaum et al., 2010). Mutated TDP-43 has recently been identified 
to impair axonal transport of mRNA in vivo, as well as in induced pluripotent stem cell (iPSC) 
derived MNs of patients with TDP-43 mutations (Alami et al., 2014). mRNP granule transport 
defects were independent of other transport reporter defects such as mitochondrial transport. It 
was hypothesised that diminished transport of mRNA to compartments such as the axon and 
NMJ may lead to a decrease in proteins particularly important for NMJ maintenance and survival 
(Polymenidou et al., 2011; Lagier-Tourenne et al., 2012).  
 
Similarly, the association of C9ORF72 dipeptide repeats and aberrant interactions on the 
microtubule network may also exist; however this is still unproven. Although the function of this 
repeat expansion is still under investigation, Droppelmann and colleagues (2014) have 
highlighted that possible interaction with microtubules may exist, due to the C9ORF72 homology 
to a guanine nucleotide exchange factor (GEF) that signals Rab-GTPases.  Rab-GTPases are 
involved in membrane trafficking of proteins (Levine et al., 2013; Droppelmann et al., 2014) and 
hence, may be dependent upon microtubules. As mentioned previously, mutations to Alsin 
(ALS2), another GEF, is implicated in juvenile onset ALS and other various motor disorders 
(Eymard-Pierre et al., 2002; Panzeri et al., 2006). Interestingly ALS2 acts through signalling 
cascades that impact microtubules, and whose loss of function may generate microtubule 
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dysfunction; a process that requires further research (Tudor et al., 2005). 
 
Vascular endothelial growth factor (VEGF) is a polymorphic risk factor for ALS, and its 
expression is reduced in patients (Brockington et al., 2006; Brockington et al., 2010). A mouse 
model that produces decreased levels of VEGF develops a motor neurodegenerative phenotype, 
with behavioural deficits and cellular loss (Oosthuyse et al., 2001). VEGF mice show decreased 
expression of the MAPS tau, MAP1b and MAP6, which has implications for stability of both the 
stable and labile domains of microtubules in ALS (Brockington et al., 2010). Furthermore, genes 
relating to transport and dynein complex cargo loading are also down regulated. This occurs well 
before MN loss, but at the time of motor behaviour phenotype generation. This may highlight a 
link between dysfunction of microtubules and other identified genes, leading to MN dysfunction, 
followed by cellular demise (Brockington et al., 2010). 
 
Recently, and with great excitement in the ALS research community was the discovery of loss of 
function NEK1 rare variant mutants as a risk factor in ALS patients (Kenna et al., 2016). 
Interestingly, NEKs (NIMA related kinases) are involved in regulation and formation of non-
motile primary cilium (Shalom et al., 2008), a process that involved regulating microtubule 
dynamics, growth and organisation (Chang et al., 2009; Cohen et al., 2013). Indeed patient 
derived fibroblasts with truncation variants of NEK1 show microtubule abnormalities (Lee, 
2013), suggesting a link between NEK1 loss of function and the generation of a pathological 
microtubule environment; however, this is yet to be investigated in mature neuronal 
microtubules, particularly in vulnerable MNs in ALS. However, it does suggest that microtubule 
dynamics may be a common denominator of ALS pathogenesis.  
1.4.3 Microtubule protein mutations: a primary cause of ALS  
Various studies have suggested that mutations to microtubules can also initiate adult onset MN 
dysfunction, suggesting that microtubules may be a primary driver for ALS pathophysiology (Al-
Chalabi et al., 1999; Puls et al., 2003; Gros-Louis et al., 2004; Wu et al., 2012; Smith et al., 
2014). Smith and Colleagues (2014) found dominant negative mutated variants in the TUBA4A 
gene on chromosome 2 in fALS patients. These mutations were reported to cause classical 
lumbar onset ALS, with upper and lower MN loss, and in some cases, FTD-like symptoms 
(Smith et al., 2014). The mutated region normally interacts with β-tubulin and the motor domain 
of kinesins and other MAPs (Liu et al., 2012; Howes et al., 2014). These variants were further 
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shown to ineffectively form tubulin dimers and displayed a decreased incorporation into 
protofibrils, inhibiting microtubule network stability (Figure 1.7 D). Similarly, other mutations 
affecting the conformation of tubulin proteins may subsequently alter the assembly of tubulin, 
resulting in an unstable microtubule structure (Tischfield et al., 2011). 
 
TUBA4A is ubiquitously expressed in all cell types, but at high levels in the nervous system 
(Rustici et al., 2013; Smith et al., 2014). The expression of TUBA4A also increases over time, 
possibly illuminating why mutations in these genes cause later age disease phenotypes, unlike 
congenital tubulin mutations, which generate developmental disorders (Tischfield et al., 2011; 
Hersheson et al., 2013). Further supporting this, and as highlighted by Smith and Colleagues 
(2014), expression of the β-tubulin subunit, TUBB4A, whose mutations cause adult onset disease 
Torsion Dystonia Type 4, increases over time, similar to the expression pattern of α-tubulin 
TUBA4A (Hersheson et al., 2013). Further impacts of tubulin alterations in ALS can be seen in 
sALS patients, where there is a down regulation of α-tubulin subunit genes (Jiang et al., 2005). 
However, how microtubule dynamics and transport are impacted as a result of TUBA4A 
mutations are still not clear. Future development of animal models with TUBA4A mutations will 
allow for the identification of its role in pathogenesis, particularly focusing on its age-dependant 
expression pattern.  
 
Collectively, disease-causing mutations have shed light on an integral role for microtubules in 
ALS. However, with the majority of ALS cases still seemingly sporadic, it remains unclear if 
altered microtubule function is the cause, or consequence, of upstream initiating pathogenic 
mechanisms. 
1.4.4 Pathogenic ALS mechanisms impact on microtubule structure and function 
Many mechanisms and molecular pathways involved in both the initiation and maintenance of 
ALS have been identified (Van Damme et al., 2005; Ferraiuolo et al., 2011; Peters et al., 2015).  
These include, but are not limited to, mitochondrial dependant energy depletion, excitotoxicity 
and calcium dysregulation and cellular oxidative stress. The interplay between these disease 
mechanisms and insults to microtubules are not well understood, however, it is becoming 
increasingly appreciated that microtubules may act as a site for mechanistic convergence, as they 
are impacted by various pathogenic molecular mechanisms associated with ALS.   
 
	 26	
One such pathological mechanism is mitochondria dependant energy depletion. A study 
conducted by Park et al. (2013) highlighted that energy depletion itself could be a cause of 
microtubule depolymerisation, which may in turn further facilitate energy depletion through the 
inability of the microtubules to facilitate movement of mitochondria (Park et al., 2013) (Figure 
1.7 E). Interestingly, microtubule pathology was identified prior to alterations to mitochondrial 
swellings, suggesting it may be a primary event in energy depletion and axon degeneration. This 
inability to recycle mitochondria may contribute to the abnormal accumulations of these 
organelles as observed in mutant SOD1 transgenic mice (Sotelo-Silveira et al., 2009). However, 
aberrant calcium dysregulation as a result of mitochondrial energy depletion, an identified toxic 
mechanism in ALS, does not seem to directly a cause microtubule dysfunction, suggesting other, 
as yet unidentified mechanism may be at play (Park et al., 2013). 
 
Similarly, excitotoxicity has also been identified as a primary mechanism in the initiation and 
maintenance of ALS (Van Damme et al., 2005; Blizzard et al., 2015). Excessive influx and 
concentrations of intracellular Ca2+, whether from damaged mitochondria (Jaiswal, 2014), 
glutamatergic over stimulation, lack of glutamate clearance or a loss of Ca2+ buffering capacity, 
can lead to MN death (Heath and Shaw, 2002). Ca2+ concentrations also have an effect on 
microtubule based transport of mitochondria through inhibition of attachment of kinesins to 
microtubules (Wang and Schwarz, 2009). Indeed, excessive intracellular Ca2+ can lead to 
aberrant cyclin dependent kinase 5 (CDK5) activity, which is particularly prominent in the SOD1 
mouse model of ALS (Patzke and Tsai, 2002). Moreover, Ca2+ can interact directly with 
microtubules, altering their dynamics (O'Brien et al., 1997) (Figure 1.7 E). Interestingly, 
heightened Ca2+ concentrations are sufficient to cause MAP containing microtubule preparations 
to depolymerise, due to an increase in β-tubulin GTP cap hydrolysis. Furthermore, Ca2+ can cause 
MAP2 loss and microtubule depolymerisation in dendrites treated with NMDA, through calpain 
proteolysis of MAP2, however, it remains unclear if microtubule destabilisation occurs prior to 
MAP2 loss (Hoskison et al., 2007). Excitotoxicity has also been shown to impact on retrograde 
transport machinery (Fujiwara and Morimoto, 2012). Indeed, this insult leads to caspase 
activation and subsequent cleavage and disintegration of the cytoskeleton, reported to be 
downstream of microtubule events (King et al., 2013). However, investigation of low dose, long 
lasting, chronic excitotoxic effects on both microtubule dynamics and transport are yet to be 
completed, as recognised ALS insults are chronic or accumulative in their nature. Investigations 
such as these will identify whether biologically relevant levels of neuronal excitotoxicity alter 
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microtubule dynamics and transport first, or contrastingly activate the CDK5-p25 and caspase 
pathways, which lead to cellular pathology. 
 
Comparably, oxidative stress occurs due to the build-up of oxidative species, which whilst being 
a process of general aging of an organism, can cause uncontrollable oxidation on proteins or 
molecules, leading to cellular dysfunction. Therefore, homeostatic control of reactive oxygen 
species (ROS) is required for proper cell function. Uncontrollable ROS production and cellular 
oxidation leads to a number of neurodegenerative diseases (Andersen, 2004). Relevant to ALS, 
and in addition to Ca2+ toxicity, dysfunctional mitochondria can also drive uncontrollable ROS 
production (Tahara et al., 2009). While ROS are required for cytoskeletal remodelling and during 
axonal growth (Munnamalai and Suter, 2009; Wilson and Gonzalez-Billault, 2015), aberrant 
ROS and increases oxidative environment can lead to deleterious impacts on microtubules, 
particularly oxidation of tubulin and selected MAPs (Landino et al., 2004). Although still poorly 
understood in neurons, increasing ROS in myocytes increase microtubule depolymerisation 
(Drum et al., 2016). Both α- and β-tubulin contain Cys residues that have the capacity to oxidize 
(Landino et al., 2007; Wilson and Gonzalez-Billault, 2015). Oxidative species added to purified 
tubulin preparations can cause a reduction in polymerisation, and increase microtubule 
depolymerisation, similar to that of increased Ca2+ levels (Landino et al., 2007) (Figure 1.7 F). 
Moreover, it has been established that oxidative stress affects microtubule integrity; this is 
evidenced by the presence of methionine sulphaoxides in the β-III tubulin in the brain of AD 
patients (Boutte et al., 2006). Furthermore, glutathionylation of tubulin, particularly in MNs, 
occurs during oxidative phases, altering microtubule dynamics and structure (Carletti et al., 
2011). Indeed, the MAPs tau and MAP2 contain Cys residues, which when oxidize, impede MAP 
function, thus causing microtubule stability issues (Landino et al., 2004). Others have identified 
that recapitulating neuronal oxidative stress through the addition of hydrogen peroxide inhibits 
axonal transport, prior to mitochondrial dysfunction or axonal degeneration (Fang et al., 2012).  
1.4.5 Altered regulation of microtubule dynamics has been associated with ALS 
Changes to microtubule dynamics in ALS have also been reported, particularly increases to 
microtubule dynamic instability.  Fanara et al. (2007) identified that hyperdynamic microtubules 
were present in the SOD1G93A mouse model of ALS, and modulation of microtubule dynamics 
can ameliorate disease progression (Fanara et al., 2007). A subsequent study found that 
microtubules are indeed more dynamic, with an increase in end binding-protein 3 (EB3) +TIP 
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comets on sciatic nerve axonal microtubules in the SOD1G93A mouse, in comparison to unmutated 
individuals (Kleele et al., 2014). End binding (EB) proteins are +TIP MAPs that bind to the 
growing phase of the labile domain of microtubules, aiding in both dynamics and microtubule 
interactions with other intracellular objects. Increases in +TIP comets signify that the microtubule 
network is hyperdynamic. It was found that increased microtubule dynamics consequently 
slowed axonal transport, occurring presymptomatically (Fanara et al., 2007; Bilsland et al., 
2010). Axonal transport dysfunction is then followed by an increase in neuronal pathology and 
subsequent mortality (Collard et al., 1995; Sasaki and Iwata, 1996; Williamson and Cleveland, 
1999; Sasaki et al., 2004). Pharmacological amelioration of microtubule hyperdynamics not only 
reverses axonal transport deficits, but also improves clinical symptoms and survival (Fanara et 
al., 2007). This hints that hyperdynamics can indeed drive transport deficits, followed by cell 
demise; however, this process is still poorly understood. A possible mechanism through which 
SOD1 mice develop microtubule hyperdynamics may be through the interaction of mutant SOD1 
and tubulin (Kabuta et al., 2009). Interestingly mutant SOD1/tubulin interactions do not diminish 
the free tubulin pool; however, it generates a destabilising effect on the microtubule network.  
 
Kabuta and colleagues (2009) suggest that homology exists between the site of mutant SOD1 
binding to tubulin and the binding site of microtubule destabilising agents such as colchicine and 
nocodazole (Kabuta et al., 2009). This may indicate that mutant SOD1 interacts in a similar 
manner to microtubule destabilising agents, increasing the dynamic instability of microtubule 
labile domains, leading to a reactive, hyperdynamic phenotype. A phenomenon less often 
considered in ALS research is the impact that intracellular aggregates, consisting of proteins such 
as misfolded SOD1 and neurofilaments, (as discussed in section 1.3.2), may have on microtubule 
dynamics. Indeed, these aberrant structures have the propensity to incorporate many different 
cytosolic proteins into the aggregate mass, with microtubule proteins being particularly prone in 
aggregate localisation. This may be an interesting avenue of research as a recent study showed 
that decreasing the neurofilaments in a pmn mice improves aberrant microtubule dynamics and 
instability that is associated with this model (Yadav et al., 2016). 
 
An increasing and popular notion is that alterations to transport proteins, tubulin, other MAPs, or 
the dysregulation of microtubule dynamics can result in aberrant microtubule structure and 
function, leading to either developmental disorders or degenerative phenotypes, such as in ALS 
(Dubey et al., 2015). Indeed, MAPs, which facilitate microtubule functions such as cytoskeletal 
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interactions, intracellular signalling and modification of microtubule dynamics and stability, are 
thought to ‘tune’ microtubule dynamics through both direct and indirect interactions (Tortosa et 
al., 2013; Sayas et al., 2015). Indeed, MAP function, whether through direct protein modification 
or signalling becomes dysfunctional, leading to microtubules becoming aberrantly affected in 
ALS. Mechanisms driving these alterations in microtubule dynamics are not well understood, nor 
are the hypothesised subsequent transport dysfunctions. Identification of whether dysfunction of 
microtubule dynamics is a common pathology between familial mutations and sporadic disease is 
paramount to understanding disease onset, its maintenance and possible therapeutic approaches. 
1.4.6 Motor protein dysfunction and axonal transport deficits in ALS. 
Intracellular transport is a major function of neuronal microtubules, with alterations in transport 
associated with a number of neurodegenerative diseases (reviewed in (Millecamps and Julien, 
2013)). A-MNs are thought to be particularly vulnerable to transport dysfunction, due to their 
axonal length. It is becoming increasingly appreciated that alterations to microtubule dynamics 
precede, and thus may aberrantly affect, axonal transport, and that the resultant transport defect 
can have deleterious effects on neuronal function (Hurd and Saxton, 1996; Fanara et al., 2007; 
Bilsland et al., 2010; Cartelli et al., 2010; Dubey et al., 2015). The transport MAPs, kinesin and 
dynein, act as carriers for organelles, proteins and other cellular cargo in a directionally 
dependant manner. Kinesin motor proteins transport cell cargo toward the plus end of the 
microtubule (anterograde), whereas dynein transport in the minus end direction (retrograde) 
(Maday et al., 2014). Kinesin can impact on the stability of microtubules, and expression of 
KIF5, a kinesin motor protein isoform, has been found to be decreased in the spinal cord and 
sciatic nerves of a mutant SOD1 mouse model (Maximino et al., 2014). This indicates that altered 
microtubule dependent transport may be depleting a-MNs via the generation of an energy and 
signalling deficit. This is also substantiated in a study by Tateno et al (2009), who showed that 
kinesin-associated protein 3 (KAP3), a kinesin subunit responsible for binding cargo such as 
choline acetyltransferase (ChAT), was selectively vulnerable to co-aggregation with misfolded 
SOD1 (Tateno et al., 2009). This phenomenon was also reported to occur in human SOD1 fALS 
patients, possibly illuminating a further source of a-MN vulnerability to dysfunctional transport 
of specific cargos in ALS. 
 
Dynein, in conjunction with its molecular binding partner and activator, dynactin (DCTN1), is 
also vulnerable, both as a primary driver of ALS, but also as a site of convergence of ALS insults 
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(Ligon et al., 2005). Dynein interacts with mutant SOD1 and is located in proteinacious 
aggregates in SOD1 mice (Ligon et al., 2005) (Figure 1.7 B). Mutant SOD1 also interacts directly 
with the assembled dynein-dynactin complex, occurring prior to disease onset, at a similar age 
when retrograde dynein mediated axonal transport dysfunction occur in SOD1G93A mice (Zhang 
et al., 2007b; Bilsland et al., 2010). The functional consequence of this is yet to be determined, 
however detrimental impacts of transport dysfunction on the ubiquitin-proteasome system and 
protein autophagy may create a positive feedback loop, whereby proteins are caught in the 
incorrect cellular compartment, which compounds aggregation (Goldberg, 2003; Strom et al., 
2008; Takalo et al., 2013). Similarly, bidirectional transport of mitochondria is affected 
presymptomatically, highlighting the cargo and directional specificity of axonal transport 
dysfunction in this model; however, the exact mechanism is not well understood (Bilsland et al., 
2010). Mutations to the p150Glued subunit of DCTN1 are associated with MN degeneration and 
ALS (Munch et al., 2004; Munch et al., 2005; Levy et al., 2006; Laird et al., 2008). The mutation 
distorts the folding of the microtubule-binding domain. An autosomal dominant variant has also 
been reported to concurrently cause FTD (Munch et al., 2005), highlighting the role of motor 
proteins in other neurodegenerative diseases.  
 
Expression of motor protein genes is altered in sALS patients and in mutant SOD1 mouse 
models. A reduction in dynactin-1 expression is observed, in the absence of alterations to kinesin 
and dynein expression; down regulation occurs prior to the deposition of neurofilament protein 
aggregates (Jiang et al., 2007; Rustici et al., 2013). Furthermore, a polymorphism and reduced 
expression in kinesin-associated protein 3 (KIFAP3) correlates with an extended life span in 
sALS patients (Landers et al., 2009); however, how this affects transport is unknown. 
Interestingly, in mutant SOD1 mice, KIFAP3 expression in increased early in the diseases 
clinical course (Dupuis et al., 2000). Similarly, a number of cytoskeletal genes are altered in the 
SOD1G93A mouse spinal cord and sciatic nerve, dependant on both age and a-MN sub 
compartment evaluated (Maximino et al., 2014). Similar gene expression changes were found in 
sALS patients, having a decrease in MAP2, MAP1b and tau protein expression, which is also 
seen in the mutant SOD1G37R mouse model (Farah et al., 2003; Jiang et al., 2007). Motor proteins 
are also susceptible to alterations in tau levels, as observed in tauopathies, which retard 
anterograde motor transport (Ebneth et al., 1998). Tau alters the flux at which kinesin and dynein 
motor complexes bind to the microtubules, but not the speed at which they travel the microtubule 
tracks (Trinczek et al., 1999), suggesting alterations to tau levels on microtubules may impact 
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transport where tau pathology and dysfunction is present. Indeed, multiple upstream effectors 
such as altered dynamics, MAP dysfunction, and protein-protein interactions can produce 
aberrant axonal transport.   
1.4.7 Targeting neuronal microtubules for therapy: an approach for ALS 
The only available treatment for ALS is the anti-excitotoxic drug, Riluzole, which acts on the 
presynaptic neuron to limit the release of glutamate into the synapse, reducing the excitotoxic 
effect of glutamate on the postsynaptic cell (Bensimon et al., 1994). Notwithstanding the 
reduction in excitotoxicity, treatment strategies involving Riluzole have limited effectiveness, 
and are only able to extend patient life by approximately 3-6 months (Gurney et al., 1998). ALS 
is a multi-factorial disease, with many cellular components affected; therefore there are a range of 
available targets for therapy, however many of them have had limited success (Turner and 
Talbot, 2008). Microtubule involvement in ALS and in particular how dynamics and function are 
impaired in disease states is an attractive target for pharmacological manipulation to improve 
disease phenotype. Indeed, this therapeutic approach has previously been undertaken in multiple 
neurodegenerative disease models, including ALS. 
 
Fanara et al (2007), established that hyperdynamic neuronal microtubules were present in a 
SOD1 mouse model of ALS and administered the microtubule modulating agent noscapine to 
attenuate this phenotype (Fanara et al., 2007). Noscapine, which can cross the blood brain barrier 
(BBB) effectively dampens hyperdynamics, leading to less depolymerisation and polymerisation 
events from occurring at the growing plus tip of the microtubule (Landen et al., 2002; Landen et 
al., 2004).  Noscapine treatment extended lifespan, attenuated microtubule dynamics and 
normalised aspects of axonal transport. This in itself gives evidence for hyperdynamics driving 
transport deficits in these mice. However, more cargo-specific and rate-specific transport assays 
are required to identify if this is the case. This therapy did not investigate whether stabilising the 
microtubule cytoskeletal network prevented axonal degeneration from progressing in these mice; 
a pathological phenomenon that requires attention. However, this study provides supporting 
evidence for the use of microtubule stabilising agents in the treatment of ALS.  
 
Histone deacetylase 6 (HDAC6) inhibitors and HDAC knockout mice have also been trialled to 
improve outcomes in ALS models, with the intention of increasing the acetylation of stable 
microtubules to improve stability and axonal transport. The inhibition or removal of HDAC6 was 
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found to improve the phenotype of mutant SOD1 mice (Taes et al., 2013). However, axonal 
transport was not directly measured. A similar study utilising HDAC6 inhibition in Charcot-
Marie-Tooth (CMT) disease showed an improvement in axonal mitochondrial transport, 
supporting HDAC6 inhibition as a candidate therapeutic for multiple neurodegenerative diseases 
(d'Ydewalle et al., 2011). 
 
Direct microtubule stabilising agents have been previously used in the medical setting in the 
treatment of cancers, as the addition of these agents perturb the formation of the mitotic spindle 
and therefore inhibit cell division (Schiff et al., 1979). The most studied microtubule targeting 
compound, taxol, has in the last decade developed a newfound use in modulating microtubules in 
neurodegenerative diseases (Michaelis et al., 2006; Brunden et al., 2011; Das and Miller, 2012; 
King et al., 2013). At high doses, taxol treated systems develop hyper-stabilised microtubules, 
preventing cell division in cancer cells; however, this can generate a painful peripheral 
neuropathy (Reyes-Gibby et al., 2009). At lower doses taxol has been found to limit microtubule 
depolymerisation and stabilise the microtubule network in a number of neurodegenerative models 
(Michaelis et al., 2006; Brunden et al., 2011; Das and Miller, 2012; King et al., 2013). Indeed, 
treatment of an in vivo tauopathy model with taxol improves MN fast axonal transport, 
highlighting the therapeutic potential of taxol for disorders effecting MNs (Zhang et al., 2005). 
The range of taxol concentrations which yield beneficial effects on neurodegeneration are very 
narrow (Shemesh and Spira, 2011). Coupled with the off target effects identified due to taxol 
therapy, limited crossover at the BBB and the dramatic alterations to microtubule stability that it 
delivers, the benefits of taxol administration in neurodegenerative disease have been brought into 
question (Baas and Ahmad, 2013; Baas, 2014). Indeed, some opponents of using taxol or taxol 
based/like compounds have highlighted that normal neuronal functioning is aberrantly effected 
including microtubule polarity reversal, microtubule dynamic changes and axonal transport 
dysfunction (Shemesh and Spira, 2010; Baas and Ahmad, 2013; Benbow et al., 2016).  
 
In relation to ALS, taxol has been shown to reduce microtubule disintegration in an in vitro 
kainic acid excitotoxic model of ALS (King et al., 2013). Excitotoxicity exposure was reported to 
induce microtubule instability upstream of caspase-3 activation, which is mitigated with taxol 
treatment. However, as characterisation of microtubule dynamics has not been completed in 
regards to excitotoxicity due to kainic acid exposure, it is difficult to assess whether taxol is 
indeed limiting the hypothesised dynamic instability of microtubules, or preventing the 
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breakdown of the microtubule network. Indeed, inhibition of caspase-3 activation in other 
excitotoxicity models reports neuroprotection and increased cell survival (Chen et al., 2001).  
However, it is important to note that taxol derivatives, which exhibit higher blood brain barrier 
permeability, need to be investigated to determine if this form of microtubule stabilisation is a is 
a viable treatment for ALS. Moreover, the impact that these derivatives have on normal neuronal 
functioning is a necessary step to ensure that these therapeutics have limited to no aberrant off-
target effects in the nervous system. 
1.5 Thesis hypothesis and aims 
Despite decades of research regarding distal pathology in ALS, the time course of degenerative 
events of the distal neuromuscular circuitry is yet to be fully characterised. As discussed in this 
chapter, research has highlighted that distal neuromuscular pathology is an early event in ALS, 
and occurs presymptomatically, due in most part to plasticity in the neuromuscular system. 
However, investigations of presymptomatic changes to the NMJ pre and post synapse are yet to 
be fully completed, particularly in regard to identifying early therapeutically targetable 
pathology. Establishing a clear time course of distal axon and NMJ alterations, particularly 
focusing on distal morphology, denervation, plasticity, and NMJ architectural proteins, will 
determine the earliest pathology to target in ALS. Indeed, microtubule involvement in ALS, as 
described in section 1.4, suggests that microtubule-targeting drugs may be of benefit in ALS, as 
they have shown promise in other neurodegenerative diseases with similar disease mechanisms. 
Stabilising the axonal microtubule cytoskeleton may offer protection against ALS pathogenesis, 
particularly axonal degeneration and the alterations identified to microtubule dynamics in ALS.  
 
Identification of distal targets for therapeutics is attractive, as distal pathology produces the ALS 
phenotype due to a loss of muscle innervation. Further, development of treatments for ALS has 
been limited in both efficacy and clinical translation. This thesis aims to investigate the time 
course of pathological alterations of the distal neuromuscular circuitry in an animal model of 
ALS. Further, it focuses on the potential for axonal protection in ALS using a microtubule 
stabilising agent, specifically targeting distal events in the neuromuscular circuitry. The impact of 
pharmacologically stabilising microtubules on neuronal development and function are also 
determined, as alterations to microtubule stability are associated with pharmacologically induced 
microtubule dysfunctions and neuropathy. 
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Thesis hypothesis: Axonal degeneration is an early pathological phenomenon in ALS, and 
protecting axonal integrity through pharmacological stabilisation of microtubules in the distal 
neuromuscular circuitry will improve outcomes in ALS. 
  
Aim 1: Characterise axonal and neuromuscular junction degeneration in the 
YFPxSOD1G93A mouse model of ALS.  
Hypothesis 1: Pathology of the distal neuromuscular circuitry is an early event in ALS, evidenced 
by presymptomatic pathology of the axon and NMJ. 
Investigations focusing on degeneration of the distal axonal segments of a-MNs, and specific 
alterations to NMJ architectural proteins in ALS are still incomplete. The first aim of this thesis 
will investigate specific alterations in axonal and NMJ morphology utilising YFP expressing 
mice to visualise the distal neuronal anatomy. In addition, alterations to NMJ architectural 
proteins will be investigated. This will be completed utilising the SOD1G93A mouse model of 
ALS, coupled with immunohistochemical and confocal microscopy techniques.   
 
Aim 2: Pharmacologically stabilise microtubules to improve outcomes in the SOD1G93A 
mouse model of ALS using Epothilone D.  
Hypothesis 2: Pharmacologically stabilising microtubules will protect the distal neuromuscular 
circuitry and improve outcomes in ALS. 
Cytoskeletal disintegration during axonopathy is a well-characterised event. Further, 
hyperdynamics of the microtubule cytoskeleton occurs early in ALS, and promotes axonal 
transport dysfunction. Stabilising axonal microtubules has been shown to halt axonal 
degeneration and improve microtubule function in various models of neurodegenerative disease. 
This has previously been shown to be beneficial in ALS, utilising the microtubule-modulating 
agent noscapine. Thus, aim 2 will determine the efficacy of pharmacologically stabilising 
microtubules against disintegration and aberrant dynamics in the SOD1G93A mouse model of ALS 
using the microtubule stabilising compound Epothilone D. The therapeutic efficacy of Epothilone 
D will be measured through survival, behavioural, clinical progression and histological analysis. 
 
Aim 3: Identify the impact Epothilone D has on neuronal development. Hypothesis 3: 
Epothilone D will affect the normal development and function of cortical neurons in a dose-
dependant manner.  
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Microtubule stabilisation, whilst being an attractive therapeutic target for many 
neurodegenerative diseases, is not without its caveats. Aberrant and off-target effects of various 
microtubule targeting compounds, such as taxol, lead to painful peripheral neuropathies, altered 
cytoskeletal organisation and microtubule dysfunction. Using an in vitro model system, aim 3 
will investigate the impact of Epothilone D on normal neuronal development and function, by 
examining the initiation of polarity, neuronal growth, neuronal health, microtubule dependant 
transport and microtubule chemical and protein expression in cells treated with Epothilone D. 
							Chapter	2	
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2 General Methods 
2.1 Animal Models 
The hSOD1G93A mouse model of ALS was utilised in these studies. Transgenic mice expressing a 
high copy number of mutant human SOD1 with a glycine (G) to Alanine (A) substitution at 
position 93 (SOD1G93A), strain number B6.Cg-Tg (SOD1*G93A)1Gur/J (Gurney et al.,1994) 
were obtained from the Jackson Laboratories (stock number 004435). A second transgenic strain 
(male) that express yellow fluorescent protein (YFP) under the control of the neuron specific 
Thy1 promoter, strain number B6.Cg-Tg (Thy1-YFP)16Jra/J was also obtained from the Jackson 
Laboratories (stock number 003709). This line exhibits high YFP expression in cortical 
projection neurons and a-MNs, making it possible to visualise cellular processed with high 
resolution and fidelity. Both transgenic strains were bred on a C57BL/6 background. Pups were 
weaned at 28 days post-natal. Mice were housed in micro isolator cages on a 12 hour light/dark 
cycle with free access to food and water, and maintained at a temperature of 20°C. Water, food 
and bedding were replenished twice weekly. Animals were monitored daily and weighed weekly 
(unless stated otherwise). In accordance with ethical guidelines associated with the SOD1G93A 
mutant line, animals reaching 80% of their maximum weight or had increasingly affected righting 
reflexes were considered at the end stage of the disease and sacrificed. This was done by 
euthanizing in CO2 for 5 minutes, after which signs of life were checked, or transcardially 
perfused for histological or molecular analysis as described in subsections below. All animal 
experiments were approved by the Ethics Committee (Animal Experimentation) of the University 
of Tasmania (approval numbers A11952, A14233, A13183 for the principal investigator 
Associate Professor Tracey Dickson).  
2.2 Genotyping 
Mice were genotyped at the time of weaning (28 days post-natal) using a clipping from the end 
portion of the tail or ear, which was removed and stored at -20°C until DNA extraction was 
undertaken. DNA was extracted using an Extract-N-Amp Tissue PCR tissue kit (Sigma-Aldrich) 
according to the manufacturer’s instructions and stored at -4°C.  
 
All offspring of the SOD1G93A cross were genotyped to identify gene status. A qPCR approach 
was utilised to identify both SOD1 transgene presence and to monitor genetic drift through copy 
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number analysis (Leitner et al., 2009). This was to ensure high copy number animals (~ 23 
copies) were being utilised for both experiments and breeding. The primer and labelled 
oligonucleotide sequences for SOD1G93A and the internal control ApoB are shown in Table 2.1, 
(GeneWorks). qPCR DNA amplification and quantitation was completed on a Qiagen Rota-gene 
Q (Qiagen), according to the reaction conditions outlined in Table 2.2.  
 
YFP status was determined utilising traditional PCR methods. Amplification of the YFP 
transgene resulted in a PCR product of 300bp, and Tcrd, used as an internal control, resulting in a 
PCR product of 200bp. The primer sequences are shown in Table 2.1. DNA was amplified by 
PCR in a Veriti thermalcycler (Life Technologies) according to the reaction conditions outlined 
in Table 2.3. A typical YFP PCR gel is shown in Figure 2.1. 
 
Primer Sequence (5’ – to 3’) 
SOD1 Forward primer (qPCR, oIMR-9665) 
SOD1 Reverse primer (qPCR oIMR-9666) 
Human SOD1 oligos (qPCR, TmolMR-0147) 
ApoB Forward primer (qPCR, oIMR-1544) 
ApoB Reverse primer (qPCR, oIMR-3580) 
Mouse ApoB oligos (qPCR, TmolMR-0105) 
YFP Forward primer (oIMR-1258) 
YFP Reverse primer (oIMR-1260) 
TCRD Forward primer (oIMR-015) 
TCRD Reverse primer (oIMR-016) 
gggaagctgttgtcccaag 
caaggggaggtaaaagagagc 
ctgcatctggttcttgcaaaacacca 
cacgtgggctccagcatt 
tcaccagtcatttctgcctttg 
ccaatggtcgggcactgctcaa 
TCTgAgTggCAAAggACCTTAgg 
CgCTgAACTTgTggCCgTTTACg 
CAAATgTTgCTTgTCTggTg 
gTCAgTCgA gTgCAC AgT TT 
Table 2.1 qPCR and PCR primer and oligonucleotide names and sequences 
 
 
Step Temp (°C) & Time 
Initiation 95°C 5 mins  
Denaturation 95°C 15 sec 
Annealing and 
elongation 
60°C 15 sec (35 
cycles) 
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Table 2.2 SOD1 qPCR reaction conditions 
 
Step Temp (°C) & Time 
Initialisation 94°C 3 mins 
Denaturation 94°C 30 secs 
Annealing 60°C 30 secs 
Elongation 72°C 45 secs 
Final Elongation 72°C 2 mins 
Hold 4°C <24 hours 
Table 2.3 YFP PCR reaction conditions 
 
2.3 Mouse tissue preparation and sectioning 
2.3.1 Perfusion and tissue dissection 
Mice were terminally anaesthetised (pentabarbitone sodium, 140mg/kg, intraperitoneal) and 
transcardially perfused with either 4% PFA/0.01M PBS for immunohistochemical and 
microscopy analysis, or ice-cold 0.01M PBS for protein quantitation. PFA fixed tissue was 
dissected and stored in 0.02% sodium azide tissue storage solution or bathed in increasing 
concentrations (4%, 16%, 30%) of sucrose cryoprotectant solution for 24 hours. PBS perfused 
tissue was snap frozen in liquid nitrogen, followed by storage at -80°C until tissue lysis was 
performed.  
2.3.2 Tissue sectioning 
PFA fixed tissue specimens were frozen in Tissue-Tek O.C.T sectioning compound (Sakura) and 
cut to the desired thickness using a Leica CM1850 cryostat (Leica) followed by mounting onto 
frosted glass slides (Dako). Sections were then dried overnight in the dark, followed by 
immunohistochemical labelling. 
2.4 Cell culture 
2.4.1 Preparation of coverslips and cell culture trays 
Glass coverslips were etched in nitric acid (70% v/v) overnight, followed by 5 milliQ® washes. 
Coverslips were then dried at 60°C overnight and autoclaved. Utilising a laminar flow hood, 
FIGURE 2.1. YFP transgene genotyping using gel electrophoresis. YFP (300bp) and 
TCRD (200bp) PCR products were separated on an agarose gel containing a UV 
excitable DNA label, followed by image capture under UV light. The presence of the 
YFP transgene was shown by a positive band at the corresponding PCR product size 
for YFP, plus the presence of the TCRD housekeeping PCR product. 
 
~ 300 bp YFP
~ 200 bp TCRD
+-
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coverslips were then placed singularly into either 6- or 24-well micro plates (Iwaki), followed by 
ultraviolet sterilisation for 30 mins. Live cell imaging 3 well micro culture vessels were placed on 
coverslips in 6 well micro plates (refer to Chapter 5). Coverslips were then coated with 1mg/ml 
poly-L-lysine (Poly-L) (Sigma) in 0.1M PBS (pH 7.4) for a minimum of 4 hours prior to addition 
of cells. Coverslips were then rinsed (1x) in sterile PBS followed by the addition of initial plating 
media: Neurobasal™ media supplemented with 2% B27, 10% foetal calf serum, (all from 
Invitrogen), 0.5mM L-glutamine, 25µM glutamate and 1% penicillin/streptomycin antibiotics (all 
from Gibco BRL, Thermo Scientific).  Micro plates were then incubated at 37°C in 5% CO2 until 
the addition of cells. 
2.4.2 Cortical neuron cultures 
Primary cortical cultures were prepared from embryonic day 15.5 (E15.5) YFP or C57Bl/6 
embryos. In brief, cortices were removed from the skull, followed by the careful removal of 
attached meninges. Cortical tissue was then mechanically disassociated with forceps, collected 
into sterile HBSS containing 0.0125% trypsin and incubated at 37°C for 5 mins. The HBSS and 
trypsin was carefully removed, followed by trypsin inactivation and cellular disassociation by 
triturating with initial plating media. Cell viability and counts were determined utilising trypan 
blue vital dye exclusion (Sigma). Cells were then plated to the desired density into pre-prepared 
micro plates and returned to the incubator. 
2.4.3 Maintenance of cortical neuronal cultures 
24 hours after plating, initial plating media was removed and replaced with Neurobasal™ media 
supplemented with 2% B27, 0.5mM L-glutamine and 1% penicillin/streptomycin antibiotics. 
This promoted the selective growth of neurites (Brewer, 1995). Half of the media was replaced 
every three to four days with fresh media. Cells were maintained at 37°C and 5% CO2 for up to 
10 days in vitro (DIV). Following experiments cultures were either fixed in 4% PFA for 
immunocytochemical analysis, or treated with lysis buffer for protein quantification. 
2.4.4 Live cell imaging 
Live cell imaging was completed utilising fluorescence, differential interference contrast (DIC) 
and phase-contrast microscopy on a Nikon Eclipse Ti inverted microscope (Nikon) within an 
enclosed incubator maintained at 37°C and 5% CO2. For live cell imaging experiments, cell 
cultures were grown and maintained in indicator free Neurobasal™ media. Selected cover slips 
were transferred to the microscope and appropriate areas for imaging were selected, as discussed 
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in relevant chapters. Live cell images were captured using a Zyla CMDS camera (Andor), and 
controlled by NIS elements (Nikon). Images were subsequently analysed using FIJI software 
(NIH). 
2.5 Immunohistochemistry and immunocytochemistry 
Animal tissue and cultures that had been previously fixed were incubated in primary antibody 
combinations in diluent (0.3% or 1% Triton-x-100 in 0.01M PBS) for the durations indicated 
hereafter at 4°C (see table 2.4 for antibody information). Following primary antibody incubation, 
specimens were washed in 0.01M PBS three times for ten minutes. Specimens were then 
incubated in secondary antibodies in PBS for 90 minutes at 4°C. Generally DAPI (1:10000 
dilution, 5mg/ml stock) was added for the final ten minutes, followed by washing with PBS and 
mounting with mounting media (Permaflur, DAKO; or ProLong® Gold, Life Technologies). 
2.6 Protein quantitation 
2.6.1 Tissue and cell lysis 
Tissue from animal’s transcardially perfused with PBS, or cortical cell cultures were prepared in 
application specific tissue lysis buffer. Generally, RIPA buffer (50mM Tris-HCL, 150mM NaCl, 
1% NP-40, 1% Sodium deoxycholate, 0.1%SDS) with EDTA free protease inhibitor tablets 
(Roche) was used for the majority of experiments, unless stated otherwise. In brief, tissue or cells 
were rinsed 1-2 times with ice cold sterile PBS, followed by the addition of RIPA lysis buffer. 
Tissue was briefly homogenised utilising a T10 basic Ultra-Turrax homogeniser (IKA). Cell 
cultures were incubated in RIPA buffer for 10 mins at 4°C, followed by cell scrapping. Both 
tissue and cells lysates were subsequently centrifuged at 15,800 RCF for 10 mins, followed by 
snap freezing in liquid nitrogen and storage at -80°C. 
2.6.2 SDS-PAGE and Western blot 
Protein concentration was determined by utilising a micro-plate DC-protein assay kit (BioRad). 
Protein lysates were separated using an SDS-PAGE mini gel tank system, generally on precast 4-
12%, 1.5mm gradient gels, using power and duration settings specified in the manufacturers 
instructions (Thermo Scientific). Separated proteins were transferred to PVDF membrane, 
normally for 60 mins at 20 volts, followed by blocking in 5% skim milk powder in TBS-T for 60 
mins. Some experiments utilised overnight transfer for high molecular weight proteins, using an 
XCell Surelock™ system at 8 volts for 12 hours at 4°C, followed by blocking (Thermo 
Scientific). Membranes were then incubated in relevant primary antibodies overnight at 4°C, 
Primary Antibodies 
Species Antibody Company IHC/ICC dilution (1:x) 
WB Dilution 
(1:x) 
Conjugated stain aBT AlexaFluor 594 Molecular probes 200 N/A 
Mouse monoclonal Acetylated-tubulin Sigma Aldrich N/A 5000 
Mouse polyclonal Alpha-tubulin Abcam N/A 5000 
Goat polyclonal Choline Acetyltransferase Millipore N/A 200 
Rabbit polyclonal Dystrophin Abcam 100 500 
Rat monoclonal EB3 Abcam N/A 500 
Rabbit polyclonal GAPDH Millipore N/A 5000 
Mouse monoclonal GFAP Abcam 1000 N/A 
Rat monoclonal GFP Nacalai tesque 3000 N/A 
Rabbit polyclonal Iba1 Wako 1000 N/A 
Rabbit polyclonal LRP-4 Millipore 100 200 
Mouse monoclonal MAP2 Millipore 1000 N/A 
Mouse monoclonal Nestin BD Transduction 500 N/A 
Rabbit polyclonal Nestin Covance N/A 200 
Rabbit monoclonal NFM Millipore 1000 1000 
Mouse monoclonal Rapsyn Sigma Aldrich 200 N/A 
Rabbit monoclonal Rapsyn Abcam N/A 200 
Mouse monoclonal SMI-312 Covance 1000 N/A 
Mouse monoclonal SMI32 Covance 1000 N/A 
Mouse monoclonal STOP/MAP6 Millipore N/A 500 
Rabbit polyclonal Synaptophysin Abcam 500 N/A 
Rabbit polyclonal Tau Dako 2000 N/A 
        
 Secondary Antibodies 
Species Conjugate Company IHC/ICC dilution (1:x) 
WB Dilution 
(1:x) 
Anti-Mouse AlexaFluor 488 Molecular Probes 750 N/A 
Anti-Mouse AlexaFluor 568 Molecular Probes 750 N/A 
Anti-Rat AlexaFluor 488 Molecular Probes 750 N/A 
Anti Rabbit AlexaFluor 488 Molecular Probes 750 N/A 
Anti Rabbit AlexaFluor 568 Molecular Probes 750 N/A 
Anti Rabbit AlexaFluor 647 Molecular Probes 750 N/A 
Anti-Goat HRP Dako N/A 5000 
Anti-Rat HRP Invitrogen N/A 2000 
Anti-Mouse HRP Dako N/A 5000 
Anti-Rabbit HRP Dako N/A 5000 Table	2.4	
	 41	
followed by 4, 5 min washed with chilled TBS-T. Secondary HRP conjugated antibodies (DAKO 
anti mouse and rabbit, 1:5000; Invitrogen anti rat, 1:2000) were incubated for 1.5 hours, followed 
by rinsing with TBS-T. Membranes were then probed by incubating with Immobilon 
chemiluminescence HRP substrate (Millipore) for 5 mins, followed by detection with Chemi-
Smart 5000 image station (Vilber Lourmat). Band quantitation was completed using ImageJ, and 
is represented as the area of pixels per band (pix2). This was then followed by analysis in 
Graphpad Prism. 
							Chapter	3	
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3 Pathology of the distal neuromuscular circuitry is an early, presymptomatic event in the 
disease course of the SOD1G93A mouse model of ALS  
3.1 Introduction 
There is increasing evidence that the a-MN distal axon and synapse is an early target for 
pathology in ALS patients (Raff et al., 2002; Wishart et al., 2006). As described previously in 
Chapter 1 of this thesis, similar degenerative changes have been widely reported in the SOD1G93A 
transgenic mouse model of ALS (Gurney et al., 1994; Fischer et al., 2004). High-copy number 
SOD1G93A mice are reported to develop progressive muscle weakness and hindlimb paralysis at 
110 days of age, compared to an onset in forelimbs at 136 days, despite similar a-MN loss and 
pathology in corresponding spinal regions (Karlsson et al., 2004; Dodge et al., 2008; Schafer and 
Hermans, 2011). These symptoms progress to a strain-dependent end-point, typically reached at 
157 days in mice on a C57Bl/6 background (Wooley et al., 2005). Symptom onset in the 
SOD1G93A mouse is largely attributed to dysfunction and degeneration of the a-MN distal axons, 
however some evidence suggests that NMJ abnormalities may precede both distal axon 
degeneration and loss of the a-MN soma in transgenic mouse models (Gurney et al., 1994; 
Fischer et al., 2004; Carrasco et al., 2016). Although, degeneration of the distal components 
appears to be a key process in ALS, the sequence of pathological changes is not fully known. 
Investigations into the evolution of this pathology may shed light on possible targets for 
therapeutic intervention; a much needed advancement in ALS research. 
 
Axonal pathology is a complex and evolving degenerative process in ALS, and has been reported 
to occur in a fibre-type specific manner (Frey et al., 2000; Banks et al., 2003). Fast-firing phasic 
a-MNs are preferentially vulnerable in both SOD1G93A models and human disease (Frey et al., 
2000; Atkin et al., 2005; Pun et al., 2006), conversely, small-calibre type I axons persist later in 
disease (Kawamura et al., 1981; Bruijn et al., 1997).  It has been identified that axon degeneration 
in the distal neuromuscular circuitry occurs early in the disease time course of both human cases 
and animal models (Frey et al., 2000; Fischer et al., 2004). This degeneration includes intra-
axonal accumulations of protein aggregates, cytoskeletal breakdown and eventual fragmentation 
of the axonal membrane via Wallerian-like mechanisms (Frey et al., 2000; Vickers et al., 2009; 
Wang et al., 2012). However presymptomatic observations of axonal degeneration are yet to be 
fully comprehended. Symptom onset in the SOD1G93A mouse model occurs firstly in the 
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hindlimbs, with forelimb function remaining spared until the later stages of the disease (Schafer 
and Hermans, 2011). However, it is currently unknown whether this preserved function is due to 
decreased axonal and NMJ degeneration in the forelimb, in comparison to hindlimb muscles. 
Identification and comparisons of pathology between forelimb and hindlimb neuromuscular 
circuitry will increase our understanding of anatomical vulnerability in these mice. 
 
It is widely accepted that some axonal responses to ALS disease mechanisms identified in the 
SOD1G93A mouse may be beneficial. For example, and as discussed in Chapter 1, the surviving 
distal neuromuscular circuitry shows a remarkable ability to reinnervate recently denervated 
muscle, with collateral branches forming from axons in close proximity to AChR patterned 
muscle that lack the pre-synaptic apparatus (Hegedus et al., 2008; Moloney et al., 2014). This 
phenomenon is hypothesised to occur relatively early in the pathogenesis of ALS, prior to the 
onset of motor symptoms. Ultimately the decrease in a-MN survival and increase in pathology 
overwhelms any regenerative capacity, resulting in loss of the neuromotor unit and symptoms 
(Williams et al., 2009; Taetzsch et al., 2017). Identification of collateral capacity early and late in 
the disease is incomplete, and offers an interesting and necessary avenue of research to focus on. 
Furthermore, although having been investigated in other ALS mouse models, distal axonal and 
NMJ alterations in the high copy number SOD1G93A mice are yet to be fully characterised using 
YFP as the primary label of the distal axon and pre-synaptic compartment (Feng et al., 2000b; 
Wong et al., 2009). 
 
The NMJ has also been implicated in the disease process, with ‘dying back’ degeneration of the 
synapse and distal axon also occurring early in the disease time course (Frey et al., 2000; Fischer 
et al., 2004). Recently it has also been identified that NMJs in SOD1G93A mice have impaired 
presymptomatic neuromuscular transmission (Rocha et al., 2013). Similarly, SOD1G93A 
dependant alterations to skeletal muscle gene expression occur presymptomatically (de Oliveira 
et al., 2014). Terminal schwann cells, which are specialised schwann cells that facilitate 
neurotransmission at the NMJ are also abnormally affected presymptomatically in SOD1 mouse 
models of ALS (Carrasco et al., 2016). However, identification of early NMJ morphological 
alterations and the implications of specific protein changes are still poorly understood in the 
SOD1G93A mouse model of ALS.  
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Appropriate expression and localisation of post-synaptic architectural proteins in the NMJ are 
necessary for NMJ maturation, function and maintenance. Indeed, a loss or mutation of such 
proteins has been shown to lead to a number neuromotor disorders due to either aberrant NMJ 
development, or denervation in childhood or early adulthood (Frail et al., 1989; Ohno et al., 
2002; Li et al., 2010; Pilgram et al., 2010; Pevzner et al., 2012; Ohkawara et al., 2014). 
Remarkably, there is limited research investigating NMJ post-synaptic architectural proteins in 
ALS (Perez-Garcia and Burden, 2012). This is significant, as the NMJ is a neuroanatomical site 
where in both patients and animal models show the greatest amount of degeneration and 
neurocircuitry loss; a direct correlation to motor/clinical phenotype (see review (Moloney et al., 
2014)). Interestingly, myocytes in the SOD1G93A mouse model show alterations in gene 
expression, endoplasmic reticulum stress and dysfunctional protein folding, suggesting the 
myocyte proteome (and thus post-synaptic proteins) may be vulnerable in ALS (de Oliveira et al., 
2014; Chen et al., 2015). However, limited evidence exists surrounding age dependant alterations 
in NMJ protein localisation and alterations in protein expression in the SOD1G93A mouse model. 
 
The current investigations utilised the SOD1G93A mouse model of ALS. It also utilised the novel 
SOD1G93A x Thy1YFP (SOD1G93AxYFP henceforth) mice to facilitate morphological analysis of 
distal axons and NMJs. The Thy1YFP mouse demonstrates yellow fluorescent protein (YFP) 
expression in spinal a-MNs (Feng et al., 2000b). The aim of this investigation was to characterise 
axonal and pre and post-synaptic NMJ degeneration, utilising YFP as a morphological 
visualisation aid. Investigations into specific alterations to the hindlimb (gastrocnemius) and 
forelimb (extensor muscles) YFP expressing distal axons and NMJs in the SOD1G93AxYFP 
mouse were completed. Identification of axonopathy and the extent of collateral branching at 
presymptomatic and symptomatic time points were also undertaken. This was followed by 
assessment of gross NMJ degeneration and morphological alterations at similar time points. Post-
synaptic architectural markers of the NMJ were also probed over the disease time course as well 
as protein levels at end stage of disease.  
3.2 Methods 
3.2.1 Animals 
Male transgenic SOD1G93A mice and the double transgenic SOD1G93AxYFP cross mice (see 
Chapter 2) were used for histological analysis. SOD1G93A and SOD1G93AxYFP mice were 
assessed daily for overt clinical symptoms and weighed weekly from 58-140 days of age to 
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evaluate disease progression. The mice used for these studies were humanely killed before 
reaching an ethical end-point, which is generally 157 days of age in this SOD1G93A model 
(Wooley et al., 2005). Motor testing demonstrated that there was no difference in Rotarod 
performance or weight between YFP transgenic mice and wild-type littermates (Figure 3.1). Age 
matched control mice (non hSOD1G93A expressing C57BL/6 and YFP mice) were used for all 
immunohistochemical and imaging analysis. 
3.2.2 Immunohistochemistry and quantitation 
Mice were terminally anaesthetised and transcardially perfused with 4% PFA (28, 56, 84, 112 
and 140 days of age for SOD1G93A; 56 and 140 days of age for SOD1G93AxYFP). The hindlimb 
gastrocnemius and forelimb extensor muscles (extensor carpi radialis longus, extensor digitorum 
communis, extensor digitorum lateralis and extensor carpi ulnaris) were dissected and 
cryoprotected. SOD1G93A muscle was cryosectioned longitudinally at 40µm to improve antibody 
penetration, whereas SOD1G93AxYFP muscle was cryosectioned at 80µm (Figure 3.2).  All 
sections were stained for post-synaptic acetylcholine receptors (AChRs) using AlexaFluor 
conjugated 594nm α-bungarotoxin (α-BTx, 1:200, Molecular Probes/Invitrogen) for 30 minutes. 
Sections for immunohistochemical analysis were washed once in ice-cold methanol (Sigma-
Aldrich) for 30seconds and permeablised with 0.1% Triton-X-100 (Sigma-Aldrich) for 4 hours at 
room temperature. Pre-synaptic motor terminals were labelled using a cocktail of mouse-anti 
phosphorylated neurofilaments (SMI-312; 1:1000; Sternberger Monoclonals/Covance), 
dephosphorylated neurofilaments (SMI-32; 1:1000; Sternberger Monoclonals/Covance) and 
rabbit-anti synaptophysin (1:500, Millipore) (Mozaffar et al., 2009). Post-synaptic structural 
proteins were labelled using antibodies to dystrophin (1:100; rabbit polyclonal; Abcam/Sapphire 
Bioscience), nestin (1:500; BD Transduction), rapsyn (1:200; Sigma-Aldrich) and LRP-4 (1:100; 
intracellular domain, Millipore). Primary antibodies or isotype controls were incubated for 1 hour 
at room temperature followed by 4oC overnight. Species-specific Alexa488 secondary antibodies 
(1:750; Molecular Probes) were incubated for 2 hours at room temperature. Sections were 
thoroughly washed and mounted with ProLong® Gold antifade mounting medium (Life 
Technologies) and fully dried prior to analysis. 
3.2.3 Quantitation of colocalisation and distal axonopathy 
SOD1G93AxYFP en-face NMJs and terminal axons were imaged using a Zeiss scanning confocal 
microscope (Zeiss 510 laser scanning microscope). Z-stacks (40µm stack, 2µm interval, 512x512 
pixels, voxel = 1.68mm3) were generated using Zen software (Zeiss) and axonal and NMJ 
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morphologies were analysed using Image J (NIH) (Valdez et al., 2010). Only en-face NMJs were 
included for morphological analysis. Analysis of immunohistochemical labels relative to α-BTx 
staining was performed using fluorescence microscopy (Leica DM-LB2). NMJs were considered 
occupied if there was evidence of complete or partial association between pre-synaptic markers 
and α-BTx (Cappello et al., 2012). Similarly, post-synaptic proteins were considered to be 
present if there was complete or partial colocalisation with α-BTx. NMJs from the gastrocnemius 
muscles were counted from three fields of view (200x), across two sections from each muscle, 
ensuring comparable regions of each muscle. All NMJs in the forelimb muscle were counted as 
part of the analysis. All counts were performed blinded to the genotype and age of the animal.  
3.2.4 Western blot quantification of neuromuscular junction protein  
End stage SOD1G93A and age matched control gastrocnemius muscle were homogenised in RIPA 
buffer (50mM Tris-HCL pH 7.4, 150mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% 
SDS), containing EDTA free protease inhibitor (Roche). The homogenate was centrifuged at 
15,800 RCF at 4°C for 10 minutes, after which supernatant was collected and analysed by SDS-
PAGE and Western blot (20ug of protein). Detection of postsynaptic NMJ proteins was 
performed using antibodies for dystrophin (1:500) and LRP4 (1:200) as mentioned previously, as 
well as nestin (1:200; Covance) and rapsyn (1:200; Abcam). GAPDDH (1:5000; Millipore) 
immunoblots were prepared from cut blots for LRP-4, Nestin and Dystrophin. Rapsyn blots were 
subsequently stripped and re-probed for GAPDH. Antibody binding was detected utilising anti-
rabbit and anti-mouse HRP-conjugated secondary antibodies (1:5000; Dako) and Immobilon 
chemiluminescent substrate (Millipore). Densitometry analysis was performed using Image J. 
3.2.5 Statistical analysis 
The proportion of NMJs with colocalisation of α-BTx and immunohistochemical markers was 
statistically analysed using GraphPad Prism (Version 5.00) using two-way analysis of variance 
(ANOVA) with Tukey’s post-hoc correction for multiple comparisons. p < 0.05 was considered 
significant. Data is expressed ± standard error of the mean (SEM). Unless otherwise stated, a 
minimum of four separate animals was used for each genotype and age (n = 4). 
FIGURE 3.1. YFP transgene does not affect weight or motor behaviour measures. 
(A) YFP transgene does not affect weight gain. (B) YFP transgene does not affect 
Rotarod performance when measured by latency to fall (seconds) and corrected for 
mouse weight (grams), (seconds per gram, sec/g). Wild-type (black) and YFP 
expressing mice (grey) were tested from 63 to 140 days of age.  

FIGURE 3.2. The name and anatomical position for the muscles used in this study 
(grey). Muscles of the (A) hindlimb and (B) forelimb are shown in lateral view. Not 
to scale. 
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3.3 Results 
3.3.1 SOD1G93A mice exhibit hindlimb distal axonopathy and increased axonal branching 
prior to symptom onset 
To characterise changes to distal axon morphology in the hindlimb, SOD1G93AxYFP transgenic 
gastrocnemius muscle sections were examined at 56 days (presymptomatic) and 140 days (late 
disease). Examination of distal axons terminating at the NMJ in YFP control mice demonstrated 
that the majority of axons exhibited intact morphology, with uninterrupted YFP expression along 
the axon length (Figure 3.3 A). However, in SOD1G93AxYFP mice it was evident that a small 
subset of axons demonstrated evidence of abnormal and pathological morphology, including 
beading and fragmentation. Beaded axons had segments that were thin and were separated by 
large concentrated membranous beads of YFP (Figure 3.3.B). Fragmented axons however, 
showed interrupted YFP expression, with large zones of axonal membrane loss (Figure 3.3 C). 
For the purpose of this study, both beaded and fragmented axons were pooled as a degenerative 
pathological phenotype. Quantitation revealed a significant (p < 0.05) decrease in the proportion 
of intact distal axons at 56 days of age in SOD1G93AxYFP mice compared with YFP controls 
(Figure 3.3 G) (SOD1G93AxYFP: 81.2% ± 4.62%; YFP: 97.5% ± 2.1%, n = 6). There was a 
further significant (p < 0.05) decrease in the proportion of intact axons at 140 days of age in 
SOD1G93AxYFP mice, with over half of the axons showing degenerative morphologies, compared 
to YFP controls, where nearly 100% remained intact  (Figure 3.3 G) (SOD1G93AxYFP: 49.77% ± 
6.66%; YFP: 98.06% ± 1.70%, n = 6).  
 
Following the establishment of presymptomatic axonal degeneration, collateral branch analysis of 
SOD1G93AxYFP distal axons was undertaken (Figure 3.3.D). Intact primary axons with at least 
one fully colocalised NMJ structure projecting from nerve bundles were selected, and collateral 
branch numbers were determined. The majority of YFP control mice presented with limited 
axonal collaterals (Figure 3.3 E). However, at presymptomatic day 56, SOD1G93AxYFP mice 
displayed a significant (p < 0.05) increase in the number of collateral branches compared to YFP 
controls (SOD1G93AxYFP: 1.409 ± 0.025; YFP: 1.248 ± 0.044, n = 5) (Figure 3.3 H). This was 
visualised as generally 1-2 primary axonal segment terminating at a NMJ (Fig. 1F). At 140 days 
the number of collateral branches increased further, with axonal segments in SOD1G93AxYFP 
mice having significantly (p < 0.0001) more branch points (SOD1G93AxYFP: 2.023 ± 0.055; 
FIGURE 3.3. Confocal images from SOD1G93AxYFP mice displaying distal 
axonopathy and an increase in axon collateral branches over the disease time course. 
(A) Control mice had mostly intact axons. (B) Degenerating axons were increased in 
56 day old SOD1G93AxYFP mice, mostly presenting a beaded morphology, (C) or a 
fragmented morphology. (D) Schematic of axonal branch quantification, as shown by 
branch order of distal axons. (E) Wild-type YFP axons had fewer branches. (F) 
SOD1G93AxYFP mice had a significant increase in axonal branches. (G) Statistical 
analysis showed that intact axons were significantly (p < 0.05) decreased at 56 days, 
and decreased further by 140 days in SOD1G93AxYFP mice. (H) Axonal branches 
were significantly (p < 0.0001) increased at 56 days in SOD1G93AxYFP mice, and 
increased further at 140 days (mean ± SEM, n = 6). Scale = 15µm.  
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YFP: 1.164 ± 0.0188, n = 5), as well as an increase in the typical degenerative axonal 
morphology reported previously (Figure 3.3 H).  
3.3.2 Hindlimb distal axonopathy is accompanied by increased NMJ morphological 
alterations 
This chapter sought to investigate whether the expression of SOD1G93A altered NMJ morphology 
in the gastrocnemius muscle of SOD1G93AxYFP mice. Firstly, SOD1G93AxYFP gastrocnemius 
tissue sections were stained with α-BTx, followed by the generation of confocal images of the 
pre- and post-synapse. Three morphologically distinct categories of NMJs were revealed. Firstly, 
intact and complex junctions were present, identifiable by the typical ‘pretzel’ morphology of the 
post-synaptic apparatus (Figure 3.4 A), and were noted to be present in presymptomatic 
SOD1G93AxYFP mice. However, abnormal NMJ morphologies were also identified, presenting as 
either less complex or degenerative. These NMJs were identified as NMJs with only one or two 
synaptic branches instead of the normal ‘pretzel’ morphology (Figure 3.4 B). Statistical analysis 
identified that there were significantly (p < 0.001) fewer complex NMJs at 56 days of age in 
SOD1G93AxYFP mice, compared to YFP controls (SOD1G93AxYFP: 76.45% ± 4.13%; YFP: 
92.38% ± 4.30%) (Figure 3.4 D). At the later disease stage NMJs showed highly degenerative 
morphology, such as blebbing and fragmentation of the membrane folds and sparse post-synaptic 
labelling (Figure 3.4 C). Further analysis found that at 140 days of age there was a significant (p 
< 0.0001) 32.17% additional decrease in intact NMJs in SOD1G93AxYFP mice (SOD1G93AxYFP: 
44.29% ± 8.39%) (Figure 3.4 D). These two abnormal NMJ morphological subtypes were also 
pooled during analysis as a ‘degenerative morphology’. 
3.3.3 SOD1G93A mice have reduced hindlimb NMJ innervation throughout disease course 
Evaluation of the colocalisation between pre- and post-synaptic labels in the gastrocnemius 
muscle of SOD1G93AxYFP hindlimb was also completed at presymptomatic and late stage 
disease, as well as immunohistochemical methods at 28, 56, 84, 112, and 140 days in non-crossed 
SOD1G93A mice. Innervation was defined as NMJs demonstrating either complete or partial 
colocalisation of pre-synaptic elements with α-BTx; degeneration was defined as total loss of 
colocalisation, resulting in only post-synaptic density labelling. At 56 days of age there was no 
significant (p > 0.05) difference in the proportion of NMJs with full colocalisation of YFP 
positive terminals and α-BTx staining in SOD1G93AxYFP mice compared with YFP controls 
(Figure 3.5 A). However, by 140 days of age, there was a significant (p < 0.0001) decrease in the 
proportion of NMJs with colocalisation between YFP and α-BTx staining in SOD1G93AxYFP 
FIGURE 3.4. NMJ analysis highlighted the presence of morphological abnormalities 
at pre-symptomatic and late disease stages. (A) Wild-type YFP control mice exhibited 
NMJs with the typical complex ‘pretzel’ morphology. (B) SOD1G93AxYFP mice 
demonstrated NMJ morphological abnormalities, with many having less complex 
synaptic structures at 56 days, (C) as well as the increasing proportion of NMJs with 
fragmented and beaded presynaptic membrane folds (arrow). (D) Intact NMJ 
morphology was significantly (p < 0.05) decreased by 56 days of age in 
SOD1G93AxYFP mice, decreasing further by 140 days (mean ± SEM, n = 6). NMJs 
counted from three fields of view (200x), across two sections from each muscle. Scale 
= 15µm. 

FIGURE 3.5. The proportion of NMJs demonstrating colocalisation between pre- and 
post-synaptic components was reduced in older SOD1G93A mice. (A) NMJs imaged by 
confocal microscopy were either fully colocalised between YFP (green) and α-BTx 
(red), (B) or demonstrated non-colocalisation between YFP and α-BTx, due to 
presynaptic loss of YFP, leaving a denervated endplate. (C) Immunohistochemical 
presynaptic markers imaged by fluorescence microscopy were either fully colocalised 
with α-BTx, (D) or the presynapse was lost, with only the α-BTx endplate visible. (E) 
SOD1G93AxYFP mice showed no decrease in the proportion of NMJs with colocalised 
YFP and α-BTx at 56 days of age (p > 0.05), however at 140 days there was a 
significant decrease (p < 0.05) in the proportion of NMJs colocalised with YFP and α-
BTx in the gastrocnemius, compared to YFP controls (n = 6). (F) 
Immunohistochemical analysis demonstrated a significantly (p < 0.05) reduced 
proportion of NMJs with pre-synaptic terminals colocalised with α-BTx at 84, 112 
and 140 days of age compared with controls (mean ± SEM, n = 4). NMJs counted 
from three fields of view (200x), across two sections from each muscle.  Scale = 
15µm.  
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mice compared with YFP controls (SOD1G93AxYFP: 51.60% ± 13.3%; YFP: 99.36% ± 0.82%) 
(Figure 3.5 B, E).  
 
To investigate protein expression changes associated with the pre-synaptic changes in the 
hindlimb, non-YFP crossed SOD1G93A and wild-type control gastrocnemius muscle sections were 
immunolabelled with a cocktail of antibodies to neurofilaments and synaptophysin to visualise 
the pre-synaptic terminal (Figure 3.5 C). Denervated NMJs had no pre-synaptic labelling 
colocalised with α-BTx (Figure 3.5 D). There was no significant (p > 0.05) difference in the 
proportion of NMJs with pre-synaptic terminal colocalisation with α-BTx staining in wild-type 
and SOD1G93A at 28 days of age. In agreement with the SOD1G93AxYFP data, there was no 
significant (p > 0.05) change in the proportion of NMJs with colocalised pre-synaptic 
immunolabelling and α-BTx staining at 56 days of age (SOD1G93A: 83.1% ± 1.10%; wild-type: 
97.3% ± 1.45%). However, at 84 and 112 days of age, there were significant (p < 0.05) 44% and 
50% decreases in the proportion of NMJs with colocalised pre-synaptic immunolabelling and α-
BTx staining (84 days, SOD1G93A: 49.5% ± 5.26%; wild-type: 88.7% ± 2.74%. 112 days, 
SOD1G93A: 58.0% ± 5.77%; wild-type: 96.5% ± 1.51%) (Figure 3.5 F). Corroborating results 
reported above in SOD1G93AxYFP mice, at 140 days of age there was a significant (p < 0.05) 
decrease in NMJ marker colocalisation, compared to wild-type controls (SOD1G93A: 23.4% ± 
6.79%; wild-type: 96.4% ± 2.0%). 
3.3.4 Hindlimb NMJ degeneration in SOD1G93A mice is accompanied by loss of post-
synaptic structural proteins  
To determine whether there is a sequential loss of specific post-synaptic proteins due to 
SOD1G93A expression, gastrocnemius muscle sections from the same mice were examined using 
immunohistochemical labelling. At 28 and 56 days of age there was no significant (p > 0.05) 
difference in the degree of colocalisation of either nestin, LRP-4, rapsyn or dystrophin with α-
BTx in the gastrocnemius muscle of wild-type and SOD1G93A mice. At 84 days of age, there was 
a significant (p < 0.05) decrease in the proportion of NMJs showing colocalisation of nestin with 
α-BTx in SOD1G93A gastrocnemius muscles compared to controls (SOD1G93A: 43.6% ± 4.24%; 
wild-type: 89.1% ± 3.56%) (Figure 3.6 A & B). Decreased numbers of NMJs with colocalisation 
of nestin with α-BTx was associated with a change in immunoreactivity to a more dispersed 
expression throughout the muscle fibre as previously reported following denervation (Vaittinen et 
al., 1999). Colocalisation of nestin immunoreactivity with α-BTx was further decreased at 112 
FIGURE 3.6. NMJ post-synaptic structural proteins are progressively lost over the 
disease time course in SOD1G93A mice, compared to age matched controls. (A) Nestin 
(green) immunoreactivity is present surrounding the healthy wild-type control NMJ 
stained with α-BTx (red) but was not colocalised with α-BTx in SOD1G93A NMJs. (B) 
The proportion of NMJs with colocalised nestin and α-BTx was significantly (p < 
0.05) reduced at 84, 112 and 140 days of age in SOD1G93A mice compared with 
controls. (C) LRP-4 (green) immunoreactivity is present surrounding the healthy 
wild-type control NMJ stained with α-BTx (red), with LRP-4 colocalisation with α-
BTx progressively decreasing in SOD1G93A NMJs from 84 days of age. (D) The 
proportion of NMJs with colocalised LRP-4 and α-BTx was significantly (p < 0.05) 
reduced at 84, 112 and 140 days of age in SOD1G93A mice compared with controls. 
(E) Dystrophin (green) immunoreactivity colocalised with α-BTx staining (red) and 
extends beyond the synapse in the wild-type NMJ, however dystrophin staining was 
absent from some SOD1G93A NMJs. (F) The proportion of NMJs with colocalised 
dystrophin and α-BTx was significantly (p < 0.05) reduced at 112 and 140 days of age 
in SOD1G93A mice compared with controls. (G) Rapsyn (green) immunoreactivity was 
localised to α-BTx staining (red) in the wild-type NMJ, however rapsyn staining was 
absent from SOD1G93A NMJs. (H) The proportion of NMJs with colocalised rapsyn 
and α-BTx was significantly (p < 0.05) reduced at 140 days of age in SOD1G93A mice 
compared with controls (mean ± SEM, n = 4). Scale = 15µm. 

	 50	
and 140 days of age, representing a final loss of 70% of α-BTx NMJs colocalised with nestin at 
140 days of age. Similarly, LRP-4 colocalisation with α-BTx in the gastrocnemius muscles was 
significantly (p < 0.01) decreased in SOD1G93A mice at 84 days of age (SOD1G93A: 82.1± 2.90%; 
wild-type: 98.68% ± 0.71%) (Figure 3.6 C & D). This also decreased further at 112 and 140 days, 
with a final loss of 35% of α-BTx labelled NMJs colocalised with LRP-4. At 112 days of age, the 
proportion of NMJs with dystrophin colocalised with α-BTx in SOD1G93A gastrocnemius was 
significantly (p < 0.05) decreased compared to wild-type tissue (SOD1G93A: 44.09% ± 5.19%; 
wild-type: 90.58% ± 5.62%) (Figure 3.6 E & F). Colocalisation of dystrophin immunoreactivity 
with α-BTx was further decreased at 140 days of age. By 140 days of age, there was a significant 
(p < 0.05) reduction in the proportion of NMJs with colocalised rapsyn and α-BTx (SOD1G93A: 
30.75% ± 2.04%; wild-type: 87.33% ± 5.91%) (Figure 3.6 G & H).  
 
3.3.5 Forelimb distal axonopathy, morphological alterations and synapse loss are evident 
at late stage disease, but are not accompanied by the loss of post-synaptic apparatus 
Disease onset in the SOD1G93A mouse characteristically begins in the hindlimbs, with the 
forelimb function remaining comparatively spared throughout disease progression (Schafer and 
Hermans, 2011). To determine whether this preservation of function is reflected by preservation 
of NMJs and whether NMJ degeneration is preceded by early structural changes, the forelimb 
muscles of SOD1G93AxYFP and SOD1G93A mice were examined using the same analysis criteria 
as used for the gastrocnemius muscle. In the forelimb, there was a significant (p < 0.0001) 23% 
decrease in the proportion of intact distal axons at 140 days of age in SOD1G93AxYFP mice 
compared with YFP controls (SOD1G93AxYFP: 73.37% ± 3.55%; YFP: 96.28% ± 1.87%) (Figure 
3.7 A). Similar to axonal degeneration, there was a significant (p < 0.05) 14% decrease in the 
proportion of α-BTx labelled NMJs demonstrating normal morphology in SOD1G93A mice 
(SOD1G93AxYFP: 72.92% ± 6.84%; YFP: 86.77% ± 3.25%) (Figure 3.7 A), suggesting that this 
morphological phenomenon is not limited to the pathophysiology of only the SOD1G93A 
gastrocnemius.  
 
NMJ synaptic colocalisation demonstrated a significant (p < 0.0001) 22% decrease in the 
proportion of YFP axon terminals colocalised with α-BTx in SOD1G93AxYFP mice at 140 days of 
age compared to YFP controls (SOD1G93AxYFP: 77.29% ± 8.58%; YFP: 98.97% ± 0.39%) 
(Figure 3.7 B and D). Similarly, there was also a significant (p < 0.05) decrease in the proportion 
FIGURE 3.7. Distal axon and NMJ degeneration is delayed in the forelimbs of 
SOD1G93A mice. (A) There was a significant (p < 0.05) decrease in the proportion of 
distal axons displaying a normal, intact morphology at 140 days of age in 
SOD1G93AxYFP mice compared with YFP controls; and significant (p < 0.05) 
decrease in the proportion of NMJs demonstrating a normal complex morphology at 
140 days in SOD1G93AxYFP mice compared with YFP controls. (B) There was a 
significant (p < 0.05) decrease in the proportion of NMJs demonstrating colocalised 
YFP and pre-synaptic terminal immunolabelled for neurofilaments and synaptophysin 
with α-BTx at 140 days of age in SOD1G93AxYFP and SOD1G93A mice forelimbs 
compared with respective controls. However, there was no significant (p > 0.05) 
change in the proportion of NMJs showing colocalised nestin, dystrophin or rapsyn 
with α-BTx at 140 days of age (mean ± SEM, n = 4 mice). (C) There was a significant 
(p < 0.05) decrease in the proportion of NMJs demonstrating colocalised LRP-4 with 
α-BTx at 84, 112 and 140 days of age in SOD1G93A mice compared to controls. 
However, the loss of LRP-4 is not progressive. (D) Forelimb NMJs were either fully 
colocalised between YFP (green) and α-BTx (red), (B) or demonstrated non-
colocalisation between YFP and α-BTx, due to presynaptic loss of YFP, leaving a 
denervated endplate. (E) Immunohistochemical presynaptic markers were either fully 
colocalised with α-BTx, (D) or the presynapse was lost, with only the α-BTx endplate 
visible. (F) In the forelimb LRP-4 (green) immunoreactivity is present surrounding 
the healthy wild-type control NMJ stained with α-BTx (red), with LRP-4 
colocalisation with α-BTx progressively decreasing in the forelimb of SOD1G93A 
NMJs from 84 days of age in the forelimb. Scale = 15µm. 
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of NMJs with pre-synaptic immunolabelling for neurofilaments and synaptophysin colocalised 
with α-BTx at 140 days of age, reflecting a 27% decrease in colocalisation (SOD1G93A: 69.8% ± 
4.75%; wild-type: 95.1% ± 2.17%) (Figure 3.7 B and E). Furthermore, there was no significant (p 
> 0.05) difference in colocalisation between pre- and post-synaptic structures prior to 140 days of 
age. Axonal degeneration and NMJ morphology was only measured at 140 days of age. 
 
To identify the differential vulnerability of forelimb NMJs to architectural protein loss, we 
evaluated the colocalisation of post-synaptic proteins identified previously in the hindlimb. There 
was no significant (p > 0.05) change in the proportion of NMJs with nestin, rapsyn and 
dystrophin colocalised with α-BTx compared to wild-type animals at any age (Figure 3.7 C). 
Conversely, analysis of LRP-4 in forelimb tissue of SOD1G93A mice demonstrated a significant (p 
< 0.01) loss of LRP-4 colocalisation at with α-BTx at 84 days of age, compared to age matched 
wild-type control mice (SOD1G93A: 91.4% ± 1.19%; wild-type: 98.2% ± 0.71%) (Figure 3.7 C 
and F). The loss of LRP-4 at 112 and 140 days was significant, but not as pronounced as found at 
matching ages in the gastrocnemius muscles, nor was it progressive between 84, 112 and 140 day 
old SOD1G93A mutant animals. These data suggest that NMJ degeneration is delayed in the 
forelimb despite axonal degeneration occurring in both hindlimb and forelimb of SOD1G93A 
muscles, however loss of LRP-4 localisation to the post-synapse occurs in both hindlimb and 
forelimbs muscle, but appears to occur at different rates. 
3.3.6 Post-synaptic structural protein levels are altered in SOD1G93A mice 
To identify if the loss of colocalisation of post-synaptic proteins with α-BTx is due to a loss of 
protein levels or a loss of protein trafficking/localisation, Western blot analysis was performed. 
End stage gastrocnemius muscle revealed alterations in protein levels, as well as unconfirmed 
protein-processing deficits. Western blot showed a significant (p < 0.05) decrease in total nestin 
in the gastrocnemius muscle in end-stage SOD1G93A mice, compared with wild-type controls 
(SOD1G93A: 0.19pix2 ± 0.01pix2; wild-type: 0.30pix2 ± 0.01 pix2) (Figure 3.8 A). However, as 
shown in Fig. 6A, a shift from 260kDa nestin to a larger nestin isoform of 350kDa occurs in 
SOD1G93A mice; 260kDa (SOD1G93A: 0.02pix2 ± 0.005pix2; wild-type: 0.28pix2 ± 0.03pix2), 
350kDa (SOD1G93A: 0.17pix2 ± 0.01pix2; wild-type: 0.02pix2 ± 0.007pix2). Conversely, there was 
a significant (p < 0.05) increase in protein levels of LRP-4, dystrophin and rapsyn in end-stage in 
the gastrocnemius muscle of end stage SOD1G93A mice; LRP-4 (SOD1G93A: 0.12pix2 ± 0.022pix2; 
wild-type: 0.016pix2 ± 0.001pix2) (Figure 3.8 B), dystrophin (SOD1G93A: 0.25pix2 ± 0.06pix2; 
FIGURE 3.8. Post-synaptic protein levels are altered in SOD1G93A mice at end stage. 
(A) LRP-4 levels were significantly (p < 0.05) increased in SOD1G93A mice at, 
compared with age-matched controls. (B) Total nestin levels were significantly (p < 
0.05) decreased in SOD1G93A mice compared with age-matched controls. However, 
there was a significant (p < 0.001) shift in protein size from 260kDa to 350kDa in 
SOD1G93A mice. (C) Dystrophin levels were significantly (p < 0.05) increased in 
SOD1G93A mice compared with age-matched controls. (D) Rapsyn levels were 
significantly (p < 0.05) increased in SOD1G93A mice compared with age-matched 
controls.  
R
ap
sy
n:
G
A
PD
H
0.0
0.2
0.4
0.6
0.8
Wild-type SOD1
0.0
0.1
0.2
0.3
0.4
D
ys
tro
ph
in
:G
A
PD
H
SOD1Wild-type
Rapsyn
GAPDH
35 kDa
35 kDa
Total 260 kDa 350 kDa
0.0
0.1
0.2
0.3
0.4
N
es
tin
:G
A
PD
H
B
D
200 kDa
35 kDa
LRP-4
GAPDH
C
A
Dystrophin
GAPDH
250 kDa
35 kDa
Wild-type
SOD
*
*
*
Wild-type SOD1
0.00
0.05
0.10
0.15
LR
P-
4:
G
A
PD
H
*
*
*
A
Nestin
GAPDH
250 kDa
35 kDa
SOD+SOD- SOD+SOD+SOD- SOD- SOD+SOD- SOD+SOD+SOD- SOD-
SOD+SOD- SOD+SOD+SOD- SOD- SOD+SOD- SOD+SOD+SOD- SOD-
	 52	
wild-type: 0.07pix2 ± 0.014pix2) (Figure 3.8 C) and rapsyn (SOD1G93A: 0.6284pix2 ± 0.048pix2; 
wild-type: 0.11pix2 ± 0.018pix2) (Figure 3.8 D).  
3.4 Discussion  
This chapter investigated the sequence of axonal and NMJ degenerative events in the SOD1G93A 
mouse model of ALS. It focused observations on pathological changes to the distal axon, 
alterations to synaptic morphology and key post-synaptic structural proteins of the NMJ in the 
hindlimb (gastrocnemius) and the less studied forelimb (extensor) muscles. The chapter 
highlighted that YFP is a highly detailed marker of distal axon and pre-synaptic alterations, with 
its expression confirming hallmark axonal pathology, as well as key early alterations to NMJ 
morphology. Novel alterations to YFP expressing axonal branch complexity and key post-
synaptic protein localisation and total protein levels in the hindlimb of the SOD1G93A mouse 
model were also identified in this chapter. 
 
3.4.1 Degeneration of the motor neuron distal axon and NMJ pathology occurs prior to 
symptom onset in SOD1G93A mice 
Distal axon degeneration, including axonal beading and fragmentation, and alterations to the 
hindlimb NMJ, are considered key and early features of pathology in the SOD1G93A mouse 
(Gurney et al., 1994; Frey et al., 2000). The process of degeneration in ALS is thought to occur in 
a ‘dying back’ fashion, with degenerative changes beginning in the a-MN axon and progressing 
proximally (Fischer et al., 2004). With the aid of the YFP reporter, hallmarks of the disease are 
shown at an early, presymptomatic time point in the gastrocnemius muscle, and these 
pathological and morphological changes can be detected in the axon and NMJ by assessing 
changes to YFP distribution (Frey et al., 2000; Fischer et al., 2004; Pun et al., 2006). These 
results are comparable to previously reported studies utilising YFP to aid in axonal and NMJ 
characterisation using confocal microscopy (Schaefer et al., 2005; Wong et al., 2009).  
 
It has been previously reported that both low and high copy number SOD1G93A mice exhibit 
axonal fragmentation, NMJ denervation, as well an increase in collateral branches over an 
imaging time course (Frey et al., 2000; Schaefer et al., 2005; Pun et al., 2006; Wong et al., 2009). 
Ngo and Colleagues (2012) have previously shown that NMJ denervation occurs at symptom 
onset, at approximately 63 – 75 days, in the gastrocnemius of the SOD1G93A mouse (Ngo et al., 
2012). Indeed, results from this chapter identified a significant decline in of NMJ innervation of 
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the gastrocnemius at 84 days, a similar age to the previously mentioned study. However, unlike 
the study in Chapter 3, Ngo and Colleagues (2012) did not study axonal or NMJ morphological 
alterations, which were identified to occur at a presymptomatic age in the SOD1G93A mouse.   
Indeed, this Chapter demonstrated that the previously reported onset of hindlimb weakness/loss 
of motor performance is preceded by degenerative axonal pathology within the gastrocnemius 
muscles in the SOD1G93A model. The lack of correlation between the appearance of pathology 
and symptom onset is often attributed to compensatory reinnervation and NMJ structural 
plasticity from remaining a-MNs following loss of vulnerable a-MN subtypes. The current data 
supports this finding, with evidence of compensatory resprouting from YFP positive axons in the 
SOD1G93AxYFP crossed transgenic mouse at a presymptomatic time point (Frey et al., 2000; 
Fischer et al., 2004; Pun et al., 2006). Collateral sprouting and attempted reinnervation in the 
SOD1G93A mouse gastrocnemius was measured by increased terminal axon branching in addition 
to an increase in the number of NMJs with reduced synaptic complexity (Feng et al., 2000b; Li et 
al., 2011).  
 
The NMJ is a highly dynamic structure, which has been shown to undergo reactive changes in 
other pathologies, such as following experimental pre-synaptic distal nerve ablation (Li et al., 
2011). Indeed, during development NMJs undergo transformation from being multi-axon 
innervated with a plaque-like morphology, to a single axon innervated pretzel morphology 
(Balice-Gordon and Lichtman, 1993). In the current study, a small subset of NMJs demonstrating 
reduced complexity whilst retaining full colocalisation between pre- and post-synaptic markers. 
Such NMJs may be newly formed synapses or attempted re-innervation in the SOD1G93A tissue. 
However, analysis used in the current study, whilst being highly stringent on NMJ selection, did 
not select specifically for NMJs with the aforementioned immature ‘plaque-like’ appearance 
(Balice-Gordon and Lichtman, 1993), which is indicative of newly formed synapses. Further, 
using the current model it was unfeasible to determine whether there are any fundamental 
abnormalities in NMJ formation as a result of SOD1 transgene expression, however the lack of 
an overt NMJ phenotype in younger animals and normal distribution of post-synaptic proteins in 
young animals was suggestive of degenerative changes occurring after NMJ formation. Although 
not quantified in the current study, others have shown that the pre-synaptic motor endplate 
undergoes axonal sprouting, similar to axonal collateral branching discussed previously (Ngo et 
al., 2012). Future research would benefit from perusing this observation further using YFP 
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expressing animal models, particularly as YFP axon volumetric analysis can help to identify fibre 
type specific regenerative capacity (Pun et al., 2006). 
 
The use of YFP expressing distal axons and NMJs highlights a novel way to identify alterations 
to cellular structures in other disease models, where axonopathy and synaptic alterations are an 
early or primary event in their pathogenesis (Vickers et al., 2009). Although these morphological 
alterations were evident in early disease in the SOD1G93A mouse, loss of pre-synaptic structures 
were only detected at 84 days, through the significant loss of colocalisation between pre- and 
post-synaptic structures of the NMJ prior to symptom onset (Frey et al., 2000; Fischer et al., 
2004; Hegedus et al., 2008).  This highlights that compensatory plasticity likely plays a major 
role in ALS, with reinnervation of skeletal muscle fibres delaying the loss of muscle function. 
3.4.2 Loss of structural proteins precedes loss of post-synaptic receptors in the hindlimb 
The current chapter aimed to investigate how NMJ changes affected a number of structural 
components of the synapse, beyond the pre-synaptic axon terminal and post-synaptic AChRs. 
Surprisingly, structural proteins such as nestin, rapsyn, dystrophin and LRP-4 are all lost from the 
NMJs prior to complete disassembly of AChRs.  
 
The intermediate filament nestin provides structural support to the NMJ (Herrmann and Aebi, 
2000; Kang et al., 2007; Mohseni et al., 2011; Yang et al., 2011), however is also a substrate for 
phosphorylation by a large number of kinases, including CDk5 (Sahlgren et al., 2003). 
Phosphorylation of nestin at Thr316 allows for AChR dissociation. During skeletal muscle 
development, nestin is distributed throughout the muscle fibre, localising to the neuromuscular 
and myotendious junctions following NMJ formation (Lendahl et al., 1990; Vaittinen et al., 
1999). Following nerve transection injury, nestin expression increases in skeletal muscle 
(Vaittinen et al., 1999) and has been shown to be increased in the cortex of the SOD1G93A mouse 
(Lee et al., 2011). Nestin colocalisation to the NMJ is progressively lost in SOD1G93A mice, 
however there were also changes to overall nestin levels. As with many other intermediate 
filaments, nestin is a target for post-translational modifications, in particular, phosphorylation and 
ubiquitination (Snider and Omary, 2014). It currently remains unclear whether the size-shift of 
nestin from our experiments could be due to aberrant processing from SOD1G93A overexpression, 
or whether there is abnormal post-translational modification occurring, such as 
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hyperphosphorylation and ubiquitination as occurs with related intermediate filaments (Ku and 
Omary, 2000; Snider and Omary, 2014).  
 
LRP-4 is a correceptor for agrin and forms an intracellular signalling complex with muscle 
specific kinase (MuSK) (Kim and Burden, 2008; Zhang et al., 2008a). The agrin-LRP-4-MuSK 
complex is required for both NMJ formation, but also NMJ maintenance and stability (Barik et 
al., 2014). Furthermore, a loss of LRP-4 can lead to a-MN pre-synaptic retraction from the NMJ 
(Barik et al., 2014). Mutations to LRP-4 result in the development of congenital myasthenic 
syndromes (CMS), and Cenani–Lenz syndrome, with autoantibodies for LRP-4 also causing 
myasthenia gravis (Li et al., 2010; Pevzner et al., 2012; Ohkawara et al., 2014). Our identification 
of LRP-4 loss may indicate a loss of the agrin-LRP-4-MuSK signalling complexes ability to 
effect both NMJ formation in the reinnervation attempt, but also a loss of NMJ maintenance that 
may lend pathogenicity to both a-MN and NMJ degeneration. This phenomenon of LRP-4 
pathology in the current chapter was identified at the approximate age of reported symptom onset 
in these mice (84 days), possibly illuminating a mechanism behind the apparent inability for 
effective reinnervation to occur to stave off motor symptoms. Indeed, the identified increase in 
LRP-4 levels could indicate a regenerative attempt by the muscle, or that mislocalisation of LRP-
4 is occurring and mutant SOD1 is driving both mislocalisation of LRP-4, up-regulation or both. 
 
Rapsyn is primarily a structural protein for post-synaptic AChR aggregation. In addition to AChR 
binding (Frail et al., 1987; Gautam et al., 1995; Zuber and Unwin, 2013), rapsyn interacts with 
the cytoskeleton (Antolik et al., 2007) and molecules such as calpain (Chen et al., 2007), β-
catenin (Zhang et al., 2007a) and α-actinin (Dobbins et al., 2008). Rapsyn deficiency results in 
CMS, and rapsyn mRNA levels has also been shown to increase in muscle following nerve 
transection (Frail et al., 1989; Ohno et al., 2002). Indeed, increased expression of rapsyn in CMS 
in vivo models improved the pathological outcome of NMJs (Losen et al., 2005). A significant 
increase in skeletal muscle rapsyn levels in the SOD1G93A mouse was identified. However, this 
was coupled with a decrease in the proportion of NMJs showing rapsyn colocalisation with α-
BTx, possibly suggesting a dysfunction in the aggregation of AChRs at the skeletal muscle 
membrane. 
 
Dystrophin is a component of the dystrophin glycoprotein complex (DGC) which is required for 
organisation and stabilisation of synaptic folds (Lyons and Slater, 1991; Knuesel et al., 1999; 
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Sanes and Lichtman, 1999; Banks et al., 2003; Shiao et al., 2004). Dystrophin also provides a 
point of linkage between the muscle plasma membrane and the F-actin component of the 
cytoskeleton (Ervasti and Campbell, 1993; Banks et al., 2009). Importantly, the DGC putatively 
acts as a scaffold for signalling proteins including nNOS, calmodulin, phosphoinositol 
triphosphate 3 and may also be involved with mitogen activated protein kinase (MAPK) 
signalling (Rando, 2001) and maintaining Ca2+ homeostasis (Gillis, 1996; Carlson, 1998). In 
Duchenne muscular dystrophy, loss of dystrophin results in progressive destabilisation of the 
NMJ (Pilgram et al., 2010). These studies suggest that the loss of dystrophin from the NMJ 
occurring late in the SOD1G93A model may reflect the increased disassembly of the AChR 
complex from the skeletal muscle membrane. The identified increase in dystrophin levels 
suggests, again, a lack of localisation and trafficking to the NMJ. It currently remains unknown 
how changes to DGC assembly in the SOD1G93A model affect the associated signalling pathways 
and the structural integrity of the post-synapse. The early and progressive loss of the NMJ 
structural proteins may have a dramatic effect on the multitude of signalling cascades that are 
required for NMJ stability, maintenance and plasticity. 
 
A possible mechanism driving the identified increase in post-synaptic protein expression in the 
SOD1G93A  gastrocnemius  may be explained by the muscles capacity for activity dependant 
changes in the architecture of the NMJ, as discussed in Chapter 1, Section 1.2.2 (Misgeld et al., 
2005; Morsch et al., 2013). Whilst previous research has shown that increased ACh at the NMJ 
can alter synaptic performance and maintenance, the innervation of the gastrocnemius muscle at 
end stage in the SOD1G93A mice is drastically decrease, suggesting that increased synaptic 
activity is not causing the identified protein expression. As stated throughout Section 3.4.2 of this 
thesis, it is more likely that surviving, denervated myocytes undergo an increase in NMJ protein 
synthesis due to a loss of activity, similar to what is identified in nerve transection studies (Frail 
et al., 1989; Vaittinen et al., 1999; Ohno et al., 2002). However, the increase in protein 
expression, particularly that of rapsyn, may instead act as the driving force for NMJ degeneration, 
as rapsyn overexpression has been found to inhibit AchR clustering (Han et al., 1999). 
3.4.3 Distal forelimb pathology is only evident in the later stages of disease in the 
SOD1G93A mouse 
The onset of disease in the SOD1G93A mouse classically begins with hindlimb weakness which 
progresses to a severe motor disability whilst the forelimb muscles remain relatively spared 
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(Gurney et al., 1994; Bendotti and Carri, 2004). Despite differences in muscle fibre type 
compositions and vulnerability between the forelimb and hindlimb muscles investigated, 
Mathewson et al., (2012) have suggested that forelimb musculature is relatively comparable 
between humans and mice, irrespective of limb function and skeletal muscle biomarkers between 
humans and mice (Hegedus et al., 2008; Elashry et al., 2009; Mathewson et al., 2012).  
 
In the present study, axonal pathology evident at the later disease stages in the forelimbs, with an 
increased proportion of beaded and fragmented axons at 140 days. Similarly, increases in 
morphological abnormalities were also evident at 140 days in SOD1G93AxYFP mice. This 
highlights that distinctive axonal and NMJ morphology alterations are delayed relative to the 
hindlimb in SOD1G93A mice. Furthermore, analysis of pre-and post-synaptic components 
indicated that the delay in functional loss of the forelimbs in SOD1G93A mice is supported by an 
absence of histological pathology until the disease is well progressed (Gurney et al., 1994). There 
was a significant decrease in the proportion of NMJs with colocalisation between pre-synaptic 
terminals and α-BTx at 140 days of age, however only the post-synaptic signalling protein LRP-4 
was lost, with no loss of rapsyn, nesting and dystrophin, despite no earlier loss of pre-synaptic 
markers at similar time points (Schafer and Hermans, 2011; Barik et al., 2014).  
 
Studies have demonstrated that spinal pathology in the SOD1G93A mouse is widespread 
throughout both the lumbar and thoracic regions (Karlsson et al., 2004; Dodge et al., 2008; 
Graffmo et al., 2013), however the delayed pathology in the forelimb muscles is suggestive of 
potential differences in the disease process which may be localised to specific regions. This is 
highlighted by the differential loss of nestin from the NMJs of the gastrocnemius and forelimb 
muscles. In the hindlimb, nestin is lost parallel to loss of the pre-synaptic component, and occurs 
prior to symptom onset, however this loss of nestin was not present in the forelimb. This 
discrepancy may arise from key differences between the motor units of the forelimb and hindlimb 
and need to be investigated further (Elashry et al., 2009; Mathewson et al., 2012).  
 
Conversely, the loss of LRP-4 from both hindlimbs and forelimbs suggests that SOD1G93A may 
play a direct involvement in its loss from the NMJ, independent of muscle fibre type, compared 
to other post-synaptic proteins studied. It is known that SOD1G93A expression in muscle can both 
cause a motor phenotype in vivo when conditionally expressed and can also lead to the aberrant 
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expression of a number of genes; however, the proteins identified in this study are yet to be 
investigated in this manner (Wong and Martin, 2010). 
 
Although the underlying mechanisms for the disparity in axon and NMJ degeneration remain to 
be fully elucidated, evidence suggests that degeneration of type II fibres occurs in a length-
dependent manner in SOD1 mice, with preferential loss of longer axons over shorter (Tallon et 
al., 2016). This recent finding provides excellent evidence for length-dependent degeneration in 
the lateral thoracic nerve and cutaneous maximus muscle and further studies may reveal whether 
a similar pattern of degeneration occurs in the gastrocnemius and forelimb extensor muscles. 
Interestingly, Nguyen and Colleagues (2012) reported that NMJ degeneration occurs in the 
forelimb at symptom onset, in the SOD1G85R mouse model, a phenomenon not found in the 
SOD1G93A model (Nguyen et al., 2012). The denervation was found to predominantly occur in the 
fast-fatigue fibres. The SOD1G85R mutant has a slower progressing disease course, which may 
suggest that the fast progressing G93A strain used in the current may be more toxic to the lumbar 
motor neuron pool, suggesting that the hindlimbs are more vulnerable to this SOD1 mutation 
than the forelimbs (Bruijn et al., 1997). Further investigations should determine whether subtle 
differences in degeneration occur from one side of the body to another. ALS in many human 
cases is characterised by asymmetrical spread of clinical symptoms (Swinnen and Robberecht, 
2014). 
3.5 Conclusion 
ALS is classically referred to as a distal axonopathy; the resulting pathology following a-MN 
dysfunction. Although this phenomenon has been known for some years, identification of the 
earliest pre and post-synaptic changes are yet to be completed. The current chapter attempted to 
identify the earliest changes to the distal axon and NMJ, with the intention of identifying the 
most prudent site for therapeutic intervention.  
 
YFP expression was instrumental in identifying axonal and NMJ morphological alterations, with 
hallmark pathology and plasticity being evident, particularly at the early, presymptomatic time 
point. This highlights the use of YFP in the detection of axonal and synaptic abnormalities in 
neurodegenerative diseases. The reported progressive loss of postsynaptic scaffolding in the 
SOD1G93A gastrocnemius muscle suggests that using α-BTx as a sole marker for the NMJ loss 
does not provide a full picture of disease progression. This loss of key structural components in 
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the hindlimb but not in the forelimb indicates that these proteins, which are involved in 
maintaining post-synaptic integrity, may play an important role in the progressive dysfunction of 
this specialised synapse. This chapter also highlighted that the post-synaptic integrity of the NMJ 
may be playing a key pathogenic role in preserving forelimb function in this model. The cause for 
this phenotypic phenomenon is not well understood, however it may reflect differences in pre- 
and post-synaptic structures, different skeletal muscle composition, or metabolism, including 
mutant SOD1 activity. Furthermore, a live imaging approach in the forelimbs and gastrocnemius 
of the SOD1G93A mouse, utilising the YFP reporter, may offer further insights into axonal 
degeneration, plasticity and NMJ morphology characterisation to establish a more holistic 
sequence of pathological events.  
 
Currently, alterations to the pre-synaptic axon and NMJ compartment in the hindlimb are the 
earliest identified pathology in the SOD1G93A mouse model, followed by alterations to synaptic 
integrity and gross innervation (Figure 3.9 A). Targeting pathology in ALS at the earliest possible 
instance will hopefully improve outcomes of the disease. To this end the distal axon in the 
SOD1G93A mouse should be considered as an attractive therapeutic target, to prevent both its 
breakdown, but to also preserve its function to limit the classic ‘distal axonopathy’ of ALS 
(Figure 3.9 B). 
 
FIGURE 3.9. Timeline of distal pathology and possible therapeutic intervention. (A) 
Axonal degeneration and morphological alterations to hindlimb NMJs are the earliest 
identified pathology in the distal neuromuscular circuit. (B) MT disintegration and 
altered dynamics are associated with the pathogenesis of ALS. Targeting MTs with 
stabilising compounds (red circles) may improve outcomes in ALS.  
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4 The microtubule stabilising agent Epothilone D modifies disease progression in a mouse 
model of Amyotrophic Lateral Sclerosis. 
4.1 Introduction 
Although being described and researched extensively for over a century, limited translation of 
effective therapeutics to combat ALS has occurred. The only current therapy for patients with 
ALS is the compound Riluzole; a drug that modestly modifies various aspects of glutamatergic 
signalling (Bensimon et al., 1994; Gurney et al., 1998; Vucic et al., 2013). However, Riluzole 
does not present a cure, delaying death by only 6-7 months in subset of patients that respond well 
to the drug (Hardiman et al., 2011). There remains a great need for new drug development, and 
the identification of novel mechanisms and therapeutic targets.  
A pathological hallmark that has the capacity to be targeted is the degeneration of the spinal a-
MN distal axon and terminal. As identified in Chapter 3, axonal pathology, consisting of beading 
and fragmentation, is an early presymptomatic event in ALS. Further, as discussed in Chapter 1 
of this thesis, axonal transport dysfunction and aberrant microtubule hyperdynamics is an early 
occurrence in the pathogenesis of ALS (Fanara et al., 2007; Bilsland et al., 2010; Kleele et al., 
2014). Evidence for microtubule involvement in ALS classically stems from the identification of 
dysfunctional axonal transport; thought to limit the delivery and recycling of mitochondria, 
proteins, mRNA, vesicles and survival factors necessary for a-MN health and longevity (Bilsland 
et al., 2010; Alami et al., 2014; Dubey et al., 2015). However, it is becoming increasingly 
apparent that the phenomenon of microtubule dynamic instability is altered in ALS, resulting in a 
shift to a hyperdynamic state (Fanara et al., 2007; Kleele et al., 2014). Indeed, many molecular 
mechanisms associated with MN vulnerability also impact on microtubule functions, as 
highlighted in Chapter 1. As discussed, Fanara and Colleagues (2007) emphasised that 
microtubule dynamics initiates the dysfunction of axonal transport in SOD1G93A mice, suggesting 
that alterations to microtubule dynamics is a primary mechanism in ALS. This is substantiated by 
the recent identification of the TUBA4A rare variant, whereby the various missense mutations to 
this tubulin isoform decrease its ability to polymerise into the microtubule polymer, altering the 
dynamics of the microtubule network (Smith et al., 2014). These include changes to tubulin 
isotype expression, altered tubulin localisation and tubulin aggregation, all of which results in a 
weakened microtubule network (Smith et al., 2014). Furthermore, Kubota and Colleagues (2009), 
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found that mutant SOD1 can alter microtubule networks by modulating tubulin polymerization 
and dynamics (Kabuta et al., 2009). Moreover, microtubules are involved in the process of axonal 
degeneration, with microtubules being a substrate for caspase and calpain; enzymes that are 
activated in disease, breaking down the axon during Wallerian-like axonal degeneration in ALS 
(Wang et al., 2012).  
Targeting the cytoskeleton to improve outcomes in neurodegenerative diseases is not a novel 
concept (Brunden et al., 2011; Baas and Ahmad, 2013; Eira et al., 2016). Diseases where 
alterations to microtubule dynamics and stability, such as AD, PD, tauopathies and 
schizophrenia, have shown that using low doses of antimitotic compounds that target 
microtubules can improve pathology and outcomes in various disease models (Andrieux et al., 
2006; Fanara et al., 2007; Green et al., 2008; Kitaoka et al., 2009; Brunden et al., 2011; Zhang et 
al., 2012; Cartelli et al., 2013). The most well characterised and utilised microtubule stabilising 
compound, taxol, has been supplemented by other compounds that have greater tubulin affinity, 
decreased off-target effects and the ability for blood brain barrier permeability and CNS retention 
(Bollag et al., 1995; Brunden et al., 2011). One such microtubule-targeting compound is 
Epothilone D (EpoD). EpoD is a member of the epothilones, a group of compounds found 
naturally in the myxobacterium Sorangium cellulosum (Bollag et al., 1995). EpoD is currently in 
clinical trials for taxol-resistant malignancies, however it is being increasingly used at lower 
doses to manipulate the microtubule cytoskeleton in the nervous system (Cheng et al., 2008; 
Brunden et al., 2010; Zagouri et al., 2015). 
Targeting microtubules to improve outcomes in ALS was initially investigated by Fanara et al 
(2007), where the compound Noscapine was utilised to ameliorate the hyperdynamic microtubule 
phenotype identified in the SOD1G93A mouse model (Fanara et al., 2007). Noscapine effectively 
‘stalls’ microtubule dynamics, limiting the amount of polymerisation/depolymerisation events 
that occur, thus decreasing microtubule hyperdynamics. Indeed the authors reported that 
noscapine attenuates microtubule dynamics, which directly improved axonal transport. Clinically 
the animals showed slower pathology progression and extended survival. However, noscapine is 
still in preclinical trials, highlighting the need to test novel compounds that also selectively target 
microtubule stability for use in ALS. Targeting the distal axon with calpain inhibitors has also 
been shown to decrease microtubule disintegration and improve outcomes in models of 
peripheral neuropathy, suggesting that protecting the distal axonal cytoskeleton is a viable 
approach to limiting pathology in diseases such as ALS (O'Hanlon et al., 2003; Moloney et al., 
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2014). These previous studies highlight that microtubule stabilisation may be an attractive target 
for ALS, to alleviate not only aberrant dynamics, but to also stabilise the microtubule 
cytoskeleton against enzymatic disintegration.  
The current investigation utilised the SOD1G93A mouse model of ALS to identify the efficacy of 
the microtubule-targeting compound EpoD to modify disease progression by targeting the distal 
axon. Investigations into the ability of EpoD to increase the stability of the microtubule network 
in the spinal cord were initially undertaken, as SOD1G93A mouse models spinal onset ALS. 
Treatment of SOD1G93A mice with low dose EpoD began at 50 days of age, in accordance with 
recommended treatment paradigms for this model and was carried out until endpoint (Scott et al., 
2008). Behavioural, clinical and pathological characterisation of disease progression was 
completed, followed by analysis of time of disease onset and survival. These investigations 
determined how EpoD modifies disease progression in ALS and develop insights into not only 
the efficacy of microtubule-targeting therapies for the disease, but also the scope for 
improvements for combination therapies. Moreover, it will further highlight the important role 
microtubules have on disease progression and maintenance.  
4.2 Methods 
4.2.1 Animals 
C57BL/6 mice were used to probe the efficacy of EpoD to induce microtubule stability in a-MNs. 
Male transgenic SOD1G93A mice were used for behavioural, clinical and pathological evaluation 
after EpoD treatment. Double transgenic SOD1G93AxYFP mice (see Chapter 2) were used for 
histological analysis of the distal axon and NMJs. All mice were assessed daily for clinical 
symptoms and weighed daily from 50 days of age (trial start) until end stage. End stage in these 
investigations was considered as 80% of maximal weight or an inability for the mouse to right 
itself (righting reflex) within 15 seconds. Following the onset of hindlimb paralysis, SOD1 mice 
were given the nutrient supplement NutraGel (Bioserve), generally from 120-130 days of age, to 
aid in dietary and water supplementation. Further, normal mouse chow was placed on the cage 
floor and moistened with drinking water. 
4.2.2 Therapeutic regime 
For initial microtubule stabilisation assay C57BL/6 mice (n=8) were injected intraperitonealy 
with either EpoD (Abcam) (2mg/kg, 50ul injection volume) or DMSO (100%, 50ul injection 
volume) every five days for two weeks. For EpoD treatment trial SOD1G93A transgenic mice 
	 63	
(n=28), their wild-type (WT) littermates (n=16), and SOD1G93AxYFP mice (n = 18), were 
randomly allocated to either EpoD (2mg/kg) or vehicle (DMSO) groups. Injections were 
administered every 5 days, starting from 50 days of age (Kennel et al., 1996; Scott et al., 2008). 
Mice were weighed at the same time daily to account for diurnal cycles.  No adverse effects due 
to the vehicle were seen. Mice were injected according to this regime until the required time point 
or endpoint was reached. Mice were then terminally anesthetised with sodium pentabarbitone and 
perfused with 4% paraformaldehyde or ice cold 0.01M PBS. All researchers were blinded to 
genotype and drug administration for the duration of the experiments. 
4.2.3 Clinical assessment 
Clinical evaluation was completed from 50 days of age until disease end stage. Mice were 
examined daily and assessed using an amended four point scoring system, with the mode score 
for the week being recorded and evaluated (Weydt et al., 2003). Evaluation categories included 
‘normal clinical presentation’ (score of 4); ‘hindlimb tremors or ‘waddle’ when motile’ (score of 
3); ‘dragging of hindlimbs, or decreased ability to extend hindlimbs when suspended by the tail’ 
(score of 2), ‘paralysis of hindlimbs and substantial decrease in ability to ambulate around the 
cage’ (score of 1); ‘inability to right within 15 seconds, or 20% loss of body weight from 
maximum, and inability to ambulate around cage’ (score of 0). Weight was also utilised as a 
clinical assessment of disease progression. 
4.2.4 Rotarod performance test 
Motor behaviour was evaluated using rotarod performance testing (TSE Systems). The rotarod 
performance test measures strength, endurance and coordination, and is considered a gold 
standard in motor phenotype testing (Weydt et al., 2003; Bohlen et al., 2009). Mice were trained 
one week prior to the commencement of experiments by experiencing various rotational speeds 
(10rpm, 20rpm and 40rpm), with an acceleration of 8rpm/minute, ensuring the mouse had to 
increase its pace to remain on the rotating rod (Galante et al., 2009). On the day of testing, mice 
were habituated in the testing room for 15 minutes. Mice were then placed on the rotating rod at 
4rpm, which served as a minimum cut-off speed for mice with later stage clinical progression, 
which can no longer grip the rod. The test program consisted of an acceleration phase from 4rpm 
to 40rpm over 300 seconds, followed by a further 60 seconds at 40rpm (Galante et al., 2009; 
Perry et al., 2010). For all experiments latency to first rotation and latency to fall were recorded. 
Rotarod performance testing was repeated three times per session with a 15 minute inter-trial-
interval between tests. Testing was completed three times per week. 
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4.2.5 Grip strength test 
Grip strength was evaluated using a digital force gauge (Ametek). Grip strength measures the 
strength of the limbs, and is a measure of both the muscle mass and innervation of the muscle 
groups concerned (Schafer and Hermans, 2011). Grip strength of the hindlimbs and forelimbs 
were evaluated, consisting of three successive measurements. This was repeated three times with 
a five-minute inter-trial-interval between tests. Grip strength (kilograms of force (kgf)) was 
measured three times a week. 
4.2.6 Behavioural statistical methods 
The primary aim of behavioural analysis was to model rotarod performance, grip strength and 
weight, investigating the relationships between treatment and genotype. This was completed in 
collaboration with the Menzies Institute for Medical Research statistics department. The goal was 
to obtain a model trajectory, which represents our mice in the current behavioural conditions over 
time, without over fitting, so that the trajectory might reasonably be generalised to the greater 
population. Due to the general non-linear nature of the behavioural and biological outcomes 
measured in the current study, we used smooth non-linear polynomials to fit the data where 
appropriate (Grajeda et al., 2016). However, much of the data presented in the current study 
employed piece wise non-linear polynomial models, where individual break points and cubic 
splines are applied concurrently in the same model to best represent, and thus fit, the data 
(Durban et al., 2005; Chen and Stanley, 2012; Grajeda et al., 2016). ‘Cut-Points’ can be added to 
non-linear models to improve fit by increasing the number of possible maxima and minima 
(‘bends’) in the curve. In some cases, they can also be used to estimate when the data 
significantly deviates from previous time points.  
 
The smooth or piecewise functions were applied within the fixed effects component of a linear 
mixed model. This approach was applied in the case of all behaviour outcomes. Linear mixed 
effect models are becoming more popular for modelling longitudinal data, as they are able to deal 
with the correlation between repeated measurements, as well as investigate variation between 
individual trajectories. This combination of piecewise polynomials within a mixed effects model 
has high utility for longitudinal biological data (Naumova et al., 2001). The final models selected 
are outlined below. Values are represented as mean plus lower and upper level confidence 
intervals. An unstructured covariance structure for random effects was applied throughout. The 
software package used was STATA 12 (StataCorp LP). 
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Latency to rotation model fit: Separate straight-line functions were fitted to the wild-type and 
SOD1G93A data, coupled with optimal ‘break points’ for SOD1G93A mice for each treatment, 
identified through a grid search. Random slopes were allowed for mouse.  Latency to fall model 
fit: A straight-line fit was applied to wild-type curve and a quadratic term for SOD1G93A mice. 
Separate terms for treatments were added with 5 cut-points to improve model fit. Random slopes 
were allowed for mouse.   Forelimb grip strength model fit: Utilised the incorporation of both 
linear and cubic terms, with the addition of an optimal break point, as data suggested two stages 
of disease progression. Random slopes were allowed for mouse. Hindlimb grip strength model 
fit: Two straight-line functions were fitted for both SOD1G93A and wild-type mice coupled with 
the fit of separate break points. Random slopes were allowed for mouse. Weight model fit: A 
separate straight line for wild-type and SOD1G93A was fit, as well as a cubic spline function with 
three cut-points, due to the subtle curvature of the data. Random slopes were allowed for mouse. 
4.2.7 Histopathology 
Mice were transcardially perfused and relevant tissue was cryosectioned as described in Chapter 
2, followed by histological analysis outlined below. 
4.2.7.1 Spinal motor neuron visualisation and quantitation 
Spinal a-MNs were quantified by firstly isolating the lumbar region of the spinal cord as 
described previously (Gunther et al., 2012; Harrison et al., 2013), followed by sectioning at 30µm 
onto slides. Every fourth lumbar section was selected for quantitation. Lumbar a-MN numbers 
were evaluated by staining with 0.125% toluidine blue in 0.75% acetic acid for 10 minutes. 
Lumbar sections (L1 – L5) were imaged using a Zeiss LAB A1, fitted with a bright field light 
source and a Zeiss AxioCam iCc5 camera (Zeiss) Images were analysed in image J, with counted 
cells being selected based on pre-reported a-MN cell area (cell area ≥450 µm2, ≤745 µm2), dark 
staining cytoplasm, a dark nucleolus and ventral horn location (Friese et al., 2009). Lateral and 
medial motor neuron columns were pooled during counts. Immunohistochemical quantitation of 
a-MNs was also used by labelling for dephosphorylated neurofilaments (SMI-32; 1:1000; 
Sternberger Monoclonals/Covance), with a-MNs selected based on diameter (≥20µm) and ventral 
location (Blizzard et al., 2015).  SMI-32 immunohistochemistry was quantitated using dual cube 
immunofluorescence  (Leica DM-LB2, Leica). 
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4.2.7.2 Quantitation of glial immunoreactivity 
Lumbar spinal sections were prepared as described above. Every fourth 30µm slide mounted 
section was firstly rehydrated and then permeablised for 4 hours in blocking diluent (1% Triton-
X 100, 5% BSA in 0.01M PBS). Primary antibodies for microglia (rabbit-anti Iba1; 1:1000; 
WAKO) and astrocytes (mouse-anti GFAP; 1:1000; Abcam) in blocking diluent were used to 
identify changes to glial activation. Primary antibodies were incubated at 4°C for a minimum of 
16 hours, followed by 4x10 minute washes in PBS. Secondary antibodies (mouse Alexa568, 
rabbit Alexa647) were diluted in PBS (1:750; Molecular Probes) and sections were incubated for 
2 hours at room temperature. Secondary antibodies were washed thoroughly and coverslipped as 
described in Chapter 2. Analysis of immunolabelled glia was performed using spinning disk 
confocal microscopy and the area of fluorescence was calculated using Image J (NIH), as 
described in Chapter 2.  
4.2.7.3 Quantitation of distal axonopathy, NMJ colocalisation and NMJ morphology 
EpoD treated SOD1G93A and SOD1G93AxYFP were perfused and the gastrocnemius muscles 
dissected and cryosectioned at 80µm onto glass slides. At 50, 70, 140 days (end stage not 
completed as hindlimb is fully paralysed). Forelimbs extensor muscles (extensor carpi radialis 
longus, extensor digitorum communis, extensor digitorum lateralis and extensor carpi ulnaris) 
were dissected and sectioned at 40µm and probed with a presynaptic antibody cocktail (as in 
Chapter 3, section 3.2.2) to visualise the NMJ. All sections were stained for post-synaptic 
acetylcholine receptors (AChRs) using AlexaFluor conjugated 594nm α-bungarotoxin (α-BTx, 
1:200, Molecular Probes/Invitrogen) for 30 minutes. Sections were washed thoroughly in PBS 
followed by mounting in Permafluor mounting media. Gastrocnemius sections were imaged 
using confocal microscopy (80µm stacks, 2µm interval, NIKON). Distal axons and NMJs were 
analysed using Image J. Forelimb muscle immunohistochemistry was quantitated using dual cube 
immunofluorescence  (Leica DM-LB2, Leica).  
4.2.8 Western blot 
PBS perfused lumbar spinal cords (15µg) were homogenised in RIPA-Inhibit (RIPA-INH) buffer 
(RIPA buffer + trichostatin-a,  (Sigma)), followed by centrifugation at 70,000g for 30 minutes at 
4°C and re-suspension in RIPA-INH buffer. Protein expression was then evaluated by Western 
blot (Brunden et al., 2010; Cartelli et al., 2013). Blots were cut to remove the need for antibody 
stripping. Tubulin acetylation levels were used as a marker of microtubule stability (mouse 
monoclonal, 1:5000, Sigma Aldrich) and neurofilament M (NFM) for a cytoskeletal loading 
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control (rabbit polyclonal, 1:1000, Millipore). Choline acetyltransferase (ChAT) levels were 
measured as an indicator of a-MN loss (goat polyclonal, 1:200, Millipore) with GAPDH (rabbit 
polyclonal, 1:5000, Millipore) used as a loading control. Blots were imaged using a Chemi-Smart 
5000 chemiluminescent imager and subsequent analysis completed using Image-J (NIH). 
4.2.9  Pathology and Western blot statistical analysis 
Analysis was performed using MS-Excel (Microsoft). Histological and Western blot analysis was 
completed using GraphPad Prism using one-way ANOVA with Tukey’s post-hoc correction for 
multiple comparisons, or t-tests, respectively. Clinical evaluation was analysed using two-way 
analysis of variance (ANOVA) with Bonferroni post-hoc correction. Survival curve analysis (log-
rank) was completed. p < 0.05 was considered significant. All results are expressed as mean ± 
standard deviation, or median for survival analysis.  
4.3 Results 
4.3.1 Epothilone D administration increases tubulin acetylation in the lumbar spinal cord 
It has been previously reported that EpoD increases biomarkers of microtubule stability in the 
cortex of mice (Brunden et al., 2010). To evaluate whether EpoD had similar effects on the 
microtubule network in the spinal cord, mice were injected twice (day 1 and day 6) with 2mg/kg 
of EpoD, followed by Western blot analysis of the lumbar spinal cord. A monoclonal antibody 
specific for acetylated tubulin chemical modifications was utilised, as acetylation is enriched on 
stable microtubules (Janke, 2014). After two injections of 2mg/kg EpoD, Western blot of the 
lumbar region showed a significant (p < 0.001) increase in the levels of tubulin acetylation 
(EpoD: 2.296 pix2 ± 0.3205 pix2; vehicle: 0.9402 pix2 ± 0.1984 pix2) (Figure 4.1). This suggests 
that recurrent injections of 2mg/kg of EpoD are sufficient to increase microtubule stability in the 
CNS, specifically in the lumbar spinal cord. 
4.3.2 Epothilone D treatment does not induce gliosis 
Microtubule-targeting compounds such as EpoD are associated with the development of painful 
peripheral neuropathies when used at high doses (Argyriou et al., 2011). Although the dose used 
in the current investigation is approximately 1/20 the average dose used in cancer therapies, the 
large number of repeated injections used in the current study have not been previously reported. 
To investigate whether the treatment regime of 2mg/kg of EpoD (20 injections over 16 weeks) 
induced pathology associated with peripheral neuropathy, glia were specifically evaluated in the 
dorsal and ventral horns of the lumbar spinal cord (Figure 4.2 A) of wild-type mice. Astrocytes 
FIGURE 4.1. Western blot of acetylated tubulin in the lumbar spinal cord of EpoD 
treated mice. Increased acetylated tubulin levels suggest an increase in the stability of 
the microtubule network in EpoD treated mice, compared to vehicle treated controls. 
(P < 0.001) (mean ± SD, n = 4 & 4 respectively). 

Figure 4.2. Confocal images of glia in the lumbar spinal cord of EpoD and vehicle 
treated wild-type mice. (A) Diagram of the mouse lumbar (L3) spinal cord, 
highlighting the dorsal and ventral horn, and the ventrally located spinal MNs. Medial 
motor neuron columns (A1) and lateral motor neuron columns (A2) are also 
highlighted. (B) Neither GFAP labelled astrocytes, (C) or Iba1 labelled microglia 
were activated by EpoD or vehicle treatment. Panels 1 – 8 represent higher 
magnification of dorsal and ventral horn. (P > 0.05) (mean ± SD, n = 6 & 4 
respectively). Scale = 60 & 500µm. 
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were labelled with GFAP, and the area of labelling compared between EpoD and vehicle treated 
wild-type mice. There was no significant difference (p > 0.05) between EpoD and vehicle treated 
mice in either the ventral horn (EpoD: 0.020 mm2 ± 0.015; vehicle: 0.019 mm2 ± 0.0095) or 
dorsal horn (EpoD: 0.016 mm2 ± 0.007; vehicle: 0.018 mm2 ± 0.0096) regions of the lumbar 
spinal cord (Figure 4.2 B). Similarly, microglia were labelled with Iba1, and the area of labelling 
compared between EpoD and vehicle treated wild-type mice. Again, there was no significant 
difference (p > 0.05) between EpoD and vehicle treated mice in either the ventral horn (EpoD: 
0.026 mm2 ± 0.007; vehicle: 0.033 mm2 ± 0.010) or the dorsal horn (EpoD: 0.029 mm2 ± 0.007; 
vehicle: 0.035 mm2 ± 0.013) regions of the lumbar spinal cord (Figure 4.2 C). These results 
suggest that the current treatment regime does not induce glial activation in the lumbar spinal 
cord of mice. 
4.3.3 Epothilone D treatment does not alter motor neuron survivability in wild-type mice 
To ensure that chronic, low dose injections of EpoD were not neurotoxic, evaluation of a-MN 
number was undertaken in wild-type treated mice. Toluidine blue stained sections were used to 
identify large a-MNs located in the ventral horn of the lumbar spinal cord (Friese et al., 2009). 
The number of a-MNs per lumbar section was not significantly different (p > 0.05) between 
treatment groups (EpoD: 10.82 ± 2.51; vehicle: 11.13 ± 2.03) (Figure 4.3). This suggests that 
chronic low dose EpoD treatment is not neurotoxic to a-MNs of the lumbar spinal cord.  
 
After initial experiments confirmed that the proposed treatment dosage altered acetylation in the 
spinal cord but did not trigger gliosis of a-MN toxicity, the proposed trial utilising both wild-type 
and SOD1G93A mice commenced. The trial consisted of 2mg/kg injections of EpoD every 5 days 
from 50 days of age. Disease progression was evaluated with motor behaviour (beginning at a 
baseline age of 49 days of age) consisting of rotarod performance and grip strength, neurological 
scoring and weight analysis, and survival. Subsequent pathology and molecular alterations were 
also evaluated. 
4.3.4 Epothilone D treatment alters rotarod performance in SOD1G93A mice 
Rotarod performance testing is an indirect measure of muscle strength, endurance and 
coordination of mice. Mice are placed on an accelerating rotating wheel, with latency until first 
rotation and latency until fall being recorded. In the current study it was measured three times a 
week between 49 and 145 days of age.  
Figure 4.3.  Histological analysis of toluidine blue stained MNs in EpoD treated wild-
type mice. Quantitation of motor neuron numbers in toluidine blue stained sections 
(cell area ≥450 µm2, ≤745 µm2), dark staining cytoplasm, a dark nucleolus and ventral 
horn location (both lateral and medial motor columns). There was no significant 
difference in MN numbers between EpoD and vehicle treated wild-type mice (P > 
0.05) (mean ± SD, n = 6 & 4 respectively). Scale = 30µm. 
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4.3.4.1 Latency to first rotation 
Rotarod performance, as measured by Latency to first rotation, is a measure of the time at which 
the mice can no longer walk continuously on the top of the rotating rod, and experience a full 
rotation without falling off (Figure 4.4 A). Statistical modelling using mixed-effect, piece wise 
polynomial models show no statistically significant difference between treatment groups at the 
start of measurement (Figure 4.4 B). However, it was revealed that SOD1G93A mice showed a 
deficit in rotarod performance when measured by latency to first rotation at the beginning of the 
study. Interestingly, wild-type mice showed a gradual decline in performance. At the conclusion 
of rotarod performance testing EpoD treated SOD1G93A mice could no longer balance on the 
rotarod bar at the 4rpm cut-off speed. During the trial wild-type mice were always able to 
complete the rotarod test regime. 
 
Estimation of the age at which transgenic SOD1G93A mice show a significant decrease in rotarod 
performance identified that there was an earlier decrease in rotarod performance as measured by 
rotation at 114.0 days in EpoD treated mice. This occurred when their performance had reached 
201.0 (187.1, 214.9) sec, compared to vehicle treated mice at 125.5 days, with a performance of 
202.5 (187.5, 217.5) sec (Figure 4.4 B). This suggests that SOD1G93A mice have an early deficit 
in rotarod performance as measured by latency to first rotation, and that EpoD treatment is 
detrimental to muscle strength, endurance and/or coordination in the later stages of the disease.  
4.3.4.2 Latency to fall 
Rotarod performance, as measured by latency to fall, measures the time at which the mice can no 
longer grip/run on the rotating bar, thus falling into the enclosure (Figure 4.5 A). Statistical 
modelling of latency to fall using non-linear regression for wild-type mice and quadratic terms 
with spline functions for SOD1G93A mice determined that SOD1G93A mice showed a deficit in 
rotarod performance from the beginning of the study, with the two curves always significantly 
different (p < 0.05) (Figure 4.5 B). Modelling estimated that when comparing genotype, 
independent of treatment, SOD1G93A mice have a peak rotarod performance at 60.9 days of age, 
with a latency to fall of 304.7 (292.5, 315.9) sec, followed by deterioration in performance. In the 
later stages of the disease EpoD treated SOD1G93A mice deteriorate slightly more rapidly than 
vehicle treated controls, similar to rotarod performance when measured by latency to first 
rotation. These results suggest that SOD1G93A mice show symptoms at the commencement of the 
study, as revealed by latency to fall rotarod performance, compared to wild-type controls. 
Figure 4.4. EpoD treatment alters rotarod performance, as measured by latency to 
rotate, in the later stages of the disease. (A) Behavioural data, with lines representing 
the mean of each genotype and treatment group. Grey dots signify individual mice. 
(B) Fitment of mixed effect polynomial models improves data representation. No 
effect due to EpoD treatment was identified early in the disease. However, at later 
stages, EpoD is significantly detrimental to rotarod performance, with performance 
declining in EpoD treated mice earlier than respective vehicle controls. Interestingly, 
SOD1G93A mice performance, regardless of treatment, was significantly worse than 
wild-type mice for the duration of the study. (P < 0.05), time in seconds (s), (n = 12 
SOD1G93A + EpoD, n = 12 SOD1G93A + vehicle, n = 8 WT + EpoD, n = 8 WT + 
vehicle). 
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Figure 4.5. EpoD treatment alters rotarod performance, as measured by latency to 
fall, in the later stages of the disease. (A) Behavioural data, with lines representing the 
mean of each genotype and treatment group. Grey dots signify individual mice. (B) 
Fitment of non-linear regression for wild-type and quadratic terms for SOD1G93A 
mice. No effect due to EpoD treatment was identified early in the disease. The solid 
vertical red line represents peak performance for both EpoD and vehicle treated 
SOD1G93A mice. At later stages, EpoD is significantly detrimental to rotarod 
performance, with performance declining in EpoD treated mice earlier than respective 
vehicle controls. Similar to latency to first rotation, the performance of SOD1G93A 
mice, regardless of treatment, was significantly worse than wild-type mice for the 
duration of the study. (P < 0.05), time in seconds (s), (n = 12 SOD1G93A + EpoD, n = 
12 SOD1G93A + vehicle, n = 8 WT + EpoD, n = 8 WT + vehicle). 
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Further, it suggests that EpoD is detrimental to rotarod performance in the later stages of the 
disease.   
4.3.5 Epothilone D treatment alters grip strength in SOD1G93A mice 
Grip strength measurements determine the highest force each animal can apply to the grip bars. 
As the SOD1G93A mouse model is a model of hindlimb onset, with differential forelimb and 
hindlimb pathology (as identified in Chapter 3), forelimb alone and hindlimb alone measurements 
were taken. 
4.3.5.1 Forelimbs 
To determine whether EpoD effects disease progression, statistical modelling of forelimb grip 
strength using multi-level mixed effect non-linear regression was performed, coupled with fitting 
of break points. These measurements were taken between 49 and 145 days of age. There was no 
significant (p > 0.05) difference in disease progression as measured by forelimb grip strength 
between treatment groups in SOD1G93A mice (Figure 4.6 A). Further, SOD1G93A and wild-type 
mice had comparable forelimb grip strength at the beginning of the trial. However, SOD1G93A 
mice showed a significant decline in grip strength until 75.5 days, when their forelimb grip was 
0.095 (0.091, 0.099) kilograms of force (kgf), followed by a period of improvement, then a 
second decline at 98.8 days, with a local maximum of 0.099 (0.097, 0.102) kgf (Figure 4.6 B). 
These results suggest that EpoD treatment does not alter disease progression in the forelimb of 
SOD1G93A mice.  
4.3.5.2 Hindlimb analysis  
To model hindlimb grip strength (Figure 4.7 A), multi-level non-linear regression models with 
break points were fitted to the data (Figure 4.7 B). Similar to forelimb data, no significant (p > 
0.05) changes to hindlimb grip strength were identified when comparing treatment groups in in 
SOD1G93A mice. Interestingly, when modelling data by genotype, irrespective of treatment, it was 
identified that SOD1G93A and wild-type mice first become significantly different (p < 0.05) from 
each other at 49.60 days, with SOD1G93A mice having an estimated grip strength of 0.084 (0.081, 
0.088) kgf, and wild-type of 0.092 (0.086, 0.094) kgf. Hindlimb grip strength of SOD1G93A mice 
is decreased from the beginning of measurements, compared to wild-type mice, with the optimal 
breakpoint of data suggesting a sharp decline at 93.0 days of age, where hindlimb grip strength is 
0.078 (0.076, 0.081) kgf. This suggests that EpoD does not effect disease progression as 
Figure 4.6. EpoD treatment does not alter forelimb grip strength during the disease 
time course. (A) Fitment of a multi-level mixed effect non-linear regression model 
accurately estimates forelimb grip strength. Grey dots signify individual mice. 
Forelimb grip strength was not significantly different between SOD1G93A  mice treated 
with either EpoD or vehicle over the course of the study. Forelimb grip strength of 
SOD1G93A  mice was not significantly different from wild-type controls at the 
beginning of the study, regardless of treatment. However, there was a significant 
decline in SOD1G93A  mice as the disease progressed, compared to wild-type mice. (B) 
Mixed effect model representing two ‘phases’ of forelimb grip strength. Initially, 
SOD1G93A  mice show an early, linear decline. This is then followed by a subtle 
improvement in grip strength, culminating in a slow, second decline in forelimb grip 
strength. (P < 0.05), (n = 12 SOD1G93A + EpoD, n = 12 SOD1G93A + vehicle, n = 8 
WT + EpoD, n = 8 WT + vehicle). 
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Figure 4.7. EpoD treatment does not alter hindlimb grip strength during the disease 
time course. (A) Behavioural data, with lines representing the mean of each genotype 
and treatment group. Grey dots signify individual mice. (B) Fitment of a multi-level 
mixed effect non-linear regression model accurately estimates hindlimb grip strength. 
Hindlimb grip strength was not significantly different between SOD1G93A  mice 
treated with either EpoD or vehicle over the course of the study. Hindlimb grip 
strength was significantly different between SOD1G93A  mice and wild-type early in 
the study, regardless of treatment. Hindlimb grip strength of SOD1G93A  mice 
decreased from the beginning of measurements, with a notable decline in grip strength 
occurring mid way through the study. (P < 0.05), (n = 12 SOD1G93A + EpoD, n = 12 
SOD1G93A + vehicle, n = 8 WT + EpoD, n = 8 WT + vehicle). 
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measured by hindlimb grip strength, and that SOD1G93A mice show early onset disease, compared 
to wild-type mice, as measured by hindlimb grip strength. 
4.3.6 Epothilone D treatment does not alter weight loss trajectory in SOD1G93A mice 
Utilising weight to track disease progression is a standard method of analysis for the SOD1G93A 
mouse model (Schafer and Hermans, 2011). The effects of time, genotype and treatment on body 
weight were evaluated from 49 to 150 days of age (Figure 4.8 A). Statistical modelling of weight 
used cubic spline functions for both SOD1G93A and wild-type mice (Figure 4.8 B). It was 
determined that there was no significant (p > 0.05) difference between treatment groups in 
SOD1G93A mice, suggesting EpoD treatment does not effect weight. However, modelling 
estimated that SOD1G93A mice weighed significantly (p < 0.05) less than their wild-type 
littermates, regardless of treatment, at 49.10 days of age (SOD1G93A: 23.1g (22.7, 23.6); wild-
type: 23.8g (23.4, 24.4). This is followed by a gradual decline in weight of SOD1G93A mice from 
their predicted maximum at 116.4 days of age, where the estimated weight is 24.2g (23.8, 24.7). 
This surprising result suggests that SOD1G93A mice already show symptoms (independent of 
treatment) at the commencement of the trial. This suggests that either our SOD1G93A high copy 
number colony shows onset prior to 50 days of age when determined by weight and that the 
methods of measurement and analysis (statistical modelling) have increased fidelity. 
4.3.7 Epothilone D treatment effects neurological symptoms in the later stages of disease 
in SOD1G93A mice 
A neurological evaluation based on the appearance of the SOD1G93A mice is used to track the 
progression of the clinical phenotype (Weydt et al., 2003). The first clinical sign of onset 
identified in the SOD1G93A mice was hindlimb tremors and difficulty extending hindlimbs whilst 
suspended by the tail, followed by progressive or simultaneous gait abnormalities, ultimately 
leading to paralysis and death (Weydt et al., 2003). Using an amended 4-point scoring system 
described by Weydt and Colleagues (2003), representing clinical progression as a percentage of 
the maximum clinical score, neurological assessment of mice revealed EpoD treatment 
significantly (p < 0.01) accelerated the time of disease onset, compared to vehicle controls, with 
onset in the EpoD treated mice occurring at 77 days of age (EpoD: 88.46% ± 12.97%), compared 
to EpoD treated wild-type controls, which showed no overt neurological symptoms throughout 
the trial. This presented as an increase in hindlimb tremors and decreased leg extension (Figure 
4.9 A). Vehicle treated SOD1G93A mice significantly (P < 0.001) differed from vehicle treated 
wild-type controls one week later, at 84 days of age (vehicle: 80.77% ± 10.96%).  
Figure 4.8. EpoD treatment does not alter weight during the disease time course. (A) 
Behavioural data, with lines representing the mean of each genotype and treatment 
group. Grey dots signify individual mice. (B) Fitment of a cubic spline function 
accurately estimates weight trajectory. Hindlimb grip strength was not significantly 
different between EpoD or vehicle treated SOD1G93A  mice over the course of the 
study. Weight, and its trajectory, was significantly different between SOD1G93A  mice 
and wild-type, regardless of treatment, from the beginning for the study. (P < 0.05), (n 
= 12 SOD1G93A + EpoD, n = 12 SOD1G93A + vehicle, n = 8 WT + EpoD, n = 8 WT + 
vehicle). 
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Figure 4.9. EpoD treatment is detrimental to neurological score and survival. (A) 
EpoD treated SOD1G93A mice exhibit a significantly (p < 0.01) worse neurological 
phenotype one week earlier than vehicle treated SOD1G93A mice, when compared to 
respective wild-type controls. In the later stages of the disease, EpoD treated 
SOD1G93A mice show a greater decline in neurological score, compared to vehicle 
treated SOD1G93A mice. (B) EpoD treated SOD1G93A mice have a significantly (p < 
0.01) reduced life span, compared to vehicle treated SOD1G93A controls. (mean ± SD, 
n = 12 SOD1G93A + EpoD, n = 12 SOD1G93A + vehicle, n = 8 WT + EpoD, n = 8 WT 
+ vehicle. 
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Neurological symptoms continued to deteriorate in EpoD treated mice at a higher rate, compared 
to vehicle controls, with EpoD injected SOD1G93A mice showing significantly (P < 0.01) reduced 
clinical scores compared to vehicle treated SOD1G93A mice at 147 days of age, and continuing 
until end stage (EpoD: 26.92% ± 16.01%; vehicle: 38.46% ± 12.97%) (Figure 4.9 A). This 
suggests that EpoD treatment hastens neurological symptoms in both early and late stages of the 
disease, and is detrimental to neurological functions in SOD1G93A mice. Wild-type mice treated 
with either EpoD or vehicle showed no overt neurological symptoms due to treatment. 
4.3.8 Epothilone D treatment decreases the life span of SOD1G93A mice 
 To determine whether there was an effect of EpoD treatment on survival, the age of mice (days) 
was recorded until the mice reached the studies ethical end stage cut off, defined as mice that 
reach 80% of their maximal weight or had increasingly affected righting reflexes. Once this stage 
was research the mice were perfused. Survival analysis estimated that EpoD treatment 
significantly (p < 0.01) decreased the life span of SOD1G93A mice, compared to vehicle treated 
controls (mode days of age, EpoD: 156 days; vehicle: 165 days) (Figure 4.9 B). This suggests 
that the treatment regime of 2mg/kg EpoD is toxic to SOD1G93A mice, and taken with rotarod and 
neurological data, is detrimental in the later stages of the disease.  
4.3.9 Epothilone D treatment alters gliosis in SOD1G93A mice 
Cellular pathology was evaluated to determine specific cell type and structural changes after 
EpoD treatment. Immunohistochemical analysis of astrocytes using GFAP as a marker showed a 
significant (p < 0.01) increase in GFAP fluorescence area in the ventral, and surprisingly also the 
dorsal, lumbar spinal cord of EpoD treated mice, compared with vehicle treated controls (dorsal, 
EpoD: 0.185mm2 ± 0.039mm2; vehicle: 0.088mm2 ± 0.021mm2) (Figure 4.10 A), (ventral, EpoD: 
0.159mm2 ± 0.035mm2; vehicle: 0.088 mm2 ± 0.138mm2) (Figure 4.10 B). There was no 
significant difference between treatment groups at earlier time points, however a steady increase 
in GFAP expression area was noted as the disease phenotype progresses. Cellular morphology 
appeared similar between both treatment groups. 
 
Similarly, immunohistochemical analysis of microglia found a significant (p < 0.05) increase in 
Iba1 fluorescence area in both the ventral and dorsal horn at end stage (dorsal, EpoD: 0.170mm2 
± 0.048mm2; vehicle: 0.099mm2 ± 0.023mm2) (Figure 4.10 C), (ventral, EpoD: 0.216mm2 ± 
0.058; vehicle: 0.122 mm2 ± 0.025) (Figure 4.10 D). There was no significant difference between 
Figure 4.10. EpoD treatment induces gliosis in SOD1G93A mice. (A) Astrocyte 
(GFAP) activation is significantly (p < 0.01) increased at end stage in the dorsal, (B) 
and ventral horns, of the lumbar spinal cord in EpoD treated SOD1G93A mice, 
compared to vehicle controls.  (C) Similarly, microglial (Iba1) activation is 
significantly (p < 0.05) increased at end stage in the dorsal, (D) and ventral horns, of 
the lumbar spinal cord in EpoD treated SOD1G93A mice, compared to vehicle controls. 
Both astrocytes and microglia morphology appear similar between EpoD and vehicle 
treated controls. (P < 0.05) (mean ± SD, n = 4 (50 & 70 days of age), 3 (140 days of 
age) and 5 (end stage), Scale = 500µm. 
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treatment groups at earlier time points. However, Iba1 fluorescence area increases as the disease 
progresses, irrespective of treatment. Cellular morphology appeared similar between both 
treatment groups. 
4.3.10 Epothilone D may protect motor neurons from degeneration early in the disease 
time course of SOD1G93A mice 
The number of a-MNs in the lumbar spinal cord were compared between EpoD and vehicle 
treated SOD1G93A mice. Investigations of toluidine blue stained lumbar spinal cord sections 
determined that treatment with EpoD protected a-MNs from degeneration at 70 days of age, with 
a-MN numbers per section comparable (p > 0.05) to that of 50 day old SOD1G93A mice (50 day:  
9.551 ± 2.111; 70 EpoD: 8.971 ± 2.583; 70 vehicle: 5.099 ± 1.143) (Figure 4.11 A). Indeed, 70 
day old EpoD treated SOD1G93A mice had significantly (p < 0.05) more a-MNs than 70 day old 
vehicle treated SOD1G93A controls. However, a-MN numbers were similar (non-significantly 
different (p > 0.05)) between treatment groups in 140 days old and end stage SOD1G93A mice.  
 
To further investigate the number of a-MNs at end stage, specific quantitation using 
immunolabelling for SMI32, a marker for a-MNs (Tsang et al., 2000), and Western blot analysis 
was used. Using these approaches determined there was a significant (p < 0.01) decrease in 
SMI32 positive a-MN numbers in EpoD treated mice, compared to vehicle treated controls 
(EpoD: 2.797 ± 0.0687; vehicle: 3.373 ± 0.08862) (Figure 4.11 B). Further, Western blot analysis 
using anti-choline acetyltransferase (ChAT), an enzyme specific to a-MNs in the spinal cord, 
identified a significant (p < 0.05) decrease in ChAT protein levels in EpoD treated end stage 
spinal cords (EpoD: 0.412 pix2 ± 0.024 pix2; vehicle: 1.000 pix2 ± 0.181 pix2) (Figure 4.11 C). 
This suggests that although EpoD confers a-MN protection early in the disease, it appears to be 
neurotoxic in the later stages of disease. 
4.3.11 Epothilone D treatment protects axons early in the disease time course of SOD1G93A 
mice  
As discussed in Chapter 1 and further determined in Chapter 3, axonal degeneration is a hallmark 
pathological event in the ALS distal neuromuscular circuitry, particularly in the hindlimb of the 
SOD1G93A mouse model. For these studies SOD1G93AxYFP mice were used to visualise distal 
morphology in 50, 70 and 140 day old mice, as in Chapter 3. Stabilisation of the microtubule 
cytoskeleton with EpoD resulted in a decrease in axonal pathology early in the disease. 70 day 
old EpoD treated SOD1G93AxYFP mice showed a similar proportion of intact axons to the earlier 
Figure 4.11. Possible early protection of MNs (arrows) in the lumbar spinal cord of 
EpoD treated SOD1G93A mice. (A) MNs were protected at 70 days of age in EpoD 
treated SOD1G93A mice, with significantly (p < 0.05) more MNs per section, 
compared to 70 day old vehicle treated mice. Indeed, 70 day old EpoD treated mice 
had comparable levels of MNs per section to the earlier, 50 day time point. However, 
at 140 days of age and end stage, MN numbers were not significantly (p > 0.05) 
different between EpoD and vehicle treated mice. (B) Further evaluation of end stage 
mice using immunohistochemical and fluorescence microscopy identified that there 
was a significant (p < 0.01) decrease in MN numbers (closed arrow) in the lumbar 
spinal cord in EpoD treated SOD1G93A mice, with an increasing presence of dark 
‘voids’ in the tissue (open arrow). (C) MN loss at end stage was confirmed with a 
significant (p < 0.05) decrease in choline acetyltransferase levels in the lumbar spinal 
cord of EpoD treated SOD1G93A mice. ChAT (5 minute exposure) and GAPDH (20 
second exposure) were measured on same membrane. (P < 0.05) (mean ± SD, n = 4 
(50 & 70 days of age), 3 (140 days of age) and 5 (end stage). Scale (A) = 200µm, (B) 
= 50µm. 
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50 day time point, with vehicle treated mice SOD1G93AxYFP mice having a significantly (p < 
0.05) decreased proportion of intact axons compared to 50 day old mice (50 day: 82.253% ± 
2.849; 70 EpoD: 77.773% ± 2.855; 70 vehicle: 68.988% ± 3.863) (Figure 4.12 A & C). However, 
the proportion of intact axons was not significantly (p > 0.05) different between treatments at 140 
days of age in SOD1G93AxYFP.  This suggests that EpoD offers early axonal protection in the 
SOD1G93AxYFP mouse model, limiting axonal degeneration. 
 
Axonal branching was evaluated in EpoD treated SOD1G93AxYFP mice. It was identified that 
there was no significant (p > 0.05) differences in axonal branch order between treatment groups 
in SOD1G93AxYFP mice at any stage of the disease (Figure 4.11 B & D). However, as identified 
in the previous chapter, axonal branch order increased over the disease time course, suggesting 
increased collateral sprouting as the disease progresses. 
4.3.12 Epothilone D treatment effects NMJ morphology but not synaptic colocalisation 
To determine whether EpoD altered NMJ pathology, SOD1G93AxYFP mice were used to probe 
for degeneration of the presynaptic compartment over the disease time course (Figure 4.13 A, 
Fully colocalised; B, partially colocalised; C, non-colocalised). Investigations found that there 
was no significant (p > 0.05) difference in the proportion of NMJs with fully colocalised YFP 
and α-BTx between treatment groups in SOD1G93AxYFP mice (Figure 4.13 E). However, there 
was an age dependant loss of NMJ pre- and post-synaptic colocalisation as the disease 
progressed, independent of treatment. This suggests that EpoD treatment does not protect the 
synaptic compartment of the distal neuromuscular circuitry in the gastrocnemius muscle. 
 
To investigate NMJ pathology at end stage, forelimb muscles were evaluated using presynaptic 
antibody cocktail as utilised in Chapter 3. This consisted of antibodies targeting the 
neurofilaments SMI-32 and SMI-312, as well as the pre-synaptic marker synaptophysin.  
Forelimb muscles were used at end stage, as the hindlimbs of SOD1G93A mice are fully paralysed 
at end stage. As forelimbs are spared until later in the disease, these were chosen for end stage 
analysis. It was identified that there was no significant (p > 0.05) difference in pre-synaptic 
labelling between treatment groups in the forelimbs of SOD1G93A mice (EpoD: 46.59% ± 3.30; 
vehicle: 42.73% ± 4.51) (Figure 4.13 F). This further suggests that EpoD does not have an effect 
on modifying NMJ pre- and post-synaptic colocalisation in SOD1G93A mice. 
 
Figure 4.12. Early protection of distal axons in the gastrocnemius muscle in EpoD 
treated SOD1G93A mice. (A) Axonal degeneration was decreased in EpoD treated 
SOD1G93A mice at 70 days, with EpoD treated mice showing comparable levels to the 
previous, 50 day old time point.  Indeed, vehicle treated mice showed a significant 
decrease in the proportion of intact axons at 70 days, compared to the previous, 50 
day old time point. However, at 140 days of age there was no significant difference in 
the proportion of intact axons between EpoD and vehicle treated mice. (B) Axonal 
branching was not significantly altered due to EpoD treatment, however, branching 
complexity increased as the disease progressed. (C) Confocal image of YFP labelled 
axons in SOD1G93A mice show beaded axons (open arrow) and fragmented axons 
(closed arrow). (D) Branch points (indicated by numbers 1 – 3) increased over the 
disease time course (arrow), with axonal branches numbered. (P < 0.05) (mean ± SD, 
n = 4 (50 & 70 days of age), 3 (140 days of age). Scale = 40µm.  

Figure 4.13. No alterations to synaptic colocalisation, but improvements to NMJ 
morphology in EpoD treated SOD1G93A mice. (A) The normal ‘pretzel’ morphology 
of the NMJ with fully colocalised pre- and post-synaptic labelling. (B) As the disease 
progressed, partially colocalised NMJs, (C) and fully denervated NMJs became more 
pronounced. The overall size of NMJs also appeared smaller. (D) Remaining, fully 
colocalised NMJs showed altered morphology. (E) Statistical analysis revealed no 
significant difference in the proportion of full pre- and post-synapse colocalisation of 
NMJs between EpoD and vehicle treated SOD1G93A mice at any time point in the 
hindlimb gastrocnemius, (F) nor at end stage in the forelimb. (G) EpoD treated 
SOD1G93A mice showed improved NMJ morphology at 140 days, compared to vehicle 
treated controls. (P < 0.05) (mean ± SD, n = 4 (50 & 70 days of age), 3 (140 days of 
age); 80-100 NMJs, 4 sections. Scale = 20µm. 
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As NMJ morphology alterations occur over the disease time course in SOD1G93A mice (as in 
Chapter 3), the morphology of fully colocalised (pre- and post-synapse) NMJs were evaluated in 
EpoD treated SOD1G93AxYFP mice (Figure 4.13 D) (Ngo et al., 2012). It was found that at 140 
days of age there was a significant (p < 0.05) reduction in the proportion of NMJs with 
degenerative morphology in EpoD treated mice, compared to vehicle treated controls (EpoD: 
49.023% ± 3.853; vehicle: 38.840% ± 4.715) (Figure 4.13 G). Furthermore, the NMJs in EpoD 
treated animals have reduced presynaptic YFP beading compared to vehicle treated controls 
(such as comparisons between Figure 4.13 panels A & D). This suggests that EpoD treatment 
reduces the degeneration of the NMJ pre-synapse by improving the morphological stability of the 
NMJ. 
4.4 Discussion 
Degeneration of the distal neuromuscular axon is a hallmark pathology of ALS, in both patients 
and in mouse models of the disease (Fischer et al., 2004). The ‘die back’ degeneration associated 
with ALS highlights the innate vulnerability of the distal axon and NMJ, both of which 
degenerate prior to the a-MN, which resides in the ventral horn of the spinal cord (Moloney et al., 
2014). The current chapter investigated the efficacy of using a microtubule stabilising agent to 
target the distal neuromuscular circuitry and prevent degeneration in the SOD1G93A mouse model 
of ALS. EpoD was hypothesised to protect microtubules of a-MNs from degeneration against 
Wallerian-like mechanisms, and by ameliorating microtubule hyperdynamics associated with 
ALS pathogenesis (Fanara et al., 2007; Kleele et al., 2014; Smith et al., 2014). The current 
chapter focused on a variety of behavioural, histological and molecular outcomes to determine 
the efficacy of EpoD treatment. The chapter highlighted that EpoD protects a-MNs and their 
axons from degeneration early in the disease course, and NMJs later in disease; however, this is 
not translated to improved synaptic health. Furthermore, results suggest early but modest 
improvements to aspects of motor behaviour, but with an ultimately detrimental effect on clinical 
and motor behaviour outcomes in the later stages of disease. Indeed, EpoD was found to decrease 
the life span of SOD1G93A mice and result in end stage a-MN neurotoxicity and increased gliosis.  
4.4.1 Epothilone D is a novel therapeutic for targeting microtubules in the lower 
neuromuscular circuitry 
There has been limited success in identifying compounds and treatments to modify or cure ALS. 
Although the initial disease causing mechanism is yet to be elucidated, many contributing 
mechanisms have been identified, as have therapeutics to target them, however, the translation 
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from preclinical to clinical trials has, thus far, been disappointing (Mitsumoto et al., 2014; Ittner 
et al., 2015; Garbuzova-Davis et al., 2016). Identification of mechanisms common to other 
neurodegenerative disorders has allowed for further development of targeted therapies for ALS. 
As described in Chapter 1, many neurodegenerative diseases feature the common cellular 
pathology of a dysfunctional microtubule environment (Dubey et al., 2015; Clark et al., 2016a). 
This dysfunction can manifest as altered dynamics of the microtubule network, aberrant axonal 
transport, or a combination of both, as is reportedly the case in ALS (Fanara et al., 2007; Bilsland 
et al., 2010; Kleele et al., 2014). However, pharmacologically targeting microtubules in a 
selective manner presents a conundrum, as intracellular signalling cascades, small molecules and 
MAPs that alter the microtubule environment can interact with a plethora of other targets and 
functions (Alami et al., 2014; Wojnacki et al., 2014; Mohan and John, 2015; Sayas et al., 2015). 
Appealingly, anti-mitotic compounds used for cancer therapies typically have higher selectivity 
for microtubules by binding to and inducing conformational changes to tubulin, thus their 
attractiveness as a repurposed therapeutic method for neurodegenerative disease (Brunden et al., 
2011; Eira et al., 2016). Indeed, the current investigation has highlighted that a low dose of EpoD 
can target and modify the microtubule environment of spinal cord a-MNs.  
 
To date the majority of microtubule-targeting compounds have aimed to alter microtubule 
dynamics in the cortex of the CNS, focusing primarily on disorders such as AD, PD, 
schizophrenia and tauopathies (Andrieux et al., 2006; Brunden et al., 2010; Zhang et al., 2012; 
Baas and Ahmad, 2013; Cartelli et al., 2013). These studies focused on stabilising the 
microtubule cytoskeleton by modifying aberrant microtubule dynamics, reducing it to normal 
physiological levels. Indeed, this method of treatment has been found to improve outcomes in in 
vitro and in vivo models of the aforementioned diseases.  
 
Of interest to the current thesis is a study by Hellal and Colleagues (2011), where the compound 
taxol was used to stabilise microtubules in a model of spinal cord injury (Hellal et al., 2011). 
Although used to promote axonal regrowth, and not protection of axons per se, this study 
highlights that stabilisation of microtubules in the spinal cord can lead to positive outcomes in 
neurological pathology. Further, targeting spinal cord microtubules with other epothilone 
analogues, such as epothilone B (EpoB), has been shown to increase the stability of microtubule 
network in the spinal cord, with positive outcomes in spinal cord injury models (Ruschel et al., 
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2015). These results suggest that epothilone analogues, such as EpoD, can target and modify the 
stability of microtubule networks in the spinal cord. 
 
More recently, Brill et al 2016 showed that epothilones stabilise microtubules in the distal axons 
of the neuromuscular circuitry, affecting axonal pruning and maintenance (Brill et al., 2016). 
Indeed, results from the current chapter support that EpoD, a compound with increased BBB 
permeability and CNS retention, compared to taxol or other epothilone analogues, can stabilise 
microtubule networks in a-MNs and their peripheral processes, identifying it as a compound that 
can potentially be used to target a-MNs in ALS (Cheng et al., 2008; Brunden et al., 2010). 
Attractively, the low dose of EpoD used in the current investigation, coupled with the increase in 
a microtubule stability marker, showed no identifiable neuropathology due to aberrant 
microtubule stabilisation, as is attributed to higher doses used in anti-mitotic caner therapy 
(Argyriou et al., 2011; Benbow et al., 2016). Further, chronic injection of EpoD (~20 weeks), did 
not lead to the development of aberrant behavioural clinical manifestations in wild-type mice, as 
shown with weight, motor function and neurological analysis. This suggested that EpoD at 
bioactive doses (to modify but not abolish microtubule dynamics) may be of use as a therapeutic 
in ALS to targets the distal neuromuscular circuitry (Brunden et al., 2014). Findings in the 
current chapter suggested that EpoD may protect the distal neuromuscular circuitry, particularly 
the a-MN soma and distal axon, at early stages of the disease. A similar study using noscapine to 
stabilise microtubules has previously been shown to improve outcomes in the SOD1G93A mouse 
model (Fanara et al., 2007). However, unlike this study, and regardless of the early benefits to 
pathology, chronic treatment with EpoD culminates in a neurotoxic effect, accelerating cellular 
pathology, motor behaviour deficits, and decreasing the lifespan of the SOD1G93A mouse. This 
suggests that whilst EpoD is a novel and attractive target for stabilising microtubules in the distal 
neuromuscular circuitry, it may have limited eficay.as a therapeutic strategy in ALS (Baas, 2014). 
4.4.2 Axonal protection as a therapy for neuromuscular disorders 
In the current investigation, low dose EpoD treatment was found to delay axonal degeneration 
early in the disease course of the SOD1G93A mouse model of ALS; however, this protection was 
not afforded later in the disease. Furthermore, early axon protection was also associated with 
improved a-MN survival. However, EpoD treatment only modestly protected NMJs by 
decreasing the proportion of NMJs with degenerative ‘beaded’ pre-synaptic morphology, and did 
not affect the proportion of NMJs with full pre-synaptic occupation of the postsynaptic endplate.  
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Similar axonal protection has been identified in an in vitro model of excitotoxicity, with 
microtubule stabilisation using taxol improving axonal pathology and cell survival, albeit in a 
caspase dependant manner (King et al., 2013). However, direct alterations to microtubule 
stability were not tested, with inhibition of enzymatic caspase action thought to offer axonal 
protection. Axonal protection using calpain inhibitors has also been shown to limit axonal 
degeneration in models of neuropathy (O'Hanlon et al., 2003). Interestingly, this method of 
axonal protection prevents microtubule disintegration via enzymatic digestion by calpain, the 
main enzyme utilised in dismantling axonal proteins, including the microtubule cytoskeleton 
(Wang et al., 2012). The effects of EpoD on caspase or calpain dependant cytoskeletal 
degenerative pathways were not directly tested in the current chapter. However, microtubule 
stabilisation has been shown to protect against Wallerian degeneration during phasic pruning of 
the a-MN distal axon, further suggesting that microtubule targeting compounds can prevent 
axonal degeneration in the distal neuromuscular circuitry (Brill et al., 2016). 
 
The use of noscapine, a microtubule-targeting compound, and alterations to microtubule 
acetylation via genetic ablation of HDAC6, has shown promise in improving outcomes in ALS, 
supporting the use of microtubule-targeting methods to modify dynamics (Fanara et al., 2007; 
Taes et al., 2013). Utilising EpoD to target microtubules was shown to improve a-MN and axonal 
pathology early in the disease course, supporting the hypothesis that EpoD can improve axonal 
pathology. However, there were no additional benefits later in disease. EpoD was found to cause 
detrimental outcomes in motor function, survival and clinical readouts later in the disease course, 
with increased a-MN cell death and glial activation; a phenomenon that was not identified in 
previous microtubule targeting treatments (Fanara et al., 2007; Taes et al., 2013). Others have 
shown that gliosis is associated with increased a-MN death in ALS (Boillee et al., 2006a; Gowing 
et al., 2008), and taken with previously described results of limited glial activation in neuropathy 
analysis of EpoD in wild-type mice, suggests that EpoD may not be impacting directly on either 
astrocytes or microglia in the current study (Friedlander, 2003). To evaluate this further, drugs 
such as minocycline, which inhibits microglial activation, may be utilised to determine if EpoD is 
causing a-MN toxicity through microglial dependant mechanisms (Kriz et al., 2002; Zhu et al., 
2002). 
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The current chapter determined that EpoD does not affect collateral branching in the distal 
neuromuscular circuitry, a reactive phenomenon that occurs in ALS, mediated in party by 
changes to microtubule dynamics in distal axons (Pun et al., 2006; Brill et al., 2016). This 
suggests that the levels of altered microtubule dynamics in the current study are not significant 
enough to impact collateral sprouting over the disease time course (Ketschek et al., 2015a), and 
that the capacity for branching is still available to the distal neuromuscular circuitry. 
Interestingly, microtubule stabilisation using taxol only affects branching during neurite 
elongation, and not during collateral formation, suggesting that microtubule stabilisation using 
EpoD may not affect the ability for distal axons to sprout and reinnervate vacant NMJ endplates 
(Letourneau et al., 1986; Gallo and Letourneau, 1999).  
 
EpoD dose not improve presynaptic colocalisation and NMJ innervation over the disease time 
course, suggesting EpoD stabilises microtubules and offers protection only in distal axons, 
allowing presynaptic degeneration to continue. However, later in the disease, alterations to NMJ 
morphology are apparent in EpoD treated mice, with NMJs showing less YFP ‘blebbing’ of the 
pre-synaptic membrane, a phenomenon associated with degeneration of the NMJ pre-synapse (Li 
and Thompson, 2011). The microtubule environment between axons and NMJs is different, 
suggesting EpoD may have different effects in these two distinct cellular compartments (Godena 
et al., 2011; Bodaleo and Gonzalez-Billault, 2016). For example, NMJ microtubules have the 
capacity to become increasingly dynamic during bouts of plasticity and phasic pruning (Bodaleo 
and Gonzalez-Billault, 2016; Brill et al., 2016). NMJ microtubules also rely heavily on axonal 
transport to recycle synaptically localised mitochondria and vesicles. Additionally, it may be 
surmised that NMJs are more vulnerable to pathogenic mechanisms in ALS than axons, with both 
pre- and post-synaptic involvement of the NMJ leading to degeneration independent of 
microtubule stabilisation (Santos and Caroni, 2003; Moloney et al., 2014). 
4.4.3  Behavioural outcomes and statistical modelling of SOD1G93A mice 
Identification of the earliest behavioural deficits in disease models is imperative to understanding 
the disease phenotype, and also to identify appropriate ages in which to draw comparisons to the 
human disease. The use of advanced statistical modelling, not typically utilised in animal 
behavioural studies, has made it easier to visualise and interpret the data from the current 
therapeutic trial (Naumova et al., 2001). Fitment of either smooth non-linear polynomials, or 
multi-level piece wise non-linear polynomial models to the data to obtain the most valid data 
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representation is used extensively for population based studies, particularly in with biological 
data, such as age and height (Durban et al., 2005; Grajeda et al., 2016). Moreover, fitment of 
break points to the data (where the fitment of two lines and their intersection represents the age at 
which the readout changes), allows for an increasingly accurate estimation of either onset, or how 
the disease is progressing due to variables such as treatment or genotype (Muggeo, 2003; Schafer 
and Hermans, 2011). Indeed, mixed effect modelled grip strength data suggests differential 
progression of the disease, with definable ‘phases’ of grip strength loss. Initially, SOD1G93A  mice 
show an early sharp 1st phase linear decline of the forelimb. Contrastingly, there is a gentle 
decline in gripstrength identified in the 1st phase decline of the hindlimb. Both forelimb and 
hindlimb gripstrength then have a 2nd phase decline. Further, forelimb gripstrength deficits occur 
at an age prior to NMJ degeneration as discussed in Chapter 3, suggesting that NMJ pathology in 
the forelimbs may not be the most appropriate readout of disease progression, and a greater 
emphasis on function may be required, such as electromyography (Kennel et al., 1996). Taken 
together, this suggests that differential progression of both pathology and gripstrength occurs 
between the forelimb and hindlimb muscles in the SOD1G93A mouse. 
Current results suggest that SOD1G93A mice perform significantly worse than wild-type mice 
from the beginning of the trial, approximately 50 days of age, using weight analysis, rotarod 
performance and grip strength testing. This is comparable to other reported alterations to motor 
behaviour in SOD1G93A mice, with abnormal gait (56 days of age) in SOD1G93A mice on a 
C57Bl/6 background, which was used in this study (Wooley et al., 2005; Kanning et al., 2010). 
Genetic background has a large influence on symptom progression and survival in SOD1 mice, 
and must be taken into account when comparing between studies (Leitner et al., 2009). 
Interestingly, a meta-analysis of C57Bl/6 SOD1G93A mice, the most common combination of 
background/transgenic mutant, estimated onset at 103 days when measuring hindlimb tremors 
(neurological onset) (Pfohl-Leszkowicz et al., 2015). Indeed, hindlimb tremors are thought to 
occur prior to generalised motor deficits in SOD1 models (Kasai et al., 2011), whereas the 
current study identified neurological onset at 70 days of age in EpoD treated mice, and 77 days 
for vehicle mice, compared to wild-type controls. Indeed, Lee and Colleagues (2013) found that 
hindlimb gripstrength and motor neuron loss occur concurrently from 70 days in C57Bl/6 
SOD1G93A mice, suggesting a strong behavioural-pathology correlation (Lee et al., 2013a). 
However, the early onset of behavioural deficits in the current chapter (gripstrength decline 
occurred 20 days earlier than Lee and Colleagues, 2013) highlights a significantly earlier 
presence of clinical symptoms in the SOD1G93A mice used in this study, compared to many others 
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(Gurney et al., 1994; Pfohl-Leszkowicz et al., 2015).  Arguably, there is still not a sound 
consensus on the best measure for onset in mouse models of ALS, although deficits to maximal 
running speed seems to be the earliest measure reported, and may be the most effective measure 
of motor behaviour alterations (Veldink et al., 2003).  
 
Furthermore, as highlighted in Figure 4.14, comparisons of pathology data from Chapter 3, and 
grip strength behavioural data from Chapter 4, suggest that hindlimb motor behavioural deficits 
occur prior to the identified axonal and NMJ pathology by approximately one week. However, no 
pathological investigations occurred between 28 and 56 days of age in the SOD1G93A mice in 
Chapter 3. Therefore, results from Chapter 4 suggest that future research should focus on this age 
range of the SOD1G93A when focusing on distal neuromuscular pathology, such as in the axon and 
NMJ. Correlation studies using sophisticated modelling techniques, such as those employed in 
this chapter may elucidate a more holistic representation and comparison of pathology and 
behavioural phenotype. 
4.4.4 Microtubule stabilisation alters behavioural outcomes 
As described previously, EpoD treatment improved a-MN and axonal pathology early in the 
disease course. Interestingly, this was not associated with improvements in motor behaviour and 
neurological scoring. This suggests that pathology and behaviour do not always match, and in 
this case, may be explained by the lack of protection at the NMJ, as destruction of synaptic 
colocalisation continued unabated. Later disease stages showed a hastened deterioration in motor 
performance and neurological scoring in EpoD treated mice, mirroring the loss of a-MNs and 
increased gliosis in the lumbar spinal cord of end stage SOD1G93A mice. This suggests that even 
at the low dose used in the current study EpoD is potentially neurotoxic, causing greater a-MN 
degeneration and aberrant glial activation, and thus negatively effecting behavioural and 
neurological outcomes (Fischer et al., 2004; Hegedus et al., 2008). Further, EpoD decreased the 
survival of SOD1G93A mice, significantly reducing the disease time course.  
4.4.5 The evolving complications of the microtubule environment in ALS 
Whilst microtubule involvement in ALS is increasingly being appreciated (Dubey et al., 2015; 
Clark et al., 2016a), the cause of microtubule dysfunction is still largely unknown. Current results 
suggest that age dependant alterations to microtubules may occur, as EpoD treated SOD1G93A 
mice show differential disease progression in pathology, and modest alterations in behaviour. 
Indeed, many age dependant pathological and molecular alterations in the SOD1G93A mouse 
FIGURE 4.14. Timeline of distal pathology and motor behaviour deficits as 
measured by grip strength. Deficits to hindlimb grip strength occur prior to the 
presence of axonal and NMJ pathology. Both hindlimb and forelimb gripstrength 
occur in two stages.  Forelimb grip strength loss occurs well before the loss of the 
corresponding forelimb distal neuromuscular circuitry (64.5 days), compared to the 
hindlimb (6.4 days).  
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model have been documented (Kanning et al., 2010; Redler and Dokholyan, 2012). Further, 
signalling pathways that directly impact normal microtubule dynamics and function are also 
affected over the disease course; however, the direct impact these mechanisms have on 
microtubules are yet to be investigated (Palazzo et al., 2001; Tudor et al., 2005; D'Ambrosi et al., 
2014; Wojnacki et al., 2014). Investigation of microtubule alterations over the disease time 
course, particularly between age, genotype and associated pathogenic mechanism are needed to 
elucidate the full involvement of microtubules disease pathogenesis. 
 
The current results suggest that reassessment of age, timing and duration of EpoD delivery will 
need to be completed, as well as the capacity for combination therapy, to improve the efficacy of 
microtubule stabilisation in ALS (Pandya et al., 2012). Further, comparing the mode of action 
between noscapine, a compound that improves the ALS phenotype, and EpoD, is necessary. 
EpoD binds the taxol binding site on β-tubulin, promoting a GTP independent conformational 
change that promotes dose dependant microtubule polymerisation and alterations to dynamics 
(Cheng et al., 2008). Conversely, the binding site on tubulin for noscapine is unknown (Ye et al., 
1998). Further, noscapine does not significantly alter microtubule mass or promote 
polymerisation. Instead, noscapine supresses microtubule dynamics by ‘stalling’ the growth and 
shrinkage phases of microtubules, thus decreasing the overall dynamics of the microtubule 
network (Zhou et al., 2002; Zhou and Giannakakou, 2005). This suggests that gross microtubule 
stabilisation may not be the best way to improve pathology in ALS. Rather, subtly altering 
microtubule dynamics in a-MNs may be a more attractive therapeutic approach to target 
pathology. 
 
Another consideration is the copy number variant of the SOD1G93A mouse model. High copy 
number mice (23-25 copies) have a significantly shorter life span and faster progressing 
pathology than low copy SOD1G93A models. Due to the high rate of disease progression, potential 
therapeutics may have benefits or positive outcomes masked, further complicating the design and 
interpretation of therapeutic trials (Zwiegers et al., 2014). Repeating therapeutic interventions in a 
slower progressing SOD1 model (for example, the low copy SOD1G93A mouse), TDP-43 and 
newer C9ORF72 animal models, may uncover a greater number of pathological and behavioural 
changes during EpoD treatment (Stallings et al., 2010; Acevedo-Arozena et al., 2011; Liu et al., 
2016). 
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The highly multifactorial nature of pathogenic mechanisms in ALS suggests that any therapy to 
modify or cure the disease will most likely be a combination-based therapy, with adjusted 
treatment type, dosage and time as the disease progresses (Bucchia et al., 2015; Goutman and 
Feldman, 2015). Indeed, EpoD treatment regimes used in cortical degenerative models may not 
be appropriate for long term management of ALS, a conclusion which is supported by the current 
study (Brunden et al., 2014). EpoD’s positive effect early in the disease, followed by 
deterioration of behavioural outcomes and pathology, suggest the disease pathology is 
heterogeneous and evolving, and that to manage this change a multi drug approach, with 
alterations to dosage and timing is necessary. Indeed, the lack of impact on NMJ pathology, 
whilst axonal pathology was reduced early in the disease, suggests that the two distinctly 
different cellular sites may require multiple targeted treatment regimes to obtain benefits. Further, 
EpoD may differentially affect microtubules over the disease time course in an age and cellular 
compartment manner, however this is still poorly understood.  
4.4.6 Conclusion 
Stabilising microtubules to attenuate axonal degeneration is an attractive therapeutic approach for 
many neurodegenerative diseases. The current chapter utilised the microtubule targeting 
compound EpoD, with the aim of protecting axons of the neuromuscular circuitry in ALS and 
improving the disease phenotype. EpoD was identified to increase microtubule stability markers 
in the lumbar spinal cord, suggesting EpoD has the capacity to modify the microtubule network 
in the distal neuromuscular circuitry. Furthermore, early protection offered by EpoD suggests that 
targeting the distal axon with low dose EpoD may only be of benefit in the earlier stages of the 
disease, with the need for adjusted treatment strategies or other combined therapies as the disease 
progresses. The current results highlight the highly heterogeneous nature of disease pathogenesis 
in ALS.  
 
Age dependant effects of EpoD on pathological, neurological and behavioural outcomes in the 
current study suggest that microtubules play an evolving role over the entire disease course. The 
role they play is still largely unknown, however, as our understanding of the normal neuronal 
function of microtubules increases, so will the complexity and targeted nature of research 
question surrounding microtubules in ALS. Similarly, the impact EpoD has on neuronal 
microtubules is still underappreciated. Future investigations into dose dependant effects of EpoD 
on normal neuronal functioning should be considered a priority due to the attractive of such 
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compounds as neurodegenerative treatments. Due to the complexity of in vivo systems, and the 
difficulty of measuring outcomes with microtubule targeting compound, whether morphological 
or functional, in vitro approaches should be considered as an appropriate method for evaluating 
the microtubule dependant effects of EpoD on neurons. 
							Chapter	5	
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5 The impact of microtubule stabilisation by Epothilone D on neuronal growth, viability 
and function 
5.1 Introduction 
Defects to the neuronal cytoskeleton occur in various neurodegenerative disorders. Compounds 
targeting cytoskeletal elements, such as microtubules, are becoming an increasingly popular 
therapeutic intervention strategy to improve cytoskeletal dysfunction and outcomes in disease 
(Eira et al., 2016). This philosophy was applied in Chapter 4, where the microtubule-targeting 
compound EpoD was used to stabilise the microtubule cytoskeleton in the SOD1G93A mouse 
model of ALS. Results showed early beneficial actions on improving a-MN survival and distal 
axonal pathology. However, this protection was not extended to the synapse or translated into 
improved motor behaviour, although modest improvements to hindlimb grip strength were 
identified. Indeed, age dependent acceleration of symptoms in EpoD treated SOD1G93A mice 
suggest that both genotype and treatment are having a detrimental effect on late stage disease 
progression. However, how this particular epothilone analogue (EpoD) alters normal neuronal 
function is poorly understood. 
 
A common misconception with the neuronal cytoskeleton is that as mature neurons are non-
mitotic, their cytoskeletal elements, such as actin, neurofilaments and microtubules are stable 
entities (Baas et al., 2016). However, as our understanding and documentation of the plastic 
nature of the nervous system increases, so does our appreciation of the similar dynamic nature the 
in neuronal cytoskeleton. Our understanding of non-dynamic stable domains, and highly dynamic 
labile domains in the normal neuronal microtubule network has highlighted that the microtubule 
system may be vulnerable to changes in this dynamic state. Indeed, changes to microtubule 
dynamics and proteins associated with the control of microtubule dynamics are associated with 
the pathogenesis of multiple neurological disorders, including ALS (Fanara et al., 2007; Kleele et 
al., 2014). 
 
Microtubule-targeting compounds are among the most successful means by which to target and 
treat various types of malignancies (Dumontet and Jordan, 2010). This is mainly due to the 
importance of microtubules in the development and mechanical action of the mitotic spindle 
during cell division, which, in cancer, develops into an uncontrolled and hyper activated process 
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(Zhou and Giannakakou, 2005). When used at concentrations high enough to inhibit cell division, 
compounds such as the taxanes and epothilones have been shown to be highly effective 
treatments for patients suffering from cancer (Dumontet and Jordan, 2010). However these drugs, 
regardless of their intended use, are not without their caveats. High doses of microtubule-
targeting drugs can hyper-stabilise the microtubule network, causing a painful and debilitating 
peripheral neuropathy (reviewed previously in (Lee and Swain, 2006; Carlson and Ocean, 2011)). 
Indeed, brain penetrant microtubule-targeting compounds such as EpoD cause similar symptoms, 
however the effect of these drugs on neuronal health in the CNS is still not well documented 
(Konner et al., 2012). Highlighting the importance of increased understanding, Masocha and 
colleagues described increased astrocyte activation and altered expression of glutamate receptor 
subunits in the cortex of mice treated with paclitaxel, suggesting that microtubule stabilisation 
which typically causes peripheral neuropathic pain, also affect cells of the CNS (Masocha, 2015).  
 
It is becoming increasingly apparent that microtubule-targeting compound concentration, target 
and measurement (outcome) are all important and intertwined in both study design and 
interpretation. Indeed, the concentration range of such compounds to obtain optimal stabilisation 
in neural systems is extremely narrow (Bollag et al., 1995). For example, studies using low dose 
of microtubule-targeting compounds (approximately 1/20th to 1/30th of the doses used in cancer 
therapy (rodent equivalent), were found to improve outcomes in models of neurodegeneration or 
cortical injury (Brunden et al., 2010; Brunden et al., 2011; Zhang et al., 2012; Cartelli et al., 
2013; Brizuela et al., 2015). These studies generally used tubulin chemical modifications as a 
biomarker for microtubule network stabilisation; a valid and reproducible test, which highlights 
the dose dependant increase in microtubule stability with increasing compound concentration 
(Brunden et al., 2011; Magiera and Janke, 2014). However, microtubule-targeting compounds 
can, like in cancer therapy, abolish microtubule dynamics via hyper-stabilisation, causing a loss 
of +TIP protein localisation and expression (Kleele et al., 2014; Benbow et al., 2016; Brill et al., 
2016). Indeed, paclitaxel has been identified to induce polar reconfiguration of axonal 
microtubules and impair axonal transport of organelles and vesicles in vitro, with no recovery of 
the resultant phenotype upon compound removal (Shemesh and Spira, 2010).  
 
Of the epothilones, EpoB has been investigated with regards to dose-dependant neuronal impact, 
with results suggesting that low to moderate concentrations cause decreased neuronal 
development, axonal health and decreased electrophysiological properties by lowering nerve 
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transduction velocities, both in vitro and in vivo (Chiorazzi et al., 2009; Jang et al., 2016). Indeed, 
considerations of dose and target must be evaluated when developing therapeutic strategies 
utilising microtubule-targeting compounds for neurodegenerative diseases and CNS injury, as 
evidence suggests that these compounds can cause drastic microtubule changes in dose-
dependant manner. 
 
The current investigation utilised a primary in vitro cortical model to identify alterations to 
normal neuronal growth, development and function caused by the dose-dependant application of 
EpoD, a process that is still poorly understood. Utilising cultured cortical neurons, a subtype of 
projection neurons expressing endogenous YFP will be selected to aid in decreasing cell 
variability. Tau immuno-staining will be utilised to separate tau positive and negative processes 
for analysis, as tau localises mainly to axonal microtubules (Conde and Caceres, 2009). The 
current investigation aims to determine the impact of EpoD on a subset of cortical neurons to 
better understand and interpret outcomes of stabilising neuronal microtubules with EpoD. 
5.2 Methods 
5.2.1 Cell culture 
As described in Chapter 2, section 2.5, neurons were isolated from the dissected and 
disassociated neocortex of 15.5-day-old embryonic thy1-YFP mice, and plated onto poly-l-lysine 
coated surface (glass or plastic) in 24 well plates (1.9 cm2), 6 well plates (3.48 cm2) or live 
imaging micro chambers (1.5 cm2), at the following densities: 24 well plate, 3 x 104 cells; 6 well 
plate, 6 x 106 cells; imaging chambers, 5 x 103 cells. 
Transgenic YFP expressing embryos and wild-type littermates were used for experiments. 
Cultures were grown according to the procedures described in Chapter 2, section 1.5. 
5.2.2 Treatment paradigms 
In order to study the effects of EpoD on normal neuronal development, neurite growth and 
function, cells were exposed to a variety of drug concentrations (0.1nM, 1nM, 10nM, 100nM 
EpoD), for 2 hours and 24 hours in mature neurons (10DIV), or 24 hours with media replacement 
(conditioned +treatment) for growth and development experiments. Naïve, untreated neurons and 
vehicle (DMSO) treated neurons were utilised as controls. 
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5.2.3 Quantification of cell viability 
Cell health was determined by either using the  alamarBlue® cell viability assay (Thermo Fisher 
Scientific) or by quantifying nuclear morphological alterations with DAPI staining (Kihlmark et 
al., 2001). AlamarBlue® reagent was diluted (1:10) in conditioned cell culture medium, followed 
by incubation with neurons for 2 hours. Redox reactions, as a measure of cell viability, was 
measured by fluorescence on a FLUOstar OPTIMA plate reader (excitation 570 nm, emission 
580; BMG Labtech).  
5.2.4 Immunocytochemistry of microtubule cytoskeleton 
Neuronal cultures were fixed in 4% PFA and were probed using immunocytochemistry methods 
described in Chapter 2, section 1.6 for: cell processes (anti-rat GFP, 1:3000, Nacalai tesque), 
axons (anti- rabbit tau, 1:2000, DAKO) and dendrites (anti-mouse MAP2, 1:1000, Millipore). 
Secondary antibodies (rat Alexa488, mouse Alexa568, rabbit Alexa647) were diluted in PBS 
(1:750; Molecular Probes) and incubated for 1.5 hours at room temperature, followed by DAPI 
nuclear staining.  
5.2.5 Confocal microscopy of neuronal cultures 
Cells were visualised using a spinning disk laser confocal (UltraVIEW® VOX, Perkin Elmer) on 
an inverted microscope (Nikon TiE, Nikon) fitted with 20x (Plan-Apo N.A. 0.75) and 40x (Plan-
Apo N.A. 0.95) objective lenses. Images were acquired using an Orca R2 camera (C10600, Orca, 
Hamamatsu) and analysed using imaging capture software (Velocity v6.3.0, 2013, Perkin Elmer). 
5.2.6 Image analysis and cell tracing 
Neurite extension was evaluated in YFP expressing cells with healthy nuclear morphology and 
robust YFP cytoplasmic fluorescence in Image J (Schneider et al., 2012). Tracings of neuronal 
cell bodies, developing axons (described as tau positive YFP processes henceforth) and dendrites 
(described as tau – negative YFP processes henceforth) were completed utilising Neurolucida 
software (MBF Bioscience).  
5.2.7 Mitochondrial transport analysis 
Culture media containing EpoD/vehicle treatment was removed from the cells and kept at 37°C 
for reapplication following staining. Cells were incubated in conditioned culture media 
containing Mitotracker® Red FM (200nM final concentration, Thermo Fischer Scientific) for 15 
minutes, followed by a 5 minute wash in conditioned culture media. EpoD/vehicle media was 
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reapplied to the cells and live cell imaging was performed as described in Chapter 2, section 
1.5.4.  
5.2.8 Western blot protein quantification 
Neuronal cultures were rinsed twice in ice-cold PBS, followed by lysis in RIPA-Inhibit buffer 
(RIPA buffer + 1µM trichostatin-a), and centrifugation at 15,800 RCF for 10 minutes at 4°C to 
remove cell debris, as described in full in Chapter 2, section 1.7.1. Protein levels were then 
evaluated by Western blot. Tubulin chemical modifications were probed to identify changes to 
microtubule stability using an antibody to acetylated tubulin (mouse monoclonal, 1:5000, Sigma 
Aldrich). Antibodies for STOP (mouse monoclonal, 1:500, Millipore) and EB3 (rat monoclonal, 
1:500, Abcam) and GAPDH (rabbit polyclonal, 1:5000, Millipore) were used. Secondary HRP 
conjugated antibodies were then used, followed by imaging, as described in Chapter 2, section 
1.7.2.  
5.2.9 Statistical analysis 
To determine the effect of EpoD on normal neuronal growth, development, function and protein 
levels data was statistically analysed using GraphPad Prism (Version 5.00, La Jolla, CA) using 
one-way analysis of variance (ANOVA) with Dunnets post-hoc correction for multiple 
comparisons. p < 0.05 was considered significant. Data is expressed ± standard deviation of the 
mean (SD). Unless otherwise stated, a minimum of three separate cultures was used for each 
experiment, with 3 technical replicates per culture (n = 3). 
5.3 Results 
5.3.1 Epothilone D causes dose a dependant decrease in neuronal viability 
Stabilisation of microtubules with compounds such as EpoD were originally utilised to induce 
cytotoxicity in tumorigenic and malignant cells. Such approaches cause painful neuropathies due 
to aberrant stabilisation of the neuronal microtubule cytoskeleton. To date, the dose dependant 
cytotoxicity of EpoD on primary neurons are yet to be investigated. Utilising a commercial cell 
viability assay, the current investigation identified that growing and developing neurons treated 
with varying doses of EpoD showed no significant changes in neuronal viability compared to 
vehicle treated control neurons between 1DIV and 2DIV (Figure 5.1 A & B).  By 3DIV (3 days 
of recurrent treatment), 100nM EpoD treated neurons showed significantly (p < 0.05) decreased 
viability compared to age matched, vehicle treated control neurons  (100nM EpoD: 434.39 ± 
53.58; vehicle: 694.56 ± 87.27) (Figure 5.1 C). This trend continued at 4DIV, with 100nM EpoD 
FIGURE 5.1. Cell viability of EpoD treated cortical neurons during initial growth. 
(A) EpoD treatment does not alter neuronal cell viability when measured by the 
alamarBlue® cell viability assay at any dose at 1 DIV, (B) or at 2 DIV. (C) However 
at 3 DIV, (D) and 4 DIV, 100nM concentrations of EpoD were detrimental to cell 
viability, with a significant drop in assay fluorescence (P < 0.1). (E) Evaluation of 
nuclear health determined a decreased proportion of healthy nuclei, with non-
condensed chromatin staining and a rounded morphology (DAPI), compared to 
unhealthy (F), which present as an increased proportion of shrunken nuclei (F, open 
arrow head), or fully condensed nuclei (F, closed arrowhead), (G) at 1 DIV in 100nM 
EpoD treated YFP neurons. Data shown are: mean ± SD, (n = 3). * P < 0.05, ** P < 
0.01, One-Way ANOVA with Dunnett’s post hoc test. Scale = 15μm. Abbreviations: 
NC, Naïve control. 
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treated cells showing significantly (p < 0.05) less neuronal viability, compared to vehicle treated 
controls (100nM EpoD: 454.67  ± 101.58; vehicle: 1025.22 ± 178.11) (Figure 5.1 D). This 
suggests that high doses of EpoD are toxic to neuronal cell growth and survival. 
 
The morphology of the nucleus was also evaluated to determine the health of YFP positive 
cortical neurons, as during apoptotic cellular demise a series of morphological alterations to the 
nucleus occurs that can be quantified into stages of degeneration (Kihlmark et al., 2001). It was 
determined that there was a significant (p < 0.05) decrease in the proportion of healthy nuclei 
(Figure 5.1 E) at 1DIV, with an increase in condensed and degenerating nuclei (Figure 5.1 F) in 
100nM EpoD treated cells, compared to vehicle treated controls (100nM EpoD: 44.45% ± 
10.29%; vehicle: 85.48% ± 11.67%) (Figure 5.1 G). At later time points (2, 3 & 4DIV) there was 
no significant (p > 0.05) difference in nuclei morphology in EpoD treated YFP neurons, 
compared to controls. This suggests that EpoD impairs the health and development of primary 
cortical neurons in a dose/and age-dependant manner. Further, it suggests that subpopulations of 
YFP positive cortical neurons may exist, which are resistant to EpoD induced microtubule hyper 
stabilisation (Jang et al., 2016).  
5.3.2 Epothilone D causes dose dependant effects on neuronal viability in relatively 
mature primary cortical neurons  
The majority of situations in which microtubule-targeting compounds will be used in disease 
models or in patients are where mature neuronal networks are fully developed. Although now 
appreciated to contain labile domains, microtubules in mature neurons are generally more stable 
than those in developing neurons, as microtubule dynamics evident during axonal path finding 
and mass network plasticity are not as essential to mature neuronal function (Kapitein and 
Hoogenraad, 2015). Neurons at 10DIV were considered relatively mature, as an increase in 
synaptic proteins, glutamate receptors, axon/dendrite connections and altered 
electrophysiological properties occur at this age (Lesuisse and Martin, 2002; Wang et al., 2008). 
Similar to developing neurons, relatively mature primary cortical neurons at 10DIV were treated 
with varying doses of EpoD and neuronal viability was assessed at 2 hours and 24 hours post 
treatment. Cortical neurons evaluated two hours post-treatment showed no significant (p > 0.05) 
changes viability in both the Alamar blue cell viability assay (Figure 5.2 A), and no alterations to 
the morphology of nuclei in YFP positive neurons (Figure 5.2 B). However, 24 hours post 
treatment, 10nM and 100nM concentrations of EpoD were found to significantly (p < 0.001 & 
FIGURE 5.2. Cell viability of EpoD treated mature cortical neurons as measured by 
the alamarBlue® cell viability assay. (A) EpoD treatment does not alter neuronal cell 
viability at two hours post treatment, (B) or cause a loss of healthy morphology of 
YFP positive neuronal nuclei. (C) However, 24 hours post treatment 10nM and 
100nM concentrations of EpoD were detrimental to cell viability (p < 0.05) (D) and 
nuclear morphology (p < 0.01), in cortical neurons. Data shown are: mean ± SD, (n = 
3). * P < 0.05, ** P < 0.01, One-Way ANOVA with Dunnett’s post hoc test. Scale = 
15μm. Abbreviations: NC, Naïve control. 
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0.01, respectively) reduce cell viability, compared to vehicle treated controls (10nM EpoD: 
2301.67 ± 82.35; 100nM EpoD: 1750.67 ± 63.69; Vehicle: 2699 ± 141.86) (Figure 5.2 C). 
Similar results were discerned upon evaluation of nuclei morphology in YFP expressing neurons, 
showing that neurons treated with both 10nM and 100nM EpoD had significantly (p < 0.05) 
decreased proportion of healthy nuclei, compared to vehicle treated control neurons (10nM 
EpoD: 71.59% ± 6.97%; 100nM EpoD: 74.33%  ± 5.06%; vehicle: 90.60% ± 2.48%) (Figure 5.2 
D). These results suggest that treatment of relatively mature (10DIV) primary cortical neurons 
with EpoD has dose-dependant effects on neuronal viability. 
5.3.3 EpoD impacts the initial outgrowth of neurites in primary cortical neurons 
The initiation of neurite outgrowth, particularly of the axon, is dependant on rearrangement and 
signalling actin, neurofilaments and microtubules to engage and promote neurite extension 
(Letourneau and Ressler, 1984; Kapitein and Hoogenraad, 2015). The initiation of neurite 
extension in EpoD treated cortical neurons was evaluated in YFP positive neurons with healthy 
nuclear morphology and robust YFP positive cytoplasmic volume (Figure 5.3 A & B). It was 
found that the proportion of neurons with evidence of neurite extension (such as Figure 5.3 A) 
was significantly (p < 0.001) decreased in neurons treated with 100nM of EpoD at 1DIV, 
compared to vehicle treated controls (100nM EpoD: 36.45% ± 10.50%; vehicle: 84.26% ± 
10.50%) (Figure 5.3 C). Neurons with healthy nuclear morphology and robust YFP labelling 
showed no significant (p > 0.05) difference in the proportion of neurons with neurite extension at 
2, 3 and 4DIV (Figure 5.3 C). This suggests that high doses or EpoD inhibit initial neurite 
extension in primary cortical neurons, however, surviving neurons are able to develop processes 
at later stages of development. 
5.3.4 EpoD impacts on growth and complexity of neurites in primary cortical neurons 
As well as being important for neurite initiation, microtubules are also important for axonal and 
dendrite growth and circuit complexity (Lewis et al., 2013; Kapitein and Hoogenraad, 2015). To 
determine whether EpoD treatment has microtubule dependant effects on these parameters, 
developing YFP positive cortical neurons were treated with varying doses of EpoD, followed by 
evaluation of neurite complexity using tracing software at 1DIV and 4DIV. 
Immunocytochemistry was utilised to specifically evaluate tau positive and tau negative neurites. 
High doses of EpoD was found to increase the proportion of less complex cortical neurons at 
1DIV (Figure 5.4 A), compared to vehicle treated neurons (Figure 5.4 B). There was no 
significant (p > 0.05) difference in the total length of tau positive processes in EpoD treated 
FIGURE 5.3. High doses of EpoD reduce initiation of neurite extension in cortical 
neurons. (A) Representative image of vehicle treated YFP positive neurons at 1 DIV 
show robust neurite extension, with tau positive neurites (closed arrowhead) and tau 
negative neurites (open arrowhead). Scale = 90μm. (B) Representative image of YFP 
positive neurons at 1 DIV, when treated with 100nM EpoD, show a decrease in 
identifiable neurites, but still have healthy nuclear morphology and YFP labelling. 
Scale = 30μm. Neurites were determined as YFP positive processes that were ≥ the 
diameter of the cell soma. (C) At 1 DIV, cortical neurons treated with 100nM of 
EpoD have significantly reduced (P < 0.001) neurite initiation. Data shown are: mean ± SD, (n = 3). ** P < 0.01, One-Way ANOVA with Dunnett’s post hoc test. 
Abbreviations: NC, Naïve control. 
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FIGURE 5.4. Neuronal process complexity at 1 DIV is affected by treatment with 
EpoD. (A) Representative tracings of YFP neurons at 4 DIV, which are less complex 
when treated with EpoD, (B) compared to vehicle treated neurons (tau +ve process, 
closed arrowhead; tau –ve process, open arrowhead). (C) Total length of tau positive 
processes are not significantly (p > 0.05) altered due to EpoD treatment. (D) Total 
length of tau negative processes are significantly (p < 0.05) decreased at higher doses 
of EpoD. (E) The proportion of tau +ve secondary order processes is significantly (p < 
0.05) decreased in 10nM and 100nM EpoD treated YFP neurons. (F) The proportion 
of tau –ve primary order processes is significantly (p < 0.01) reduced in 10nM and 
100nM EpoD treated YFP neurons. Scale = 45μm. Data shown are: mean ± SD, (n = 
3). * P < 0.05, ** P < 0.01, One-Way ANOVA with Dunnett’s post hoc test. Scale = 
15μm. Abbreviations: NC, Naïve control. 
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neuronal cultures, compared to vehicle treated controls (Figure 5.4 C). However, evaluation of 
tau negative processes determined a significant (p < 0.05) decrease in the total process length in 
both 10nM and 100nM EpoD treated YFP cortical neurons, compared to vehicle treated controls 
(10nM EpoD: 20.95µm ± 4.75µm; 100nM EpoD: 23.08µm  ± 9.14µm; vehicle: 41.81µm ± 
15.97µm) (Figure 5.4 D). 
 
Assessment of the branching complexity of YFP positive neurons was undertaken to determine 
the impact of EpoD treatment on neuronal development at 1DIV. It was identified that tau 
positive processes had no significant (p > 0.05) difference in the proportion of primary order 
processes (Figure 5.4 E). However there was a significant (p < 0.05) decrease in the proportion 
of tau positive secondary processes in both 10nM and 100nM EpoD treated YFP neurons, 
compared to vehicle treated controls (10nM EpoD: 9.14% ± 15.14%; 100nM EpoD: 7.57% ± 
11.88%; vehicle: 28.41% ± 4.87%) (Figure 5.4 E). There was no significant (p > 0.05) difference 
in the complexity of YFP positive neurons with tertiary processes due to EpoD treatment (Figure 
5.4 E). 
 
Branching complexity of tau negative processes in YFP neurons at 1DIV was also evaluated. It 
was identified that 10nM and 100nM EpoD treated YFP neurons exhibited a significant (p < 
0.01) decrease in the proportion of primary order processes, compared to vehicle treated controls 
(10nM EpoD: 42.17% ± 21.14%; 100nM EpoD: 29.26% ± 10.11%; vehicle: 76.47% ± 21.51%) 
(Figure 5.4 F). These results suggest that high doses of EpoD impact on the development on 
neuronal process length and complexity, and impact tau negative processes significantly greater 
than positive processes. 
 
Similar to the earlier 1DIV time point, high concentrations of EpoD were found to reduce the 
complexity of  cortical neurons at 4DIV (Figure 5.5 A), compared to vehicle treated neurons 
which had typically more longer and more highly branched neurites (Figure 5.5 B). It was 
determined that at 4DIV EpoD significantly (p < 0.05) reduced the total length of tau positive 
processes in YFP neurons when treated with 10nM and 100nM EpoD, compared to vehicle 
controls (10nM EpoD: 214.24µm ± 44.15µm; 100nM EpoD: 141.81µm  ± 42.69µm; vehicle: 
479.31µm ± 145.60µm) (Figure 5.5 C). Similarly, tau negative processes exhibit significantly (p 
< 0.05) reduced total process length when treated with 10nM and 100nM of EpoD, compared to 
FIGURE 5.5. Neuronal process complexity at 4 DIV is affected by treatment with 
EpoD. (A) Representative tracings of YFP neurons at 4 DIV, which are less complex 
when treated with EpoD, (B) compared to vehicle treated neurons (tau +ve process, 
closed arrowhead; tau –ve process, open arrowhead). (C) Total length of tau +ve 
processes are significantly (p < 0.001) decreased in 10nM and 100nM EpoD treated 
YFP neurons. (D) Total length of tau negative processes are significantly decreased in 
10nM (p < 0.05) and 100nM (p < 0.01) EpoD treated YFP neurons. (E) The 
proportion of tau +ve secondary order processes is significantly (p < 0.001) decreased 
in 10nM and 100nM EpoD treated YFP neurons. Tertiary order processes are also 
significantly decreased (p < 0.0001) in 1nM and 10nM EpoD treated YFP neurons, 
with no tertiary tau+ process in 100nM treated cells. (F) The proportion of tau –ve 
primary order processes is significantly (p < 0.05) reduced in 10nM and 100nM EpoD 
treated YFP neurons. Scale = 75μm. Data shown are: mean ± SD, (n = 3). One-Way 
ANOVA with Dunnett’s post hoc test. Scale = 15μm. Abbreviations: NC, Naïve 
control. 
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vehicle treated controls (10nM EpoD: 93.81µm ± 16.18µm; 100nM EpoD: 80.87µm  ± 19.32µm; 
vehicle: 170.49µm ± 15.59µm) (Figure 5.4 D). 
 
Branching complexity at 4DIV in YFP neurons revealed that primary level tau positive processes 
were not significantly (p > 0.05) altered due to EpoD treatment (Figure 5.5 E). However, the 
proportion of YFP neurons with secondary order tau positive processes were significantly (p < 
0.001) decreased in 10nM and 100nM EpoD treated YFP neurons, compared to vehicle treated 
controls (10nM EpoD: 38.91% ± 38.87%; 100nM EpoD: 10.23%  ± 11.16%; vehicle: 93.75% ± 
7.98%) (Figure 5.4 E). The proportion of tertiary order tau positive processes were also 
significantly (p < 0.0001) decreased in 1nM and 10nM EpoD treated YFP neurons, with 100nM 
EpoD treated YFP neurons exhibiting no tertiary order processes (1nM EpoD: 28.66% ± 20.74%; 
10nM EpoD: 11.52%  ± 14.28%; vehicle: 78.89% ± 17.00%) (Figure 5.5 E). 
 
Evaluation of branching complexity of tau negative processes at 4DIV showed a significant (p < 
0.05) decrease in the proportion of primary processes in 100nM EpoD treated YFP neurons, 
compared to vehicle treated controls (100nM EpoD: 60.96% ± 6.14%; vehicle: 100% ± 0%) 
(Figure 5.5 F). However, there was no significant (p > 0.05) decrease in the proportion of 
secondary processes in EpoD treated YFP neurons. These results suggest that EpoD impacts on 
the growth and complexity of both tau positive and negative processes, with high doses of EpoD 
impeding the growth of YFP cortical neurons. 
5.3.5 EpoD alters the expression of microtubule proteins and microtubules chemical 
modifications in cortical neurons 
Microtubule-targeting compounds such as EpoD affect the stability of the microtubule network, 
altering tubulin chemical modifications and the levels of proteins that are associated with both 
stability and dynamics (Benbow et al., 2011; Brunden et al., 2011). Qualitative evaluation of 
mature (10DIV) YFP cortical neuronal cultures treated with varying concentrations of EpoD 
revealed dose-dependant loss of YFP expression and MAP2 expression (Figure 5.6 A - E). It was 
identified that 0.1nM and 1nM EpoD treatments had no overt effect on YFP or MAP2 
immunocytochemical labelling (Figure 5.6 B & C). However, 10nM and 100nM doses showed 
remarkable decrease in YFP and MAP2 expression (Figure 5.6 D & E). These observations 
suggest that YFP cells are vulnerable to high concentrations of EpoD, and that EpoD treatment 
triggers MAP2 loss from dendrites of mature cultured neurons. 
FIGURE 5.6. Immunohistochemical analysis of NFM, YFP and MAP2 expression in 
mature (10 DIV) cortical neurons treated with EpoD. (A) Vehicle treated culture, (B) 
0.1nM EpoD treated culture and (C) 1nM EpoD treated culture show no loss of YFP 
or MAP2 immunofluorescence. (D) 10nM EpoD treated culture and (E) 100nM EpoD 
treated culture show a reduction in YFP and MAP2 immunofluorescence. NFM 
appears unaltered due to EpoD treatment. Scale = 120µm. 
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To probe microtubule protein expression further, relatively mature (10DIV) neurons were treated 
for 24 hours with varying concentrations of EpoD, followed by protein lysis and quantitation by 
Western blot. It was determined that low concentrations of EpoD does not significantly (p > 
0.05) alter microtubule mass (α-tubulin levels) (Figure 5.7 A). In order to examine the efficacy of 
EpoD on microtubule stabilisation in vitro, tubulin acetylation, a biomarker for microtubule 
stability, was evaluated (Brunden et al., 2011). After 24 hours of treatment, tubulin acetylation in 
100nM EpoD treated neurons was significantly (p < 0.01) increased, compared to vehicle treated 
controls (100nM EpoD: 2.087 ± 0.437; vehicle: 1.115 ± 0.114) (Figure 5.7 B). Lower doses of 
EpoD were comparable to vehicle controls.  
 
Levels of EB3, a +TIP protein (as described in Chapter 1) was evaluated, as it is a protein 
associated with the dynamics of the microtubule network (Benbow et al., 2016). EB3 protein 
levels following 24 hour EpoD treatment were significantly (p < 0.01) decreased in neurons 
treated with 100nM of EpoD, with no changes in neurons treated with lower concentrations 
(100nM EpoD: 0.133 ± 0.060; vehicle: 0.384 ± 0.125) (Figure 5.7 C).  
 
STOP is a MAP that is associated with the stable domains of the microtubule network (as in 
Chapter 1) (Bosc et al., 1996). EpoD stabilises microtubule networks in a dose dependant 
manner; identification of whether STOP levels also increase in a dose dependant manner during 
EpoD treatment is important, as altering STOP levels may have effects on microtubule dynamics 
and function. Indeed, it was determined that STOP levels are significantly (p < 0.05) increased in 
neurons treated with 10nM of EpoD, compared to vehicle treated control neurons (100nM EpoD: 
0.471 ± 0.238; vehicle: 0.213 ± 0.190) (Figure 5.7 D). Surprisingly, STOP levels in 100nM EpoD 
treatments were comparable to vehicle treated controls. These results suggest that alterations to 
microtubule protein levels are dose dependant in EpoD treatment. 
5.3.6 EpoD impairs mitochondrial transport in cortical neurons 
Mitochondrial transport is important to meet the energy needs throughout the various 
compartments of the neuron, relying on the microtubule transport machinery to deliver and 
recycle mitochondria, as discussed in Chapter 1. Utilising live cell imaging, mitochondrial 
transport was evaluated in EpoD treated cortical neurons. In vehicle treated control cultures, 
mitochondrial transport is readily observed at a high speed (Figure 5.8 A). However, 
FIGURE 5.7. EpoD alters the expression of MT proteins and a tubulin chemical 
modification in a dose dependant manner. (A) MT mass, as measured by α-tubulin 
levels, is not altered by low concentrations of EpoD. (B) Tubulin acetylation, a 
marker of MT stability, is significantly (p < 0.01) increased in 100nM EpoD treated 
neurons. (C) EB3 levels, a marker of MT dynamics, is significantly (p < 0.01) 
decreased in 100nM EpoD treated neurons. (D) STOP levels, a protein implicated in 
MT stabilisation, is significantly (p < 0.05) increased in 10nM EpoD treated neurons.  
(mean ± SD, n = 3). 
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FIGURE 5.8. Mitochondrial transport in EpoD treated cortical neurons. (A) 
Mitochondria in vehicle treated controls move at a normal speed (arrows), (B) 
whereas neurons treated with high concentrations of EpoD show reduced 
mitochondrial speed. (C) The maximum speed of mitochondria two hours post EpoD 
treatment is significantly decreased in 10nM (p < 0.01) and 100nM EpoD (p < 0.001) 
treated neuronal cultures, compared to vehicle treated cultures. (D) Similarly, the 
average speed of mitochondria two hours post treatment is significantly (p < 0.0001) 
decreased in 10nM and 100nM EpoD treated neuronal cultures, compared to vehicle 
treated cultures. (E) The proportion of moving mitochondria is significantly decreased 
in 10nM (p < 0.01) and 100nM (p < 0.0001) EpoD treated neuronal cultures, 
compared to vehicle treated cultures. (F) The maximum speed of mitochondria 24 
hours post EpoD treatment is significantly decreased in 0.1nM (p < 0.05), 1nM (p < 
0.05), 10nM (p < 0.01) and 100nM (p < 0.0001) EpoD treated neuronal cultures, 
compared to vehicle treated cultures. (G) Similarly, the average speed of 
mitochondria 24 hours post treatment is significantly decreased in 0.1nM (p < 0.05), 
1nM (p < 0.05), 10nM (p < 0.0001) and 100nM (p < 0.0001) EpoD treated neuronal 
cultures, compared to vehicle treated cultures. (H) The proportion of moving 
mitochondria is significantly (p < 0.0001) decreased in 10nM and 100nM EpoD 
treated neuronal cultures 24 hour post treatment, compared to vehicle treated cultures. 
Scale = 50μm. Data shown are: mean ± SD, (n = 3). * P < 0.05, ** P < 0.01, One-
Way ANOVA with Dunnett’s post hoc test. Scale = 15μm. Abbreviations: NC, Naïve 
control. 
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mitochondrial transport is affected in a dose dependant manner in EpoD treated neurons (Figure 
5.8 B). It was determined that the maximum transport speed of mitochondria is significantly (p < 
0.01) impaired after 2 hours treatment in 10nM and 100nM EpoD treated cortical neurons, 
compared to vehicle treated controls (10nM EpoD: 1.40µm/s ± 0.25µm/s; 100nM EpoD: 
1.35µm/s ± 0.31µm/s; vehicle: 1.78µm/s ± 0.27µm/s) (Figure 5.8 C). Further, the average 
transport speed of mitochondria 2 hours after treatment is significantly (p < 0.001) decreased in 
10nM and 100nM EpoD treated neurons, compared to vehicle treated controls (10nM EpoD: 
0.63µm/s ± 0.12µm/s; 100nM EpoD: 0.58µm/s ± 0.12µm/s; vehicle: 0.90µm/s ± 0.13µm/s) 
(Figure 5.8 D). The proportion of moving mitochondria was also evaluated, with 10nM and 
100nM EpoD treatments triggering a significant (p < 0.01) decrease in the proportion of moving 
mitochondria in cultured cortical neurons, compared to vehicle treated controls (10nM EpoD: 
26.07% ± 5.81%; 100nM EpoD: 21.00% ± 8.25%; vehicle: 39.50% ± 7.76%) (Figure 5.8 E). 
 
Similarly, 24 hours post treatment the maximum transport speed of mitochondrial was 
significantly (p < 0.05) impaired in 0.1nM, 1nM, 10nM and 100nM EpoD treated cortical 
neurons, compared to vehicle treated controls (0.1nM EpoD: 1.45µm/s ± 0.17µm/s; 1nM EpoD: 
1.51µm/s ± 0.33µm/s; 10nM EpoD: 1.32µm/s ± 0.44µm/s; 100nM EpoD: 1.15µm/s ± 0.24µm/s; 
vehicle: 1.88µm/s ± 0.30µm/s) (Figure 5.8 F). Further, the average transport speed of 
mitochondria 24 hours after treatment is significantly (p < 0.05) decreased in 0.1nM, 1nM, 10nM 
and 100nM EpoD treated neurons, compared to vehicle treated controls (0.1nM EpoD: 0.71µm/s 
± 0.12µm/s; 1nM EpoD: 0.71µm/s ± 0.17µm/s; 10nM EpoD: 0.59µm/s ± 0.19µm/s; 100nM 
EpoD: 0.51µm/s ± 0.19µm/s; vehicle: 0.93µm/s ± 0.13µm/s) (Figure 5.8 G). The proportion of 
moving mitochondria was significantly (p < 0.0001) reduced in 10nM and 100nM EpoD 
treatments, compared to vehicle treated controls  (10nM EpoD: 20.50% ± 4.70%; 100nM EpoD: 
11.66% ± 5.71%; vehicle: 34.19% ± 4.40%) (Figure 5.8 H). These results suggest that EpoD 
impairs mitochondrial transport in a dose dependant manner, with individual concentrations 
having an increasingly detrimental effect on transport speed over time. 
5.4 Discussion 
Targeting microtubules as a pharmacological intervention is becoming an increasingly attractive 
and investigated therapeutic strategy for various neurodegenerative diseases and injury (Brunden 
et al., 2010; Brunden et al., 2011; Zhang et al., 2012; Cartelli et al., 2013; Brizuela et al., 2015). 
However, despite the increased use of these CNS penetrant, microtubule targeting compounds, 
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the consequence of cortical neurons exposure is still poorly understood (Baas and Ahmad, 2013). 
The current chapter investigated the effect low concentrations of EpoD has on growth, survival 
and function of cortical neurons in vitro. EpoD was hypothesised to alter microtubule dependant 
outcomes, such as neurite growth, complexity and length, microtubule stability, microtubule 
dependant transport and cellular viability in a dose dependant manner. The current chapter 
highlights that EpoD impairs various aspects of cortical neurons, with a strong emphasis on the 
dose dependant nature of the compound. Furthermore, results suggest that cultured neurons 
treated in an environment comparable to EpoD doses previously used in in vivo models of 
neurodegeneration, such as in Chapter 4, may be experiencing microtubule dependant 
dysfunction, particularly when considering protein levels and organelle transport. 
5.4.1 Reported in vivo CNS concentrations of Epothilone D effect the health of cortical 
neurons in vitro 
Many studies utilising EpoD as a possible neurodegenerative disease therapeutic use doses 
between 1mg/ml to 3mg/ml (Andrieux et al., 2006; Brunden et al., 2010; Brunden et al., 2011; 
Zhang et al., 2012). It was reported that low dose EpoD is retained in the CNS at bioactive levels 
for days, with cells experiencing an environment of low nanomolar concentrations of EpoD 
(Brunden et al., 2011). In the current investigation concentrations were chosen ranging from 
picomolar to high nanomolar levels of EpoD to represent these previously reported in vivo 
findings (Brunden et al., 2011). It was identified that EpoD concentrations similar to those 
reported in the CNS of EpoD treated mice are neurotoxic to cultured cortical neurons. Indeed, 
low dose EpoD treatment was found to cause decreased cell viability, growth and impair 
microtubule transport. Similar phenomenon have been reported previously when treating 
neuronal cultures with microtubule targeting compounds. For example, Letourneau and Ressler 
(1984) treated cultured chick sensory neurons with various concentrations of taxol, reporting that 
higher doses cause inhibition of neurite initiation and growth, which is rescued at lower doses 
(Letourneau and Ressler, 1984).  
 
More relevant to the current study, Jang and Coleagues (2016) treated various types of neurons 
with EpoB, reporting that EpoB exhibits both beneficial and negative effects depending on both 
neuronal subtype, dosage and age of the neurons (Jang et al., 2016). For example, EpoB was 
found to decrease cell viability and prevent axonal growth at nanomolar concentrations. 
However, the authors report that picomolar concentrations of EpoB promoted axonal growth in 
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cortical neurons, a phenomenon not identified in the current study utilising EpoD. In the current 
Chapter, only 0.1nM EpoD treatments were in the picomolar range, suggesting that future 
experiments may benefit using lower concentrations of EpoD. Indeed, the current chapter did not 
find any proportion of axonal growth with EpoD treatment. However, one cell population was 
selected in the current study (YFP positive cortical neurons), whereas Jang et al., did not select 
for individual cortical subtypes (Jang et al., 2016). Our laboratory has previously shown that 
picomolar (0.1nM) concentrations of EpoD promotes axonal regeneration in a scratch assay 
injury model, further promoting the use of sub nanomolar concentrations of EpoD to improve 
neuronal growth (Brizuela et al., 2015).  
 
Results from the current chapter suggest that doses being used for targeting microtubules in 
neurodegenerative diseases may be neurotoxic to cortical neurons, however, as such compounds 
work in a dose-dependant manner, evaluation of target and desired outcome will need to be 
considered. High doses of microtubule targeting compounds cause painful peripheral 
neuropathies, whereas the popular conception is that low doses (such as those used to treat 
neurodegenerative diseases) are safe (Carlson and Ocean, 2011; Baas and Ahmad, 2013). Current 
results suggest that although high doses of EpoD cause a reduction in cortical neuron viability 
and healthy, low doses have long lasting effects on organelle transport, as was shown with 
impaired mitochondrial transport in mature neurons. This highlights that whilst low doses of 
microtubule targeting compounds, such as EpoD utilised in Chapter 4, may not cause a 
neuropathic phenotype, there may exist an underlying dysfunction to microtubule dependant 
processes, such as microtubule dependant transport (Shemesh and Spira, 2010). Similar results 
were described by Shemesh and Spira (2010), who showed that 10nM and 100nM of paclitaxel 
causes polar reconfiguration of neuronal microtubules and decreases mitochondrial transport 
(Shemesh and Spira, 2010). Indeed, others have shown that low doses of taxol decreases the 
ability for neurons to produce collateral branches, findings which were identified in the current 
study, with a reduction in complexity of both tau positive and negative (axons and dendrites, 
respectively) branches (Letourneau et al., 1986). It should be noted that although the current 
study reports EpoD treatment alters both tau positive and negative processes, our laboratory has 
also shown that stabilisation of cortical neurons with EpoD can decrease the expression of tau 
isoforms (Brizuela et al., 2015). Regardless, this Chapters aim was to characterise morphometric 
analysis of tau positive and negative processes (axons and dendrites respectively). Further, no 
	 98	
gross alterations to tau immunolabelling were evident between EpoD concentrations during 
image analysis.   
5.4.2 Epothilone D effects neurons without increasing microtubule stability 
In the current study, alterations to neuronal growth, health and function occurred at 
concentrations of EpoD that did not increase stability markers of the microtubule network. At 24 
hours after treatments, only 100nM EpoD treatments showed increased microtubule stability in 
vitro, and it has been previously reported that even at two hours post treatment 100nM EpoD 
shows significant increase in microtubule stabilisation (Brizuela et al., 2015). Whilst it was 
identified that growth, viability and organelle transport was impaired at 100nM, lower doses of 
EpoD also impair neuronal function (Jang et al., 2016).  
 
Evaluation of mitochondrial transport suggests that higher doses of EpoD have a hastened effect 
on inducing transport dysfunction, whereas lower concentrations cause transport dysfunction 24 
hours post treatment. Further, whilst there is a significant impairment in the transport speed of 
mitochondria in neurons treated with low concentration of EpoD, the proportion of moving 
mitochondria remains unchanged until a higher concentration of EpoD is used. The mechanisms 
behind this were not investigated, however, as dynamics and stability of the microtubule network 
correlates with microtubule dependent transport efficiency (Fanara et al., 2007; Shemesh and 
Spira, 2010), it may be due to dose dependent EpoD alterations to microtubule network stability 
(Brunden et al., 2011).  
5.4.3 Epothilone D alters protein levels of MAPs  
This chapter determined that alterations to the protein levels of MAPs and tubulin acetylation 
occur in a dose dependant manner with EpoD treatment. Increases in markers of stability 
(acetylation and STOP) and a decrease in EB3 levels with increasing EpoD concentrations 
suggest that the microtubule network becomes increasingly stabilised in treated neurons. Many 
studies use tubulin acetylation as a biomarker for microtubule stability, however, others evaluate 
microtubule dynamics and stability by analysing EB3 comets (Shemesh and Spira, 2010; Kleele 
et al., 2014; Brill et al., 2016). Indeed, using this technique has shown that the microtubule 
targeting compound paclitaxel reduces the density of EB3 comets, thus signifying a reduction in 
microtubule dynamics and increased microtubule stability (Shemesh and Spira, 2010). The 
current chapter showed that 100nM EpoD treated neurons exhibited increased acetylation with a 
concurrent decrease in EB3 protein levels, suggesting this mechanism may also occur in EpoD 
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treated neurons. A study by Benbow et al (2016) showed that a similar phenomenon occurs in 
vivo, where mice treated with high doses of paclitaxel, where treated mice showed supressed EB3 
immunofluorescence in the sciatic nerve (Benbow et al., 2016). Further, EpoB treatment in vivo 
decreases EB3 comets in the distal axon during phasic pruning (Brill et al., 2016). This suggests 
that microtubule stabilisation with microtubule targeting compounds such as EpoD causes 
alterations to EB3 protein levels and microtubule +TIP localisation. 
 
Interestingly, STOP protein levels are increased at 10nM concentrations of EpoD, but were 
reduced back to levels comparable with vehicle controls in 100nM EpoD treated cultures. The 
cause of this differential response of STOP protein levels is unknown. However it is quite 
surprising, as 100nM EpoD doses were shown to increase tubulin acetylation and stability, it 
would not be unreasonable to assume STOP levels would also be increased at this concentration 
of EpoD. STOP is a protein that binds to microtubules in response to cold induced 
depolymerisation (Slaughter and Black, 2003). STOP has a number of calmodulin binding sites 
(Bosc et al., 2001), and can be regulated by calmodulin (Lefevre et al., 2013), and is susceptible 
to increasing intracellular calcium levels. Therefore the reduction in STOP levels in 100nM 
EpoD treatments may be due to increased intracellular calcium due to decreased cellular viability 
(Job et al., 1981). Interestingly, STOP-null mice are used as a model of schizophrenia, as 
microtubules have been implicated in the disorder (Andrieux et al., 2006; Fournet et al., 2012; 
Volle et al., 2013). EpoD treatment of STOP-null mice improves this disorder by stabilising 
microtubules (Fournet et al., 2012), suggesting the stability properties of both STOP and EpoD 
affect the stable microtubule domains to a high extent. It will be interesting to identify whether 
these MAPs (such as STOP and EB3) are affected during dosages of EpoD comparable to those 
used for cancer therapy (Cheng et al., 2008).  
5.4.4 Conclusion 
Microtubule targeting compounds are increasingly being considered for their therapeutic 
potential in various neurodegenerative diseases. However, how these compounds effect normal 
neuronal functioning is still poorly understood. It was found that EpoD impaired normal neuronal 
growth, viability and caused dysfunction to microtubule dependant transport at concentrations 
comparable to those used in Chapter 4 and in previous preclinical neurodegenerative trials (Table 
5.1).  
 
EpoD	
concentration	
(nM)	
1DIV	 4DIV	 Mature	2hr	
after	treatment	
Mature	24	hr	after	
treatment	
0.1	 No	impact	 No	impact	 No	impact	 êMitochondria speed  	
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These findings suggest that consideration of dose of EpoD, as well as the intended target or 
outcome are of vital consideration when utilising EpoD as a potential therapeutic intervention in 
neurodegenerative diseases. Indeed, this becomes of greater importance where the microtubule 
network may be differentially altered in disease states, where both timing and dose then become 
relevant. Future studies utilising pharmacological manipulation of microtubule stability would 
benefit from a greater understanding of the microtubule environment, and how such microtubule 
targeting compounds affect the microtubule cytoskeleton.  
							Chapter	6	
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6 General discussion  
Although having been researched for over a century, there has been limited to no translation of 
treatment strategies to modify disease outcomes in ALS. ALS is thought to have a long pre 
clinical stage, hampering early detection of the disease, particularly in the vast majority of 
sporadic ALS cases who have no underlying familial link (Eisen et al., 2014). Currently ALS 
research is heavily focused on the development of biomarkers to detect ALS, allowing for an 
earlier window of treatment that may improve patient outcomes (Cudkowicz et al., 2010; 
Shepheard et al., 2014; Thompson et al., 2016). However, such strategies are complex in ALS, as 
ALS is considered a highly heterogeneous disease in its mechanisms. This is highlighted by the 
plethora of ALS causing mutations, where seemingly unrelated mutations culminate in the 
degeneration of MNs (Ticozzi et al., 2011; Marangi and Traynor, 2015). Indeed, ALS is also 
multifaceted in its pathophysiological mechanisms for which both the upper and lower motor 
circuitry is vulnerable. The clinical phenotype of ALS, such as muscle paralysis and wastage, 
which is described in Chapter 1 of this thesis, is caused by the destruction of the neuromuscular 
circuitry necessary for activation of muscle movement and survival (Miller et al., 2006; Moloney 
et al., 2014). When a critical portion of this circuit is lost from a given anatomical location, 
symptoms of ALS appear (Kennel et al., 1996; Hegedus et al., 2008). Identification of the earliest 
pathology in the distal portion of this circuit, such as the axon and NMJ synapse, is crucial for the 
design and implementation of treatment strategies to improve outcomes in ALS. 
 
The loss of muscle innervation in ALS is thought to progress in a ‘distal die-back’ manner, where 
the synaptic and axonal processes degenerate prior to the loss of the a-MN soma (Fischer et al., 
2004; Fischer and Glass, 2007; Moloney et al., 2014). Microtubules are implicated not only in 
axonal degeneration, but are also reported to be hyperdynamic (Fanara et al., 2007; Kleele et al., 
2014), and are implicated in axonal transport dysfunction in ALS (Bilsland et al., 2010). 
Targeting microtubules to improve axonal pathology has been shown to improve outcomes in 
models of neurodegenerative diseases with similar pathological mechanisms to ALS (Brunden et 
al., 2010; Cartelli et al., 2013; King et al., 2013). Such treatment strategies hold promise in ALS, 
where stabilising microtubules in the distal neuromuscular circuitry may improve outcomes and 
prevent degeneration and modify disease progression (Fanara et al., 2007). This thesis has 
explored the concept of protecting the distal neuromuscular circuitry with microtubule targeting 
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compounds. This thesis characterised the progression of pathology in the distal neuromuscular 
circuitry to determine the earliest pathological phenomenon to target in a new treatment strategy. 
Further, this thesis explored the utility of a microtubule stabilising compound EpoD, and impact 
EpoD may have in normal neuronal systems, raising considerations for their use. 
6.1 Characterisation of the distal neuromuscular circuit 
Characterisation of the early changes to the distal neuromuscular circuitry to aid in identification 
of therapeutic targets is still not fully complete. Chapter 3 of this thesis evaluated the time course 
of pathology in pre- and post-synaptic compartments of the NMJ, with particular focus on the 
distal axon, NMJ degeneration and morphology, as well as synaptic architectural proteins. Data 
obtained from the SOD1G93A mouse model of ALS determined that the earliest pathological 
phenomenon identified in the distal neuromuscular circuitry is the generation of axonal and NMJ 
pathology (Pun et al., 2006; Fischer and Glass, 2007; Hegedus et al., 2008). This degeneration 
occurs firstly in the hindlimb of the SOD1G93A mouse model, with delayed pathology in the 
forelimb, cementing the hindlimb as the primary site of pathological characterisation in this 
model (Beers et al., 2011). Indeed, data agreed with previous reports that distal pathology is 
progressive (Frey et al., 2000; Fischer et al., 2004), with presynaptic alterations occurring first 
(such as axonal and NMJ pathology), followed by novel alterations to the post-synaptic apparatus 
of the NMJ, particularly a loss of synaptic localisation of architectural protein involved in 
stability and maintenance (Darabid et al., 2014). Interestingly, these architectural proteins had 
elevated levels in the SOD1G93A mouse muscle (LRP-4, rapsyn, dystrophin), or showed evidence 
of misprocessing (nestin). These proteins are either implicated already in ALS pathophysiology, 
with nestin expression altered in SOD1G93A hippocampus (Lee et al., 2011), or implicated in other 
genetic neuromuscular disorders, as described in Chapter 1. Collectively, these results suggest the 
NMJ may be vulnerable to pathology when key architectural proteins are altered in ALS. Early 
axonal pathology and degeneration of the distal synapse, as stated previously, is thought to begin 
years to decades prior to the onset of overt symptoms in ALS (Frey et al., 2000; Miller et al., 
2006). As disease screening is improved in ALS patients, targeting this pathology may allow for 
improved outcomes.  
 
The early presence of axonal pathology in the SOD1G93A mouse model identified in this thesis’ 
studies, as well reported in human patients (Ellis et al., 1999; Fischer et al., 2004; Moloney et al., 
2014), endorses the use of a therapeutic intervention that has the capacity to protect the distal 
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axon from degeneration. Chapter 4 explored the efficacy of the microtubule targeting compound 
EpoD to improve outcomes in the SOD1G93A mouse model by protecting the distal axon (Brunden 
et al., 2014; Eira et al., 2016). 
6.2 Targeting microtubules to protect the distal axon and improve outcomes in ALS 
Microtubule involvement in ALS is becoming increasingly more appreciated, particularly being 
implicated in axonal degeneration (Zhai et al., 2003; Wang et al., 2012; Ma, 2013; Park et al., 
2013), and also as a primary mechanisms of disease, leading to a hyperdynamic phenotype of the 
microtubule network (Devon et al., 2006; Fanara et al., 2007; Bilsland et al., 2010; Alami et al., 
2014; Smith et al., 2014). Microtubules are a highly vulnerably intracellular organelle, as they 
can also be impacted downstream of other identified ALS mechanisms, as described in Chapter 1. 
Chapter 4 investigated to capacity for axonal protection in ALS by stabilizing microtubules, as 
axonal degeneration identified in Chapter 3 was the earliest pathological event in the distal 
neuromuscular circuitry (Clark et al., 2016b). Microtubule stabilization to improve axonal 
pathology through treatment with EpoD has been shown to improve other models of 
neurodegenerative disease (Brunden et al., 2010; Zhang et al., 2012; Cartelli et al., 2013). Indeed, 
these diseases suffer similar microtubule pathology, as identified during axonal degeneration, but 
also changes to microtubule dynamics; stabilization offers an attractive therapeutic target across 
multiple neurological diseases (Brunden et al., 2011; Brunden et al., 2014; Eira et al., 2016). 
Previously, such therapeutics have been used primarily to target pathology in the cortex, 
generally for neurodegenerative disorders, but also traumatic brain injury (Zhang et al., 2005; 
Ruschel et al., 2015). A number of studies have utilised taxanes and epothilones to target and 
improve outcomes in animal models of tauopathies and spinal cord injury (Zhang et al., 2005; 
Ruschel et al., 2015); however, the current thesis was the first to utilise EpoD to target spinal 
cord. Epothilones have been reported to stabilize microtubules in the distal processes in which the 
current thesis endeavoured to target in ALS, suggesting that such treatment strategies have merit 
(Brill et al., 2016). 
 
Protection of neuronal soma and axons by treatment with microtubule stabilizing compounds was 
supported in Chapter 4, with EpoD protecting both the cell soma and distal axon of the 
neuromuscular circuitry early in the disease. Indeed, this treatment was identified to promote 
soma and axonal protection at an age where mice show similar clinical phenotype of decreased 
EMG readings, a phenomenon utilized in the diagnosis of ALS patients, suggesting possible 
	 104	
clinical translation (Kennel et al., 1996; Scott et al., 2008). Interestingly, data from Chapter 4 
suggests that EpoD does not protect the NMJ from degeneration. The discrepancy between the 
axon and NMJ but may be explained by the subtle differences in microtubule dynamics and 
environment between the two distal compartments (Yan and Broadie, 2007; Bodaleo and 
Gonzalez-Billault, 2016).  
 
The use of multi-level mixed effects linear regression models, non-linear polynomials (cubics) 
and break point analysis is a sophisticated method for data representation, interpretation and 
estimation of disease progression and drug effect (Durban et al., 2005; Chen and Stanley, 2012; 
Grajeda et al., 2016). Indeed, Chapter 4 highlighted the utility of using such methods, with results 
suggesting somatic and axonal protection was not associated with improvements in motor 
behaviour. This implies that EpoD is effective at targeting an aspect of distal pathology, with 
limited to no behavioural or neurological benefits at comparable ages. Indeed, EpoD was 
concluded to be detrimental to motor and neurological functioning later in disease stages, and 
decreased the life span of treated SOD1G93A mice. This was also associated with possible 
neurotoxic effect of EpoD on lumbar a-MNs in the later stages of the disease, and increased 
levels of gliosis (Clement et al., 2003; King et al., 2011; Radford et al., 2015). This highlights 
that both dose and timing of EpoD treatments need to be re-evaluated, particularly as ALS 
pathophysiology is a progressive and evolving process, as described in Chapter 1 and reported in 
Chapter 3.  
 
Further, whilst microtubule pathology in ALS is increasingly being understood, future research 
into this increasingly involved mechanism may uncover new targets and ages at which to test 
pharmacological agents in the various ALS animal models available (Dubey et al., 2015; Clark et 
al., 2016a; Eira et al., 2016). For example, many downstream signalling mechanisms reportedly 
altered in ALS are yet to be investigated in regards to microtubule function and dynamics (Hall 
and Lalli, 2010; Gonzalez-Billault et al., 2012; Wojnacki et al., 2014) These include the Rho-Rac 
GTPase pathways (Wen et al., 2004; Wojnacki et al., 2014), which have been implicated in 
altered actin and immunological function in ALS (D'Ambrosi et al., 2014; Droppelmann et al., 
2014), as well as the CDK5-p25 pathways (Nikolic et al., 1996; Ahlijanian et al., 2000), which 
are implicated in excitotoxic dependant phosphorylation events in ALS (Patzke and Tsai, 2002). 
Indeed, the familial mutations to Alsin are though to alter such signalling pathways, supporting 
this hypothesis (Kunita et al., 2007). These signalling pathways have the capacity to effect many 
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different aspects of the microtubule network, and it should be noted, are involved in microtubule 
network development and dynamics during neurogenesis and axonal path finding (Palazzo et al., 
2001; Wojnacki et al., 2014), suggesting aberrant signalling may cause microtubule dysfunction 
in adult onset disorders. 
 
Regardless of the mechanism behind microtubule dysfunction, many studies report aberrant 
impacts of utilising microtubule targeting compounds to improve microtubule pathology. This is 
due to their association with pathologically altering the microtubule environment, causing gross 
microtubule dysfunction and cellular demise (Shemesh and Spira, 2010; Baas, 2013; Benbow et 
al., 2016). Although Chapter 3 highlighted that axonal protection is an attractive target, results 
from Chapter 4 suggest that such a therapeutic model may only work at particular ages, for a 
particular time. This raises the option of combination therapies for ALS treatment, a direction 
that is being increasingly considered in ALS research (Turner and Talbot, 2008; Goutman and 
Feldman, 2015). Re-evaluation of dose and timing of EpoD treatment, coupled with utilising 
compounds to target other pathology, such as NMJ stabilization and aberrant gliosis, may 
cumulatively improve pathology and offer beneficial outcomes to the behavioural, clinical and 
survival phenotypes in ALS (Zhu et al., 2002; Krakora et al., 2012; Musaro, 2013). 
 
The possibility of EpoD dependent neurotoxicity reported in Chapter 4 suggest that the 
microtubule targeting compounds and their aberrant effect on neuronal function can occur at low-
doses (Baas, 2013). Interestingly, limited research has characterized the impact such compounds 
have on normal neuronal function (Letourneau and Ressler, 1984; Letourneau et al., 1986; Baas 
and Ahmad, 2013; Jang et al., 2016). Low doses of such compounds, such as those used in 
Chapter 4, are thought to be safe, limiting changes to microtubule dynamics to levels where 
microtubule dependent processes can still function at a physiologically normal level (Brunden et 
al., 2011; Brunden et al., 2014; Eira et al., 2016). However, increasing evidence suggests that 
even low doses of microtubule targeting compounds can have overt effects on neuronal growth, 
health and function (Letourneau and Ressler, 1984; Letourneau et al., 1986; Brill et al., 2016; 
Jang et al., 2016). 
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6.3 Pharmacological stabilisation of neuronal microtubules is a complex process 
As described in Chapters 1, 4 and 5, microtubule targeting compounds are becoming increasingly 
considered as a potential therapeutic strategy for neurological disorders and injury (Brunden et 
al., 2014; Brizuela et al., 2015; Ruschel et al., 2015; Eira et al., 2016). However, limited attention 
has been given to how these compounds impact on normal neuronal function, even when utilized 
at doses substantially lower than used in cancer therapy (Albright et al., 2011; Brunden et al., 
2011). The high doses used in cancer therapies cause aberrant hyper stabilisation of the 
microtubule network, a process that causes altered microtubule dependent transport (Shemesh 
and Spira, 2010), expression of microtubule proteins (Benbow et al., 2016), and causes peripheral 
neuropathy (Lee and Swain, 2006; Argyriou et al., 2011). Surprisingly, lower doses reported to 
be beneficial in models of neurodegenerative diseases, such as those used in Chapter 4, were 
found to be detrimental to neuronal growth, health and function in Chapter 5 (Jang et al., 2016).  
 
Data from Chapter 5 suggests that low nanomolar concentrations of EpoD, comparable to the 
concentration of EpoD reported to be at the cell body in Chapter 4 (Albright et al., 2011; Brunden 
et al., 2011), are neurotoxic to cultured mouse primary cortical neurons (Jang et al., 2016). This 
chapter evaluated a number of outcomes that are dependent on microtubules, such as neurite 
outgrowth and complexity, as well as organelle transport. Similar to data reported previously 
using paclitaxel and EpoB, EpoD was found to negatively impact neurite outgrowth, length and 
complexity (Letourneau et al., 1986; Jang et al., 2016). Further, aberrant microtubule stabilization 
was found to decrease transport of mitochondria (Shemesh and Spira, 2010), a phenomenon that 
was supported in Chapter 5 with increasing concentrations of EpoD on cultured primary neurons. 
 
Microtubule targeting compounds such as EpoD were designed to be cytotoxic to malignant cells. 
Data from Chapter 5 suggests that low concentrations of EpoD may significantly alter 
microtubule dynamics and cause a decrease in neuronal cell viability, both during phases of 
growth (1-4 days in vitro, DIV) or in relatively mature neurons (10 DIV) (Jang et al., 2016).  
 
Data from this thesis supports that neurotoxicity identified in Chapter 4 may be caused by as yet 
unreported aberrant effects of low dose EpoD treatments. These effects may be exacerbated in 
ALS, as microtubule dynamics are thought to be important in disease progression, as discussed in 
Chapter 1 (Fanara et al., 2007). It should then be reiterated that dose and timing of such 
therapeutics should be re-evaluated for use in ALS. Regardless, low doses of EpoD was found to 
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be neuroprotective early in the disease in the SOD1G93A mouse model, limiting the early a-MN 
soma and axonal degeneration, suggesting that EpoD may still hold promise as a future 
therapeutic for ALS, most likely in combination with other therapeutic compounds (Goutman and 
Feldman, 2015; Ittner et al., 2015; Turner and Swash, 2015). 
6.4 Future directions and limitations 
This thesis focused on the characterisation of the distal neuromuscular circuitry, microtubule 
targeted axonal protection and the impact of a microtubule targeting compound on normal neuron 
function. Firstly, characterisation of the distal neuromuscular circuitry in Chapter 3 focused only 
on static time points in the SOD1G93A mouse model. Our laboratory has previously utilised in vivo 
live-imaging techniques to repeatedly visualise changes to YFP expressing distal axonal and 
NMJ morphology over a number of weeks (Feng et al., 2000b; Blizzard et al., 2015). Utilising 
this method would further benefit the characterisation of distal disease progression in the 
SOD1G93A mouse. Further, only post-synaptic architectural proteins were investigated in the 
SOD1G93A mouse model. However, formation, maturation and stability of the NMJ rely on both 
pre- and post-synaptic NMJ proteins, such as those described in Chapter 1. Presynaptic proteins 
implicated in other neuromuscular disorders such as various laminin isoforms (Nishimune et al., 
2004; Chand et al., 2015; Chand et al., 2017; Lee et al., 2017b) would be an interesting avenue of 
research in ALS, as other architectural proteins were found to be impacted in Chapter 3 of this 
thesis. This thesis, particularly in Chapters 3 and 4, focused on morphological pathology in the 
distal neuromuscular circuitry, rather than function aspects. To gain a better understanding of the 
disease phenotype in the SOD1G93A mouse (Chapter 3), as well as any functional impacts of 
EpoD in this model (Chapter 4), direct analysis of NMJ function, such as electromyography 
techniques to measure nerve-synapse-muscle signal transmission, should be utilised (Kennel et 
al., 1996; Rizzuto et al., 2015).  
 
Although length dependant and fibre type vulnerability of a-MNs was described in Chapter 1, it 
was not characterised in either Chapter 3, or evaluated with EpoD treatment in Chapter 4. Indeed, 
longer axons preferentially degenerate prior to shorter axons in ALS (Tallon et al., 2016), 
suggesting length dependant vulnerability in the neuromuscular circuitry. Similarly, fast-fatigue 
a-MNs degenerate earlier in disease, followed by fatigue-resistant and slow (Pun et al., 2006). 
Evaluation of fibre type vulnerability and pathology in both Chapters 3 and 4 would of benefited 
from 3D rendering of confocal images, coupled with a-MN axonal fiber type selection utilising 
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volumetric analysis (Pun et al., 2006). Further, correlating a-MN loss in the SOD1G93A mouse 
model with results obtained in Chapter 3 would build a more holistic picture of distal 
degeneration and should be considered for future studies (Frey et al., 2000; Hegedus et al., 2008). 
A more thorough stereological approach to a-MN identification, with particular emphasis on 
identification and quantitation of the a-MNs located in the lateral and medial motor columns, 
would be more appropriate approach when investigating a-MN pathology in ALS (Weber et al., 
1997; Mohan et al., 2014). Similarly, glial activation was measured by increased 
immunofluorescence of both astrocyte and microglial markers. Future studies would benefit from 
assessing changes to glia cell density, as well as changes to their morphology, such as microglia 
transforming from an inactive stellate morphology, to a rounded and large cell with few processes 
(David and Kroner, 2011; Brettschneider et al., 2012). 
 
Treatment of the SOD1G93A mouse model of ALS with EpoD was found to improve a-MN soma 
and axon pathology early in the disease, with late stage deficits and possible neurotoxicity. To 
further investigate the efficacy of microtubule stabilisation using EpoD in the SOD1G93A mouse 
model, revaluation of timing and dosage of EpoD treatment should be completed, as Chapter 5 
highlighted that even substantial low nanomolar and high picomolar concentrations of EpoD can 
alter neuronal outcomes (Jang et al., 2016). Indeed, many studies testing new therapies for ALS 
combine them with riluzole, the only positive disease-modifying agent available for ALS 
treatment. It would be interesting to identify how EpoD alters outcomes in the SOD1G93A mouse 
model in combination with Riluzole, coupled with alterations to EpoD dosage and timing of 
treatment (Waibel et al., 2004; Del Signore et al., 2009). Further, as discussed in Chapter 4, 
Section 4.4.2, pharmacological inhibition of microgliosis using minocycline, a compound shown 
to improve outcomes in the SOD1G93A mouse model, may further aid in any positive benefits of 
EpoD treatment in ALS (Yrjanheikki et al., 1999; Kriz et al., 2002). 
 
Another consideration is testing therapeutics such as EpoD in the SOD1G93A mouse model of 
ALS. The lack of a cure for ALS is somewhat compounded by the limited success in translating 
positive findings from preclinical animal studies to human clinical trials (Turner and Talbot, 
2008; Ittner et al., 2015).  This is mainly due to the use of single ALS models to represent a 
disease that is multifactorial in both familial and sporadic insults. However, various compounds 
and molecular pathways have been identified and are currently under clinical trials (Bucchia et 
al., 2015; Ittner et al., 2015). There are currently over 70 active phase I through to phase III 
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clinical trials taking place throughout the world (ALS Theraputic Development Institute, 2016). 
Although the SOD1 mouse model has been instrumental in advances in ALS, recent opinions 
highlight poor clinical study design, various methodological issues, and unexpected biological 
and pharmacological issue arising during mouse to human translation (Mitsumoto et al., 2014; 
Ittner et al., 2015; Garbuzova-Davis et al., 2016). Moreover, a ‘one size does not fit all’ approach 
to treatment of ALS is continuing to gain traction, with tailored patient treatment, or combination 
therapies, most likely to be utilised to combat the disease in the future (Goutman and Feldman, 
2015). Another consideration is the copy number variant of the SOD1G93A mouse model. High 
copy number mice (23-25 copies) have a significantly shorter life span and faster progressing 
pathology than low copy SOD1G93A models. Due to the high rate of disease progression, potential 
therapeutics may have benefits or positive outcomes masked, further complicating the design and 
interpretation of therapeutic trials (Zwiegers et al., 2014). Therefore, it is recommended trials use 
multiple transgenic mouse models of ALS to gain insight into how potential therapeutics affect 
different disease mechanisms (Ittner et al., 2015; Philips and Rothstein, 2015). 
 
Data from Chapter 5 of this thesis suggests that low doses of EpoD can have detrimental effects 
on growth, viability and function of primary cortical neurons (Jang et al., 2016). Paclitaxel, a 
compound with similar actions to EpoD, has been shown to induce microtubule polarity 
reconfiguration in axons, creating a ‘mixed’ microtubule orientation comparable to those in 
dendrites (Yau et al., 2016), where in normal axons microtubules reside in a ‘plus end out’, 
unidirectional configuration (Shemesh and Spira, 2010; Baas and Ahmad, 2013; Kevenaar and 
Hoogenraad, 2015). Further, end binding protein +TIP density, such as EB3, is a direct measure 
of microtubule dynamics (Kleele et al., 2014). Identifying both EB3 density and polar 
configuration with EpoD treatment is an interesting and necessary avenue of research to identify 
the full impact of EpoD on neuronal microtubules. Further, evaluation of EpoDs affects in vivo is 
also paramount to understand the full extent of EpoDs impact on normal neuronal function. For 
example, evaluating cellular pathology and microtubule protein expression following treatment 
with varying doses of EpoD, up to the maximum tolerated dose, will highlight the full extent of 
EpoDs effect on the neuronal microtubule cytoskeleton (Benbow et al., 2016). In the current 
thesis, mitochondrial transport was measured with no selection of directionality. Identification of 
EpoDs impact on anterograde and retrograde transport will identify whether one or both transport 
directions are vulnerable to stabilisation with Mt targeting compounds such as EpoD. Further, it 
is also critical to consider evaluating primary a-MN in future experiments, as other have 
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identified different neuronal populations have dissimilar outcomes when treated with microtubule 
targeting compounds (Jang et al., 2016). 
 
Data from this thesis has highlighted that microtubule involvement in ALS may be more complex 
than alterations to microtubule dynamics and axonal transport, with progressive microtubule 
pathology most likely occurring over the disease course. Further, characterisation of the impact of 
microtubule targeting compounds on the nervous system needs to be a priority if they are to be 
promoted as a potential therapeutic strategy for targeting neurological diseases and injury. 
6.5 Conclusions 
Pathology of the distal neuromuscular circuitry is a complex and evolving process in ALS. This 
thesis provided significant insight into the characterisation of distal degeneration in the SOD1G93A 
mouse model of ALS, the efficacy of EpoD in the protection against distal axon degeneration, 
and the impact of low-dose EpoD on neurons. In summary, the findings in this thesis indicate that 
axonal pathology is an early targetable event in the pathogenesis of ALS and that EpoD protects 
a-MNs and axons from degeneration early in the disease. However, EpoD was found to be 
detrimental to normal neuronal function, with future evaluation of microtubule targeting 
compounds recommended as these compounds become more popular in the treatment of 
neurological disorders.  
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8 Appendix 
	
8.1 Commonly used Solutions 
0.01 M Phostohate buffered saline (PBS), pH 7.4 – makes 1L 
• 2mM NaH2PO4.2H2O (Ajax) 
• 8mM Na2HPO (BDH) 
• 154mM NaCl (BDA) 
• Made to 1L in milli-Q® water 
4% Paraformaldehyde (PFA) – makes 100mL 
• 1.33M paraformaldehyde (Sigma) 
• 20mM Na2HPO  
• 80mM NaH2PO4.2H2O stock solution 
• Made to 100mL in milli-Q® water 
30% Sucrose Cryo-Protection Solution – makes 1L 
• 876mM Sucrose (Sigma) 
• 1000mL 0.01M PBS 
0.02% Tissue Storage Solution – makes 1L 
• 3.1mM Sodium azide (Sigma)  
• 1000mL PBS 
0.3% Triton/PBS diluent 
•  600µL 100% Triton-X100 (Sigma) 
• 200mL 0.01M PBS 
1% Triton/PBS diluent blocking diluent 
•  2mL 100% Triton-X100 (Sigma) 
• 5% (w/v) BSA 
• 200mL 0.01M PBS 
50x TAE Buffer for Gel electrophoresis – makes 1L  
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• 2M Tris base (Sigma) 
• 57.1mL Glacial acid (Millipore) 
• 50mM EDTA (Sigma) 
• Made to 1L in milli-Q® water 
4x Sample buffer 
• 900µL 4% Laemelli protein sample buffer (Bio-Rad) 
• 100µL β-Mercaptoethanol (Bio-Rad) 
Lell lysis buffer (RIPA) 
• 50mM Tris-HCL 
• 150mM NaCl 
• 1% (v/v) NP-40 (Sigma) 
• 1% (w/v) Sodium Deoxycholate (Sigma) 
• 0.1% SDS (v/v) 
• Protease inhibitor tablet (1 per 10mL) (Roche) 
Running buffer 
• 25mM Tris base  
• 192mM Glycine (Sigma) 
• 0.1% SDS 
• Made to 1L in milli-Q® water 
Transfer buffer  
• 25mM Tris base 
• 192mM Glycine 
• 20% (v/v) Ethanol (Sigma) 
• Made to 1L in milli-Q® water 
Tris buffered saline solution with tween (TBS-T) pH 7.5 
• 25mM Tris base (Sigma) 
• 150mM NaCl 
• 0.2% Tween-20 
• Made to 2L in milli-Q® water 
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• Adjust pH to 7.4 with 10M HCL 
TBS-T/5% skim milk powder  
• 100mL TBS-T 
• 5g (w/v) skim milk powder  
 
 
		
